Ferrocene conjugates as potential anticancer agents by Dago N’Da, David
   
 
 
 
i
SYNTHESIS OF METHOTREXATE AND 
FERROCENE CONJUGATES AS POTENTIAL 
ANTICANCER AGENTS 
 
 
David Dago N’Da 
 
 
A thesis submitted to the faculty of Science, University of the Witwatersrand, in 
fulfilment of the requirements for the degree of Doctor of Philosophy of Science. 
 
 
 
Johannesburg, 2004 
 
 
 
 
 
 
 
 
 
   
 
 
 
ii
 
 
 
 
Declaration 
I declare that this thesis in my own, unaided work. It is being submitted for the 
degree of Doctor of Philosophy of Science in the University of the Witwatersrand, 
Johannesburg, South Africa. It has not been submitted before for any degree or 
examination in any other University.  
 
 
________________________________________ 
David Dago N’Da 
 
 
 
________________________day of __________________, 2005 
 
 
 
   
 
 
 
iii
ABSTRACT 
 
Methotrexate (MTX) is a highly potent drug against leukemia and other 
neoplasias. The drug is notorious, however, for exerting toxic side effects and 
inducing drug resistance in the target cells as a result of deficiencies in the active 
carrier-mediated membrane-crossing mechanism. The bioreversible binding to a 
water-soluble and biocompatible carrier polymer is an advanced technology 
designed to circumvent critical pharmacological hurdles the drug must clear for 
efficacious biological action.  
The present project aimed at the anchoring of MTX and other drugs to various 
primary amine-functionalized polymeric carriers and the evaluation of the 
cytotoxic performance of the resulting conjugates in cell culture tests.  
 
The polymeric carriers used were polyaspartamides, prepared by an aminolytic 
ring-opening process of polysuccinimide, and poly(amidoamines), on the other 
hand, obtained by the copolymerization of methylenebisacrylamide with mono-N- 
tert-butoxycarbonyl-protected primary diamine and bifunctional amines. 
The anchoring was achieved through formation of biofissionable amide bonds. 
The in vitro biological evaluation against various human cell lines revealed the 
polymer-MTX conjugates to be more active than the clinically used parent drug.  
 
In order to demonstrate the multidrug-binding capacity of the polyaspartamide-
type carriers, and at the same time ensuring target-specific drug delivery, folic 
acid, a potential cell entry facilitator, was co-conjugated to selected polymeric 
conjugates containing MTX or ferrocene.  
The in vitro inhibition of cell growth by the folate-drug co-conjugates was also 
evaluated against the same human cell lines.  
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C H A P T E R   1 
INTRODUCTION 
 
1.1  Cancer Problem 
Cancer presents one of the most formidable health problems worldwide. More 
than 10 million people are diagnosed with cancer every year. The world health 
organization (WHO) estimated that there will be 15 million new cases every year 
by 2020. Cancerous diseases cause 6 million deaths every year, almost 12% of 
worldwide mortality. Lung, colorectal and stomach cancer are among the five 
most common cancers in the world for both men and women. Lung and stomach 
cancers are most common among men worldwide, while for women, the most 
common forms are breast and cervical cancer. The incidence and mortality rates 
of certain types of cancer have wide geographical differences, which are attributed 
to racial, cultural, and especially environmental influences. 
In South Africa, cancer poses a lifetime risk to one in four South African men and 
one in five women, and strikes population groups differently. The age, race, 
gender and socio-economic status also play an important part in determining the 
prevalence of particular cancers.  
The cancers affecting South African women, in order of prevalence, are: cervical, 
breast, colorectal, lung, and oesophageal cancer. The risk of cervical cancer is one 
in 29, while that of breast cancer is one in 31. The significant trend is that cervical 
cancer has overtaken breast cancer. Cervical cancer comprises 13.4% of all 
cancers among women from 15 to 29 years old, with young black women being 
particularly vulnerable. 
Prostate, lung, oesophageal, bladder and colorectal cancer rate among the top five 
cancers affecting all South African men. The leader, prostate cancer, has risen 
from a risk of one in 31 to one in 24. Statistics for lung cancer and oesophageal 
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cancer, both fuelled by smoking, show a slight increase, with the incidence of 
lung cancer much higher among men than women, and among white and coloured 
men than black men.  
1.2 Cancer and HIV-AIDS 
The immunodeficiency state in HIV infection predisposes one to the development 
of both opportunistic infections and neoplasms. In the latter case, lymphoma is 
usually a late manifestation. The incidence of different types of lymphoma 
(Hodgkin's disease, non-Hodgkins lymphoma (NHL) and T-cell lymphoma) is 
increased in HIV-infected individuals, though only immunoblastic and primary 
central nervous system lymphoma are increased significantly. Three kinds of 
HIV-associated lymphoma (Burkitt's, immunoblastic and primary central nervous 
system lymphoma) are classified as AIDS-related illnesses. 
In its latest report, the National Cancer Registry (NCR) of South Africa 
emphasized the increasing rate of cancers associated with HIV nationwide, e.g., 
soft tissue cancer (Kaposi's sarcoma) which is a threat to the youth. Kaposi's 
sarcoma which mostly affects the skin, is now the third and fourth most common 
cancer in men and women aged 15 to 29 years, respectively. More scaring is the 
rapid risk of expansion. Kaposi's sarcoma, which is classified as an "Aids-
defining" disease, almost doubled within five years (1993-1997) 1. Given the 
alarming rate of HIV-AIDS in the South-African youth, the report appears as a 
warning. Indeed, at the end of 1999 there were an estimated 4.2 million adults and 
children in South Africa living with HIV and AIDS. The adult rate of infection 
was 19.94%, meaning nearly one in five South Africans was living with HIV and 
AIDS. Of these, 2.3 million were women, and 95 000 children.  
In light of these statistics, it stands to reason that the burden imposed on the 
National Health Services in controlling neoplasias or, at least, alleviating their 
impact on human suffering, is staggering. 
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1.3 Objectives of the Study 
The worldwide incidence of neoplasias, in conjunction with the increasing 
prevalence at the national level in each country, renders the cancer control a 
public health and economic issue. It should, therefore, be regarded as a high 
priority. The fight against cancer has always been a priority for the scientific 
community involved in medical research since the first cancer case was 
discovered two centuries ago.  
Chemotherapy constitutes one of the modalities of cancer treatment, either per se 
or in conjunction with other treatment regimens. However, despite much progress 
in the chemotherapy of cancerous diseases, antitumor drugs in current clinical use 
generally suffer from a series of deficiencies, including excessive organ toxicity, 
lack of cell specificity, short circulation half lives, and a pronounced tendency to 
induce resistance in the target cells. As a consequence, complete cures by 
chemotherapy are still rare indeed.  
 
The primary objective of the research project was to address the problem of the 
lacking drug efficaciousness by providing a vehicle for improved pharmacokinetic 
utilization of anticancer agents. The bioreversible conjugation of selected 
anticancer drug models with water-soluble macromolecular carriers designed in 
accordance with specific biomedical requirements was the route of 
accomplishment of this objective. The conjugates were to be constructed so as to 
act as prodrugs delivering the monomeric bioactive agent at the site of action in 
intracellular space for interaction with nuclear DNA or proteinaceous constituents.  
 
The second objective was the biological activity evaluation of the synthesized 
polymer-drug conjugates against various human cancer cell lines. These included 
the human adenocarcinoma of the cervix (HeLa), the colorectal adenocarcinoma, 
(Colo 320 DM), the human leukemic lymphoblast (CEM/S) and its resistant sub-
line (CEM/E). The motivation was to compare the potency of these conjugates 
with the parent drugs presently in clinical use. 
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The principal drug system chosen was based on the antifolate agent, methotrexate 
(MTX). Other drug systems, including ferrocene compounds, and the vitamin B, 
folic acid (FA), were identified for co-conjugation with MTX in an effort to 
provide macromolecular drugs for combination therapy. 
 
After an overview of the modalities for cancer treatment in Chapter 2, the 
background of the polymeric anticancer drug conjugates will be reviewed in 
Chapter 3, followed by Chapter 4, where the results leading to the achievement of 
the objectives of this project will be discussed. The conclusion and future 
prospects will be stressed in Chapter 5 while Chapter 6 will cover the 
experimental efforts of this study. 
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C H A P T E R 2 
OVERVIEW OF CANCER TREATMENT 
MODALITIES 
There are many modalities for cancer treatment. They are highly variable and 
dependent on a number of factors such as the type, location and amount of disease 
and the health status of the patient. The treatments are designed to directly kill or 
remove the cancer cells or to lead to their eventual death by depriving them of 
signals needed for cell division or to stimulate the host immune system after kill 
or removal of theses cells. However, some are effectively utilized whereas others 
are still in their infancy. The four principal modalities utilized are surgery, 
radiation, chemotherapy, and immunotherapy. They will be reviewed in this 
chapter with more emphasis on chemotherapy as it is the impetus of this study, 
and so will be some new therapies which are still in their infancy. 
The cancers treatments may be divided into different categories based on their 
goal, mode of action, and are often used in combination, either simultaneously or 
sequentially. 
2.1 Surgery 
 
Surgery, the oldest modality, consisting of removing the primary tumor, is by far 
the most effective treatment of cancer. It also has an important role in diagnosing 
and staging of cancer.  
Although offering the greatest chance to cure many types of cancer by removing 
the primary tumors, surgery is ineffective for metastasized or disseminated 
tumors. There are many types of surgery, and they are highly goal-oriented. 
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2.1.1 Prophylactic surgery 
 
Prophylactic surgery, also called preventive surgery, aims at removing a body 
tissue likely to become malignant. Sometimes it is used to remove an entire organ 
when an individual has an inherited condition that makes development of cancer 
likely. A typical case is when a human female with a very strong family history of 
breast cancer is found to have a mutation in her DNA in a breast cancer gene 
(BRCA1 or BRCA2). These genes, accounting for approximately 5-10% of all 
breast cancer cases 2 and 80% of familial breast cancer cases 3, 4, make her a 
candidate for prophylactic mastectomy (breast removal).  
 
2.1.2 Diagnostic and staging surgery 
 
Diagnostic surgery is used to get a tissue sample to identify a specific cancer and 
make a diagnosis, which is often confirmed only by cellular microscopy, and 
staging surgery 5, a tool to determine the extent and the amount of disease.   
2.1.3 Curative surgery  
Curative surgery is the mostly known. Thought as primary treatment of cancer, it 
involves the removal of a tumor when it appears to be confined to one area. 
Curative surgery is performed when the hope of taking out all of the cancerous 
tissue still exists. It may be used along with chemotherapy or radiation therapy, 
which can be given before or after the operation. In some cases, radiation therapy 
is used during an operation, and is therefore termed intraoperative radiation 
therapy. 
2.1.4 Cytoreductive and palliative surgery  
Cytoreductive surgery, also known as debulking surgery, is performed in some 
cases when removing a tumor entirely would cause too much damage to an organ 
or surrounding areas. In these cases, the surgeon may remove as much of the 
tumor as possible and then try to treat the remaining portion with radiation 
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therapy or chemotherapy. Debulking surgery is commonly used for advanced 
cancer of the ovary. 
Palliative surgery refers to the treatment of complications of advanced disease. It 
is not intended to cure the cancer. It can also be used to correct a problem that is 
causing discomfort or disability. For example, some cancers in the abdomen may 
grow large enough to obstruct (block off) the intestine. This may require surgery 
for effective relief. Palliative surgery may also be used to treat pain when it is 
hard to control by other means. 
2.1.5 Supportive and restorative surgery 
Supportive surgery is used in combination with other modalities. Typically, a 
vascular access device such as a catheter port can be placed into a vein to help 
deliver chemotherapy treatments, thus reducing the number of needle sticks 
needed.  
Restorative reconstructive surgery 6, 7 is used to restore a person’s appearance or 
the function of an organ or body part after primary surgery. Typical examples are 
breast reconstruction after mastectomy or the use of tissue flaps, bone grafts, or 
prosthetic (metal or plastic) materials after surgery for oral cavity cancers.  
2.2 Radiation Therapy 
Radiation, which constitutes the second modality in cancer treatment, is often 
administered in attempts to eliminate and halt the development of secondary 
tumors resulting from residual and undetectable cancer cells that frequently 
remain in the body after surgery. It may also be used in early stages to cure or 
control the disease, or to shrink the tumor before surgery. Radiation alters the 
genetic code which controls the cell growth and division. Thus, radiation 
functions as a treatment by interference with the normal life cycle of a cell in the 
body, exclusively in the mitotic phase, M.  
Ionizing radiation is the common radiation used in cancer treatment. In principle, 
the radiation forms ions on passing through tissues and dislodges electrons from 
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atoms. These species, in turn, cause cell death or a genetic change by interfering 
with the cell M phase.  The efficacy of the therapy is radiation energy-dependent, 
and the higher the energy the more deeply the radiation can penetrate into the 
tissues. Thus, ionizing radiation can be divided into two major types, viz, photons 
(x- and γ-rays) and particulate radiations (electrons, protons, neutrons, α, and β 
particles). Of these, neutron radiation is used for some cancer of the head, neck, 
and prostate. Figure 2.1, below, depicts the cell cycle phases. 
 
Figure 2.1: Cell cycle phases  
G0: Cell resting phase.  
G1: RNA and protein synthesis phase. 
S: DNA replicating phase. 
G2: Cell pre-splitting phase.  
M or mitosis phase: The cell has actually split into two new cells.  
Other forms of radiation include stereotactic radiation (or therapy), which delivers 
a large precise radiation dose to a small tumor area. It is mostly used for brain 
cancer therapy. Iintraoperative radiation therapy (IORT), more often employed in 
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abdominal or pelvic cancers, delivers radiation at the time of surgery directly to 
the area of cancer, thus reducing the amount of tissue exposed to radiation as 
normal tissues can be moved out of the way during surgery and protected, 
allowing a higher dose of radiation to the cancer. 
2.3 Chemotherapy 
Like radiation therapy, chemotherapy is administered in attempts to eliminate and 
halt the development of secondary tumors resulting from residual and 
undetectable cancer cells that frequently remain in the body after surgery.  
Many anticancer agents and other chemical entities exert immune-stimulating 
effects on the cancer patient’s immune system during chemotherapy.  
The toxic effects of chemical agents on the cancerous cell for the most part 
involve interference with the cell’s replicative mechanism and, thus, with 
intracellular nucleic acid synthesis and the ultimate role played by the nuclear 
DNA in mitosis. The effectiveness of the anticancer drugs is generally, although 
not exclusively, at an optimal level whenever the target tissue consists of rapidly 
dividing cells, as is generally the case in a malignant system. However, the human 
body contains a number of compartments in which normal, i.e., healthy cells are 
required to replicate at a high rate in order to fulfil their physiological role, e.g., 
the bone marrow, the linings of the gut and the urinary tract. It is, indeed, in these 
compartments where most of the systemically acting anticancer drugs exert their 
most undesirable toxic side effects, as the rapidly proliferating cells do not 
provide sufficiently long time intervals during which normal DNA repair 
mechanisms, mediated by selective repair enzymes, can remain operative 8-10. 
2.3.1 Anticancer drugs 
Anticancer drugs are divided into several categories based on the mechanism of 
cytotoxic activity and the cell cycle phase interference. Although on occasional 
instances, the mechanisms of cytotoxic activity associated with particular classes 
may loosely coincide, in general, the members within a given class function by a 
mechanism particular to that class. The anticancer activity is dependent on growth 
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fraction (fraction of cells actively dividing with respect to the entire population of 
viable cells), and mass doubling time (the time taken by a tumor to double in 
size). Tumors with a high growth fraction are more susceptible to the cytotoxic 
effects of anticancer drugs than those with a high percentage of dormant cells. 
Dividing-cells are drug sensitive. Thus, tumors with shorter mass doubling times 
are more amenable to treatment with drugs. As tumors get larger, the mass 
doubling time increases and the growth fraction decreases. Unfortunately, normal 
tissues with high growth fractions (bone marrow, oral and intestinal mucosa, hair 
follicles) are also damaged by anticancer drugs, and treatment with many of these 
drugs may produce bone marrow depression, gastrointestinal tract ulceration, and 
alopecia 11. Tumor size is another limiting factor to successful chemotherapy in 
malignant disease. Drugs may not be able to penetrate into a solid tumor in 
amounts sufficient to kill the cells. Also, most cells in a bulky tumor may be in a 
nonproliferative stage at the time of treatment and thus survive to re-establish the 
tumor mass. Thus, the longer a tumor has been present the greater is the likelihood 
that it has already metastasized. Therefore, for any tumor therapy to be completely 
effective the most invasive metastatic cells must be killed. Moreover, the response 
to certain cell phase-specific drugs depends on the percent of cells in a sensitive 
phase during the time of exposure to pharmacologically effective concentrations 
of drug. In general, for cycle phase-specific agents such exposure should be for at 
least two cell cycle times. Cells in the G0 phase are, for the most part, refractory to 
chemotherapy. These cells may re-enter the cell cycle and result in disease 
recurrence. Most anticancer drugs are effective against cells in one particular 
phase of the cycle and have their greatest activity during S phase when cells are 
undergoing DNA synthesis.  
Drug resistance is one of the most important problems encountered with cancer 
chemotherapy, and several different biochemical mechanisms by which tumor 
cells develop resistance to anticancer drugs have been identified. These include:  
(a) Decreased intracellular drug levels resulting from increased drug efflux 12 or 
decreased inward transport. Anthracyclines, dactinomycin, vinca alkaloids, 
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and epidopodophyllotoxins are among the drugs becoming ineffective by 
this mechanism.  
(b) Increased drug inactivation. Included in this group are the alkylating agents, 
antimetabolites and bleomycin.  
(c) Decreased conversion of drug to an active form. This mechanism is mostly 
common among the antimetabolites (5-FU, 6-MP, etc.) which must first be 
converted into nucleotide before therapeutic activity can be observed. 
(d) Altered amount of target enzyme or receptor (gene amplification). 
2.3.1.1 Alkylating drugs  
These drugs are active against chronic leukemias, non-Hodgkin’s lymphoma, 
Hodgkin's disease, multiple myeloma, and certain cancers of the lung, breast, and 
ovary. Cyclophosphamide and mechlorethamine (nitrogen mustard) are two 
representatives of this class. They are covalent DNA-binding drugs, and act by 
forming strong electrophiles through the formation of carbenium ion 
intermediates. This results in the formation of covalent linkages by alkylation of 
various nucleophilic moieties. The chemotherapeutic and cytotoxic effects are 
directly related to the alkylation of DNA, mainly through the N-7 atom of 
guanine, although other moieties are also alkylated. The formation of one covalent 
bond with nucleophiles can result in mutagenesis or teratogenesis, but the 
formation of two of these bonds through crosslinking can produce cytotoxicity. 
Bifunctional alkylating agents can undergo a second cyclization of the second side 
chain and form a covalent bond with another nucleophilic group. The second 
group can be N-7 of another guanine or some other nucleophilic moiety. These 
bifunctional alkylating agents such as nitrogen mustard react with another 
nucleophilic moiety resulting in the crosslinking of two nucleic acid chains or the 
linking of a nucleic acid to a protein. This type of alteration causes a major 
disruption in nucleic acid function. Cytotoxicity of bifunctional alkylators 
correlates very closely with interstrand crosslinkage of DNA. Some of the cellular 
responses produced include cell-cycle blocking, DNA repair and apoptosis. The 
nucleophilic groups of proteins, RNA and many other molecules are potential 
targets of the alkylating agents.  
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The alkylating agents are generally considered to be cell-cycle phase non-specific 
and are known to be mostly cytotoxic to rapidly proliferating cells.  DNA 
alkylation occurs anytime in the cell cycle, but the biological consequences are 
more severe during the replicating S phase. The biochemical mechanisms 
identified as a cause of resistance to these drugs include decreased cellular uptake 
of the drug, increased production of nucleophiles such as glutathione and 
increased repair of DNA. Of these, increased inactivation and decreased uptake of 
drug are of clinical importance. Figure 2.2 below depicts the structures of two 
alkylating agents. 
P
O
N
H
ON
Cl
Cl
Cl
N
Cl
CH3
Cyclophosphamide Nitrogen mustard: Mechloroethamine
Figure 2.2: Structures of two DNA alkylating agents 
 
2.3.1.2  Antibiotics 
The antibiotic-type drugs have evolved from natural sources, but as they are 
presented in small quantities in biological material, worldwide efforts have 
focused on the development and synthesis of analogs and relatives possessing 
structural entities, such as planar fused-ring systems. These analogs are capable of 
intercalating between nuclear bases in the DNA double helix or otherwise 
interfering with protein synthesis, replication or transcription. Although, all of 
them are noncovalent DNA-binding drugs, they differ slightly in their mechanism 
of action. 
Antitumor antibiotics: These drugs are noncovalent DNA-binding agents. They 
interact with DNA in a variety of different ways including intercalation, DNA 
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strand breakage and inhibition of the enzyme topoisomerase II. Although isolated 
from natural sources and antibiotics, they lack the specificity of the antimicrobial 
antibiotics, and therefore produce significant toxicity.  
Dactinomycin, a representative of this class, is the only antitumor antibiotic in 
clinical use. It functions as a drug by intercalation between guanine-cytosine base 
pairs in the DNA helix, inhibiting RNA and DNA polymerase. This results in the 
cytotoxic effect, and ultimately apoptosis, and this cytotoxicity is cell cycle phase 
non-specific, although more acute in the G1 phase. Dactinomycin is used to treat 
Wilm's tumor, choriocarcinoma, and soft tissue sarcomas. Resistance to this 
anticancer agent is mediated by the expression of P-glycoprotein causing 
increased efflux of the drug. The major side effect from dactinomycin use is 
immunosuppression due to bone marrow suppression. Nausea, vomiting, and 
diarrhoea are other side effects related to the use of this drug. Dactinomycin is one 
of several drugs considered part of the multidrug resistant (MDR) complex. 
Figure 2.3 shows its structure. 
O
L-Me-Val
Ser
L-Pro
D-val
Thr
O
L-Me-Val
Ser
L-Pro
D-val
Thr
O
N
O O
CH3 CH3
NH2
O
Figure 2.3: Structure of dactinomycin
Me: methyl
Pro: proline
Ser: serine
Val: valine
Thr: threonine
 
Anthracycline antibiotics: The anthracyclines are among the most important 
antitumor drugs clinically available. Doxorubicin 13, 14, daunorubicin 14, and 
idarubicin are the mostly known of this class of anticancer agents. Anthracycline 
antibiotics (doxorubicin and daunorubicin) intercalate into DNA and inhibit DNA 
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and RNA synthesis, alter membrane signal transduction (phosphatidyl inositol 
pathway), and generate oxygen radicals. These oxygen radicals are produced by 
the cytochrome p450 system in the liver and are potent denaturing agents. 
Anthracycine antibiotics are a broad spectrum of anticancer agents that are used to 
treat many carcinomas, sarcomas, and leukemias. While Doxorubicin 15 is widely 
used for the treatment of several solid tumors (carcinomas and sarcomas), 
daunorubicin and idarubicin are used exclusively for the treatment of leukaemia.  
Resistance to anthracycine antibiotics is mediated by the expression of P-
glycoprotein, which causes increased efflux of these anticancer drugs. Side effects 
include cardiotoxicity, myelosuppression, rash, nausea, vomiting, alopecia, and 
diarrhoea. The structures of these antibiotics are shown below. 
R1                 R2
Idarubicin        -H                   -CH3
Daunorubicin  -OCH3             -CH3
Doxorubicin    -OCH3              -CH2OH
O
O
OH
OH
OH O
O
O
CH3
H2N
OH
Figure 2.4: Structures of anthracycline antibiotics
R1
R2
 
Anthracenediones: These drugs are analogs of the anthracyclines. They lack the 
sugar moiety of the anthracyclines, but retain the planar polycyclic aromatic ring 
structure that permits intercalation into DNA. They have shown impressive 
clinical activity, including less cardiac toxicity, which results mostly in 
nonproduction of quinone-type free radicals. Mitoxantrone, a representative of 
this class, is an intercalating agent that is effective in treating various tumors 14. 
Mitoxantrone interacts with DNA by a high-affinity intercalation. The 
diaminoalkyl groups present in the side chains of the antitumor drug are 
responsible for its ability to induce, after metabolic activation, interstrand covalent 
cross-links in DNA of tumor cells 16. As for the anthracyclines, intercalation of 
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mitoxantrone into DNA interferes with the strand-reunion reaction of 
topoisomerase II, resulting in production of protein-linked double-strand DNA 
breaks. 
Although mitoxantrone is cytotoxic to cells throughout the cell cycle, cells in late 
S phase are more sensitive. The structure of this drug is depicted below. 
OH
OH
O
O
HN(CH2)2NH(CH2)2OH
HN(CH2)2NH(CH2)2OH
Figure 2.5: Structure of mitoxantrone
 
Bleomycins: The bleomycins are a group of antitumor agents isolated from 
Streptomyces vericillus. Clinical bleomycin is a metal-chelating water-soluble 
glycopeptide that interacts with DNA in the early G2 phase of the cell cycle to 
cause strand breakage after oxidation from bleomycin-DNA-Fe (II) to bleomycin-
Fe (III). This strand breakage induces chromosomal abnormalities and cell death. 
Bleomycin is highly active against squamous cell tumors of the head, neck and 
lungs, effective against germ cell tumors of the testis and ovary, and is also used 
to treat testicular carcinomas along with cisplatin and vinblastine. One of the most 
common resistance mechanisms is an increased degradation of drug by certain 
amidase enzymes. Side effects include pulmonary toxicity, alopecia, and 
hyperpigmentation of the hands. In contrast to many other anticancer drugs, 
bleomycin rarely causes myelosuppression. 
2.3.1.3 Antimetabolites 
Antimetabolites are structural analogs of naturally occurring compounds. They 
interfere with the production of nucleic acids and work through a variety of 
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mechanisms including competition for binding sites on enzymes and 
incorporation into nucleic acids. Antimetabolites inhibit the growth of the most 
rapidly proliferating cells in the body (e.g., bone marrow, gastrointestinal tract, 
etc.), and are divided into three categories: antifolates, purine analogs and 
pyrimidine antimetabolites.  
Antifolate antimetabolites: They produced both the first striking remissions in 
leukaemia 17 and the first cure of a solid tumor, choriocarcinoma. 
(a) Methotrexate  
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Figure 2.6: Structure of methotrexate 
COOH (α)
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History of clinical use: Methotrexate (Figure 2.6), a folate antimetabolite 
synthesized five decades ago, has been in clinical use for more than 35 years. It 
has a long history of use in the treatment of various immunologic diseases. MTX 
began as a drug for cancer treatment, particularly childhood leukaemia, in the 
early 1940s 18. In the 1960s it was used for the treatment of rheumatoid arthritis 
and psoriasis. In the mid-1980s 19 many rheumatologists reported their 
experiences with MTX use in studies of rheumatoid arthritis. Guidelines for MTX 
use were then developed to address dosing, liver biopsy and monitoring strategies, 
which were aimed at reducing the incidence of adverse affects 20. Currently, 
methotrexate is indicated for the treatment of acute lymphocytic leukemia (ALL), 
as well as for rheumatoid arthritis and psoriasis. The drug has also been found 
efficacious in the treatment of other diseases, including asthma, systemic lupus 
erythematosus, Crohn’s disease, myositis, vasculitis and ectopic pregnancy 21-23. 
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MTX is also used for its steroid-sparing properties in asthmatic patients and others 
who may have side effects related to corticosteroid use 24.  The literature reports 
MTX as a key component in the treatment of HIV-related lymphomas and other 
germ cell neoplasias 25, 26, as well as of the late MTX-induced expression of HIV-
LTR (long terminal repeat), MTX being a chemotherapeutic agent that is not 
directly DNA damaging 27. 
However, clinical MTX effectiveness is often hampered by the development of 
acquired resistance. In particular, in human and murine tumors an impaired 
cellular uptake of the drug occurs as a consequence of a defective active carrier 
system (reduced folate carrier (RFC)), which regulates the cell entrance of folate 
analogs. Several biochemical mechanisms of resistance have been demonstrated. 
Of these, the major ones are decreased drug uptake, amplification of the 
dihydrofolate reductase gene and thus an increase in the target enzyme, gene 
mutations, and decreased ability to form methotrexate polyglutamate inside cells 
28-30. 
 
Mode of action: The passive diffusion of MTX through cell membrane is limited, 
due to its hydrophilic nature. Indeed, MTX is highly polar; and owing to this 
polarity, at the nearly neutral pH of biological fluids, it is present mainly in the 
doubly anionic species form. This leads to inhibition of cell penetration. As a 
consequence, only a small portion of MTX successfully enters the intracellular 
space by passive diffusion while the major portion enters by carrier-mediated 
mechanism. The main pharmacological target of action of MTX is the competitive 
inhibition of dihydrofolate-reductase (DHFR), an intracellular enzyme which 
reduces folic acid to tetrahydrofolate cofactors, which are in turn key 
intermediates in several important biochemical pathways, among which are the de 
novo biosynthesis of purines and of thymidylate. Mathews and al. 31, using Raman 
spectra of the MTX-DHFR complex, showed that the inhibition occurs as result of 
ionic binding between the N-1 of the pterin portion and the enzyme. Lack of 
reduced folates, purines and thymine in actively proliferating cells, such as those 
of the tumors, leads to a blockage of DNA and RNA synthesis, and eventually to 
cell death.  
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The affinity of MTX to some folate-requiring enzymes in the biosynthetic 
pathways towards purines and thymidylate has been found to increase as the 
number of γ-glutamyl residues increases. Moreover, the increased polarity of the 
polyglutamylated species of MTX hampers their efflux from cells.  
 
Medical limitations: MTX exerts its primary toxic effects against the rapidly 
replicating cells of the bone marrow and gastrointestinal epithelium. The severity 
of the clinical effects depends largely on the duration of exposure to inhibitory 
levels of the drug. All of the stem-cell types of the marrow can be affected to 
produce leucopoenia, thrombocytopenia and, with long-term administration, 
anaemia. Mucositis is one of the earliest signs of toxicity, and its appearance is an 
indication of the need for the administered dose to be reduced. Methotrexate also 
causes kidney damage, which is a frequent complication of high-dose therapy. It 
is manifested by elevated serum creatinine and decreased creatinine clearance. 
Crystalline deposits of methotrexate and methotrexate-derived material have been 
found in the renal tubule, which seems to account for most of the nephrotoxicity. 
Alkalinizing the urine to increase the solubility and ensuring good urine flow 
minimizes most of the nephrotoxicity due to high-dose methotrexate. Both low- 
and high-dose therapy can cause hepatotoxicity. High-dose therapy results in 
elevated liver enzymes and low dose therapy produces a different type of 
hepatotoxicity which includes cirrhosis. Methotrexate can also cause a reversible 
pulmonary syndrome, which has been observed primarily in children undergoing 
maintenance therapy. Intrathecal and high-dose administration is accompanied by 
several types of neurotoxicity. These range from acute manifestations to long-
term delayed toxicity in the form of encephalopathy. Nausea and anorexia 
frequently occur as acute side effects of methotrexate therapy 32. To overcome the 
dose-limiting toxicity of MTX, and to allow the use of protocols with very high 
doses of MTX for the treatment of resistant cell lines or to achieve cytotoxic drug 
concentrations across the blood-brain barrier, in clinical use, a strategy named 
“folinic acid rescue therapy” has been devised 33. Although the biochemical 
mechanism is still debated, intravenous administration of leucovorin (a racemic 
mixture of isomers of folinic acid) at a scheduled time after the infusion of high-
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dose MTX therapy was found to be beneficial to healthy cells, and protects them 
from the cytotoxic action of MTX. In a moderate-dose therapy, MTX is 
administered in combination with other chemotherapeutic agents for the 
maintenance of remissions 34.  
 
Methotrexate-anolog drugs: The shortcomings observed with MTX, namely, the 
systemic toxicity and cell non-specificity, led to the development of various 
strategies, and the search for analogs is one of them. A number of structural 
analogs of MTX have been investigated as new candidate antifolate drugs 35, and 
raltitraxed (N-[(5-{methyl[(2-methyl-4-oxo-3,4-dihydro-6-quinazolinyl) 
methyl]amino}-2-thienyl)carbonyl]glutamic acid) is currently licensed for 
therapeutic use despite being nephrotoxic 36. These compounds, if present in 
biological samples such as plasma, serum, saliva, urine, cerebrospinal fluid, and 
tissue specimens, can be extracted, separated and detected under a variety of 
chromatographic conditions. They can be classified into two broad categories: 
“classical” antifolates, prototyped by MTX, which retain an aryl-glutamate or a 
chemically equivalent group, and “non-classical” antifolates, which lack the 
hydrophilic portion of the molecule. Figures 2.7 (a) and (b) show the structures of 
these analogs. 
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Certain “non-classical” DHFR inhibitors are well-established as anti-infective 
agents, and some are currently tested as candidate antitumor drugs. Owing to lack 
of the aryl-glutamate moiety, these drugs are much more lipophilic than MTX and 
“classical” antifolates, and can thus enter even tumor cells with impaired classical 
folate transport or cross the blood-brain barrier. 
Trimetrexate is a highly hydrophobic, non-glutamylable analog of MTX, which 
carries a substituted quinazoline system in place of the pterine portions, a 
trimethoxyaniline group in place of the para-aminobenzoic acid portion 37. 
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Figure 2.7 (b): Structures of some non-classical antitumor antifolate drugs
 
(b) Folic acid 
 
Folic acid, or pteroylglutamic acid, consists of a pteridine that is linked to para-
aminobenzoic acid (PABA) and glutamic acid. 
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Figure 2.8: Structure of folic acid
Glutamic acid para-aminobenzoic acid Pteridine 
Pteroyl (pteroic acid)
COOH (γ)
 
Physiological role: As a pharmaceutical product, folic acid (FA) is a vitamin, a 
nutritional supplement, and a diagnostic aid in folate deficiency 38. FA, referring 
to the folate form, is a well-known water-soluble vitamin of the B-complex. It is 
mainly evolved from natural sources, but as it is available in small quantities in 
biological material, worldwide efforts focused on its development and synthesis. 
The pharmaceutical product is chemically synthesized, and the L-enantiomer is 
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the biologically active form. Folic acid is involved in many metabolic 
mechanisms leading to the synthesis of DNA and normal erythropoiesis. In 
intestinal cell, FA is mostly reduced to tetrahydrofolate (H4folate), the active form 
of this vitamin in a two-step reaction, which is catalyzed by the enzyme folate 
reductase. Inhibitors of this enzyme, like MTX, act as antifolate. Figure 2.9 
depicts the fate of folic acid in the biological environment.  
 
NADPH + H            NADP+
FA Dihydrofolic acid Tetrahydrofolic acid
Figure 2.9: Two-step conversion of folic acid to the active tetrahydrofolate by 
                    the enzyme folate reductase and its inhibition by methotrexate
Methotrexate
+ NADPH + H            NADP+ +
Folate 
reductase
Dihydrofolate
reductase (DHFR)
 
 
H4folate functions as a coenzyme, a carrier of various activated one-carbon units 
in metabolic reactions. Folic acid and vitamin B12 metabolic pathways intersect at 
the conversion of homocysteine to methionine. FA is also proven to be completely 
ineffective 39 against any type of cancerous disease. However, it is also known to 
impact deeply on cancer development. Indeed, folate deficiency appears to play a 
crucial role early in cervical carcinogenesis by facilitating genetic modification at 
a fragile chromosomal site 40. Also, the interest in folic acid has grown with the 
evidence that modest supplementation could prevent hyperhomocysteinemia, 
which is an independent risk factor for atherosclerotic cardiovascular disease. 
Folic acid plays a crucial role in DNA synthesis, where it enables cells to replicate 
normally. This is particularly critical during foetal development. During 
pregnancy, especially the first trimester, folic acid intake is important in 
preventing a wide range of birth defects, most notably neural tube defects. 
Deficiency in FA leads to anaemia. Indeed, normal physiologic changes in 
pregnancy affect the haemoglobin concentration, and there is a relative or absolute 
reduction. The most common anaemias during pregnancy are iron deficiency 
anaemia and folate deficiency macrocytic anaemia, which occur in women on 
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inadequate diets and not receiving prenatal iron and folate supplements. In an 
attempt to assess the effects of iron and folate supplementation on haematological 
and biochemical parameters and on outcome in pregnancy, Kulier and al. 
concluded that routine supplementation raises or maintains the iron, ferritin and 
folate levels in the serum and red cells, and results in a substantial reduction of the 
proportion of women with haemoglobin below 10g/dL in late pregnancy 41. In 
light of its physiological key role, FAO (Food and agricultural organization) and 
WHO recommended folic acid intakes in terms of free folate 42. 
 
Mechanism of intracellular uptake: Folic acid is transported into cells either 
through a receptor-mediated endocytosis 43 facilitated by the folate receptor, or 
with the help of carrier proteins, such as the reduced folate carrier (RFC). The 
membrane-associated folate receptor is known to be overexpressed on the surface 
of a variety of human tumor cells, including cancers of the ovary, colon, kidney, 
uterus, testis, brain, lung, breast, and myelocytic blood cells, while it is highly 
restricted in most normal tissues 44. Thus, when folic acid molecules are 
covalently linked to proteins, the folate-protein conjugates are internalized into 
cells via the receptor-mediated mechanism 131. In this process, the ligand (folate)-
bound receptor is sequestered in caveolae, internalized into postcaveolar plasma 
vesicles, released from the receptor via an intravesicular reduction in pH, and 
subsequently transported into the cytoplasm. The ligand-free receptor is then 
recycled to the cell surface by reopening of the caveolae.  
Purine analog antimetabolites: 6-Mercaptopurine (6-MP) and 6- thioguanine (6-
TG) are the two major anticancer drugs in this category. These drugs are analogs 
of hypoxanthine and guanine, respectively. In addition to being anticancer drugs, 
they are also immunosuppressive and antiviral. The antipurines can both inhibit 
nucleotide and nucleic acid synthesis and be incorporated into nucleic acid.  
They function at multiple sites and their cytotoxic activity is the result of 
combined effects on these different sites. Typically, 6-MP is first converted to 6-
mercaptopurine ribose phosphate (6-MPRP), the nucleotide-active form that 
inhibits amidotransferase and dehydrogenase. Amidotransferase is the enzyme 
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involved in the synthesis of the purine bases (adenine and guanine) while 
dehydrogenase is the key enzyme in guanine nucleotide biosynthesis. Additionally 
6-MPRP can be incorporated into DNA and RNA, thus forming a strand of 
nucleic acid with an aberrant structure. This renders the resulting modified nucleic 
acids unable to direct proper protein synthesis.  
Therapeutically, both drugs are used primarily in the treatment of leukemias. Side 
effects include myelosuppression, rash, nausea, vomiting, hepatotoxicity, and 
diarrhoea. All of these effects are the result of the killing of rapidly dividing cells 
such as those found in the intestinal tract. The structures of these purine analogs 
are shown below.  
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Figure 2.10: Structures of purine analog antimetabolites
 
Pyrimidine antimetabolites: Pyrimidine analogs have also been used in the 
treatment of diseases as diverse as cancer, psoriasis, fungal infections and viral 
infections. The best characterized and most important representatives of this class 
are 5-fluorouracil (5-FU) and Ara-C. 
 In contrast to MTX that inhibits indirectly the enzyme thymidylate synthetase 
through inhibition of dihydrofolate reductase, 5-FU is a direct inhibitor of this key 
enzyme. In this inhibition process, 5-FU is first converted to the nucleotide 5'-
FUMP, which, after several different pathways, can either be incorporated into 
RNA or converted to the deoxynucleotide (F-dUMP). The inhibition of the 
enzyme thymidylate synthetase by F-dUMP leads to deletion of TTP, a necessary 
constituent of DNA, resulting in cell death. 
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The major biochemical mechanisms of resistance associated with the use of 5-FU 
include decreased conversion to the nucleotide form and increased breakdown of 
the nucleotide. 5-FU is used in the treatment of several common solid tumors.  It 
is partially effective against metastatic carcinomas of the breast and the 
gastrointestinal tract. Combination with leucovorin has been very successful as 
the leucovorin enhances formation of the ternary complex. The toxicities of this 
drug are administration mode-dependent, and anorexia and nausea are among the 
earliest observed symptoms.  
In its mechanism of action, cytosine arabinoside (Ara-C) is first converted to the 
monophosphate nucleotide (AraCMP) by deoxycytidine kinase. The 
monophosphate then reacts with appropriate kinases to form the Ara-C di- and 
triphosphate nucleotide (AraCTP), which, on accumulation, causes inhibition of 
DNA chain elongation when Ara-C is incorporated at the terminal position of a 
growing DNA chain. Unlike other antimetabolites, the effects of Ara-C are 
directed exclusively towards DNA, and it has little or no effect on RNA synthesis 
or function. Ara-C is primarily used either alone or in combination with 
daunorubicin for the treatment of acute myelocytic leukaemia due to its potent 
myelosuppressive action. It has occasionally been used to treat acute lymphocytic 
leukemia, and in high doses for non-Hodgkin’s lymphoma and chronic myelocytic 
leukaemia. The principal toxicity is bone marrow depression, which is manifested 
as granulocytopenia and thrombocytopenia. Other toxicities include oral 
ulceration, nausea, vomiting and diarrhoea, and peripheral neurotoxicity with high 
dose therapy. Figure 2.11 depicts the structures of both pyrimidine 
antimetabolites. 
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Figure 2.11: Structures of pyrimidine antimetabolites
 
2.3.1.8 Other chemotherapeutic drugs 
Among other numerous anticancer agents, one should cite hormonally acting or 
hormone-blocking agents, intercalating agents of the cisplatin-type, 
photochemically activated drugs, hypoxia-selective cytotoxins, radiation 
sensitizers, the enzyme-type agents such L-asparaginase, and the mitotic-type 
inhibitors such as vinblastine, vincristine, and vinorelbine. Those mitotic-type 
inhibitors are active specifically during the M phase of the cell cycle. Also 
included are the enzyme-type agents such L-asparginase as well as the organoiron 
drug of the ferrocene-type. 
Although they vary in the mechanism of action and frequently also in their 
pharmacokinetic pathways, these drugs generally have in common a cytotoxic 
effect, which results from interaction with endocytic nuclear material.  
The ferrocene drug system  
 
Over the past 30 years platinum-based drugs, notably cisplatin and carboplatin, 
have dominated the treatment of various cancers by chemical agents. However, 
these drugs cause serious side effects, including renal impairment, neurotoxicity 
and ototoxicity (loss of balance/hearing). Thus, there has been considerable 
interest and increased research activity in developing other transition metal 
compounds as anticancer drugs, which are less toxic than the platinum-based 
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drugs. Among these derivatives, metallocenes and metallocene dihalides proved 
to be particularly active against a number of tumors 45, and, despite the fact that 
their activity seems to follow mechanistic paths which differ from those of 
cisplatin, both drugs have a DNA intracellular target.  
The first metallocene discovered was ferrocene, and its particular structure was 
brought out by Wilkinson 46 in the early 1950s. Ever since, there has been a rapid 
growth in the study of ferrocene compounds for several reasons, which include 
their highly promising antiproliferative activity against various murine and human 
cancer lines, and their unusual stability owing to the sandwich structure conferred 
by the binding of the iron center by the two Cp (cyclopentadienyl) rings.  
 
Behavior in physiological environment: One of the important characteristics 
displayed by the ferrocene complex is its outstanding oxidation-reduction 
behaviour. It readily converts to the ferricenium ion, which is a free radical of 
high stability. This one-electron transfer reaction is reversible (Scheme a), and has 
some implications in the biological realm. Electron transfer and free-radical 
reactions play a vital role in biological processes, and therefore the ferricenium-
ferrocene system should be a topic of major interest in both biochemical and 
biomedical research. Many investigations dealing with the biological behavior and 
functioning of ferrocene compounds have indeed been reported. Thus, under 
enzymatic control, ferrocene is oxidized by hydrogen peroxide, whereas 
ferricenium ion is reduced by NADH and metalloproteins (Scheme b). Besides, 
ferricenium ion reacts with the biologically important superoxide anion radical, 
leading to a regeneration of ferrocene and dioxygen (Scheme c). A reverse 
electron transfer reaction, resulting in oxidation of the ferrocene complex to its 
ferricenium salt, occurs with ferrcenylcarboxylates in their interaction with the 
highly reactive hydroxyl radical, transforming the latter to a harmless hydroxyl 
anion (Scheme d). Scheme 2.1 below gathers the different reactions of the 
ferrocene complex in the biological environment. 
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Free-radical chemistry plays a vital role in cancer generation and in various 
phases of growth and control of neoplasia. Effective inhibition and detoxification 
processes in the cancerous organism may well be involved in the aforementioned 
superoxide and free radical-scavenging reactions. A deactivating recombination of 
ferrocene in its oxidized state with the free-radical form of ribonucleotide 
reductase, an important enzymatic link in DNA synthesis, may represent another 
potential contribution to the inhibition of the cell’s proliferation process. The 
preparation of numerous ferricenium compounds and their evaluation for 
antiproliferative activity against ascitic murine tumors and several human tumor 
clonogenic cultures are reported in review articles 47, 48. For those salts tested that 
were insoluble, like the ferrocene parent itself, no activity was revealed in the 
screens. In contrast, ferricenium salts comprising the picrate, tetrachloroferrate 
(III), µ-oxo-bis(trichloroferrate(III)), trichloroacetate, or chloride counter ions, 
were found to be active, and they all showed good water solubility with high 
saturation limits. Under optimal conditions, in the Ehrlich ascites screening test, 
best results (cure rates of 100%) were displayed by the picrate and the 
trichloroacetate salts. A moderate activity was even detected with ferrocenylacetic 
acid, a water-soluble derivative of unoxidized ferrocene. Ferricenium salts, 
dissolved in aqueous medium at physiological pH (∼7.4), are unstable, and this 
would indicate too short half lives in vivo of such compounds in the central 
circulation system for effective survival en route to the target tissue. However, the 
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results drawn from ferrocenylacetic acid behavior suggest that the administration 
of a ferrocene compound in vivo in the ferricenium state may not be necessary. 
The oxidation-reduction equilibrium distribution of ferricenium and ferrocene 
species in any body compartment is likely to be solely under the control of the 
biological environment 49, i.e. pH and enzymatic activity in that compartment, and 
not of the oxidation state in which the ferrocene compound was initially 
administered. Thus, the biological effects encountered in vitro should also be 
shown in vivo irrespective of the compounds’ initial oxidation state, the only 
prerequisite being water solubility of the compound, which should be highly 
sufficient for rapid dissolution and dissipation in the aqueous fluid system. Unlike 
the platinum-based compounds, the cytotoxic activity of ferrocene compounds, 
namely ferricenium salts, is probably not based on their direct binding to DNA, 
but on their ability to regenerate oxygen-active species which induce oxidative 
DNA damage. 
 
Interest in the antitumor activity of ferrocene derivatives, usually associated with 
ferricenium compounds, recently increased when it was observed that ferrocene 
itself has a marked antitumor effect in experiments with tumor-bearing mice. 
Indeed, Kovjazin and al. 50, investigating the antitumor properties of ferrocene, 
conducted in vivo experiments in mice bearing established lung metastases of B-
16 melanoma. The results showed unexpectedly ferrocene to possess outstanding 
antitumor effects resembling a bell-shaped curve. This was attributed to its 
immune stimulatory potential which was induced by lymphocyte activation. The 
Figure 4.12 below depicts the proposed mechanism of ferrocene action 50.   
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2.3.2 Deficiencies of chemotherapy 
 
Despite progress made in chemotherapy, either alone or in conjunction with other 
modalities for the treatment of cancerous diseases. However, in general, the 
overall success rate has remained modest and unsatisfactory. Thus, with most 
cancers, complete eradication is rare. Remission of limited duration and 
reappearance of malignant symptoms are frequent as a result of a variety of 
deficiencies associated with present-day anticancer drugs. Typical deficiencies 
include the following: 
(a) Inadequate water solubility, which hampers swift and efficacious drug 
distribution in the body’s aqueous fluid system, and results in enhanced exposure 
to macrophage activity. 
(b) Decreased serum half-life as a consequence of catabolism, protein binding, 
capture by the reticuloendothelial system, or efficacious excretion mechanisms. 
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(c) Excessive systemic toxicity, which grossly diminishes therapeutic drug 
effectiveness and oftentimes necessitates premature termination of therapy. 
(d) Monophasic salt-like or charged structure, which inhibits membrane 
penetration and cell entry through normal passive diffusion. As a result, only a 
small fraction of the medicinal agent will successfully enter intracellular space for 
interaction with nuclear DNA or proteinaceous constituents. 
(e) Lack of cell specificity, with ensuing drug distribution into both normal and 
transformed cells. In consequence, drug application will be excessively wasteful, 
and healthy tissues will be exposed to toxic side effects. 
(f) Induced drug resistance, which results in lack of long-term effectiveness. As a 
consequence, treatment by drug-specific therapy must be discontinued after initial 
promising remission, and this leads to early recurrence of cancerous lesions. 
2.3.3 Combination therapy  
Combination chemotherapy is a strategy of fundamental importance involving 
multiple drug administration to produce additive and even synergistic effects 
without enhancing overall drug toxicity. A specific goal of combination therapy is 
the broadening of the activity spectrum through the use of two or more agents 
functioning by different mechanisms and exerting different toxicity effects. 
Numerous combinations of both time-proven and novel drug models have been 
administered clinically. Thus, co-administration of doxorubicin, bleomycin, and 
vinscristine has been used as therapy for AIDS-related Kaposi’s sarcoma and 
other germ cell neoplasm 51.  Methotrexate is commonly used in combination with 
5-fluorouracil and cyclophosphamide in the adjuvant treatment of breast cancer 
 
Although much progress has been made, cancer chemotherapy is still 
unsatisfactory owing to the aforementioned deficiencies. Therefore, intensive 
investigations of site specific polymer-drug delivery must be undertaken in order 
to allow the development of ultraspecific targeted macromolecular drugs. These 
macromolecular drugs have the advantage of increasing the potency while 
simultaneously reducing resistance to therapy and toxic effects of current 
anticancer drugs. 
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2.4 Immunotherapy 
Immunotherapy is the fourth modality, which is still much in its infancy.  Aiming 
at stimulating of the host’s own immune system, it is described as a biologic 
response modifier or biologic therapy. Immunotherapy is sometimes used by 
itself, but it is most often used as an adjuvant (along with or after another type of 
therapy) to add to the anticancer effects of the main therapy. Although the thought 
of using one’s own immune system to fight cancer is appealing, immunotherapy 
currently has a small role in treating the most common types of cancer. In general, 
immunotherapy is most likely to be effective when treating small cancers, and 
will probably be less effective for more advanced stages of a disease. In the 
presence, or after removal, of cancerous cells, the immunotherapy either 
stimulates the host’s own immune system, and is designated as active specific 
immunotherapy 52 (e.g. cancer 53 and dendritic vaccines) or uses the immune 
system components such as antibodies created outside, and is known as passive 
immunotherapy (e.g. naked 54 and conjugated monoclonal antibody therapy). The 
most promising tumor cell vaccines are currently under study in clinical trials 
against several cancer malignancies including melanoma 55, kidney, ovarian, 
breast 56, colorectal and lung cancer, as well as leukaemia. 
2.5 Antiangiogenesis Therapy 
Antiangiogenesis therapy in cancer treatment refers to the use of drugs or other 
substances to stop tumors from developing new blood vessels, leading to tumor 
death 57. Most antiangiogenic drugs work by preventing the first step in the 
making of new blood vessels, that is, the growth of the endothelial cells forming 
the inner lining of the blood vessels. They present two main advantages over 
chemotherapeutic drugs: Firstly, they are non toxic to normal cells, and therefore 
can be applied over a long period without interruption, thus leading to higher 
effectiveness, and secondly, since they do not lead to cell resistance, they could be 
active for much longer periods of time. 
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2.6 Gene Therapy 
Gene therapy is one of the modalities for cancer malignancies treatment, which is 
still in its infancy. Gene therapy consists of inserting a specific gene into cells to 
restore a missing function, or to give the cells a new function, as cancer is the 
result of cell’s genetic mutations. This therapy is used in a variety of ways in the 
clinical trials. These comprise the addition of functioning genes to cells with 
abnormal or missing genes, blocking genes from making cancer cells resistant to 
chemotherapy or adding genes to tumor cells for easy detection and elimination 
by the host’s immune system, or adding genes to immune system cells, and 
stopping genes from contributing to angiogenesis (blood vessel formation), or 
adding angiogenesis inhibitor genes to cancer cells. 
The main obstacle to the use of gene therapy is the finding of the appropriate 
vectors for the gene delivery. Many vectors are under investigation. Of these, one 
should cite the viruses, which are known to be extremely efficient in the delivery 
of foreign genes into cells and tissues 58, as well as the non-viral vectors such as 
cationic liposomes and cationic polymers 59, 60. 
2.7 Photodynamic Therapy 
Photodynamic therapy (PDT), also called photoradiation therapy, phototherapy, or 
photochemotherapy, is a treatment that combines a light source and a 
photosensitizing agent (a light-activated drug) to destroy cancer cells. The 
mechanism of action is described as follows: On exposure to light, the 
photosensitizing agent reacts with oxygen to form chemicals that destroy 
cancerous cells. The use of PDT is limited by the depth of penetration of light in 
the tissue. Therefore, PDT is mainly used to treat areas on or just under the skin, 
or in the lining of internal organs.  
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CHAPTER 3 
POLYMERIC ANTICANCER DRUG 
CONJUGATES 
Background and Literature review  
The use of therapeutic systems to obtain a controlled drug release in cancer is a 
more and more exploited approach in the modern pharmaceutical technology 61, 62. 
Growing interest in this field arises on the one hand from the often unsuccessful 
research for effective and non-toxic new drugs and on the other hand from new 
knowledge of the biochemical events around and inside tumor tissues. Indeed, 
following administration, the active agent is distributed over the entire body and 
reaches not only the target cells or tissues but also interacts with healthy cells. 
This leads to peripheral toxicities and low therapeutic efficiency, and prompts the 
search for novel therapeutic strategies. Many drug delivery systems have been 
explored, including drug-antibody conjugates (immunoconjugates), conjugates 
obtained by linking drugs to natural or synthetic polymers (macromolecular 
prodrugs) 63-65, vesicular or particulate systems (liposomes  66, nanoparticles 67, 
microparticles for regional therapy 68) and polymeric implants 69. Unfortunately 
some of these systems have often disappointed early expectations.  In the case of 
immunoconjugates, the inefficacy was mainly due to the limited access of these 
relatively big molecules into tumor mass, the heterogeneity of tumor cells and the 
different humoral response among patients 70. Therefore, a strong interest was 
developed in the potentially promising systems, and water-soluble carriers 
covalently linked to the drug through a biodegradable spacer constitute one of 
them. 
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3.1 Polymers as Drug Carriers 
Modification of biologically active compounds with polymers is one of the 
methods for altering and controlling their pharmacokinetics, biodistribution, and 
toxicity 71. Polymers chosen as drug carriers are either natural or synthetic 
macromolecules. They must meet certain requirements in order to maximize their 
potential as polymeric drug carriers by decreasing the toxicity and (or) increasing 
the therapeutic index of the anticancer drug.  
3.1.1 Requirements for polymeric drug carrier 
 
These include hydrosolubility, biodegradability; biocompatibility, and chemical 
composition. 
 
3.1.1.1 Hydrosolubility 
 
Solubility in aqueous media is a necessary criterion for any polymer intended to 
be used as a drug carrier in the biomedical field. Such polymer should be linear 
and highly flexible. This will have the advantage of increasing the positive 
entropy of the solution, and therefore favour the dissolution process, and the 
presence of intra- or extrachain hydrophilic entities such hydroxyl- and amino- 
terminals. These hydrophilic entities are of excellent utility as they are capable of 
undergoing effective hydration. The ability to incorporate charged species into the 
polymer also leads to its hydrosolubility property. Moreover, the use of 
poly(ethylene oxide) (PEO) in the polymer therapeutic field rose in interest owing 
to its numerous properties such as the solubility in both aqueous and organic 
media, ease of chemical modification, and biocompatibility 72, 73, which are also 
imparted once PEO  is incorporated into a polymer. 
  
3.1.1.2 Biodegradability 
 
To prevent rapid excretion by kidneys observed with low molecular weight 
compounds, the candidate carrier must be sufficiently large. However, its 
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backbone must comprise segments amenable to hydrolytic and enzymatic 
cleavage in order to allow for the biodegradation and resultant catabolic 
elimination following drug release. If non-biodegradable such as the synthetic 
polymers with carbon-carbon backbone, the polymer should have a molecular 
weight not exceeding the renal threshold 30 000 - 50 000. The failure to comply 
with this requirement will result in deposit and accumulation in various organs. 
However, the biodegradability of a polymeric carbon backbone can be increased if 
the latter is equipped with peptide, saccharide or nucleotide sequences, as they are 
recognized and biodegraded by the numerous enzymes present in the lysosomal 
compartment of the cell. 
 
3.1.1.3 Biocompatibility 
 
The polymeric backbone must be non-toxic, non-immunogenic, and non-
thrombogenic in order to avoid any carrier-generated toxic, immunogenic and 
blood-clotting side effects. Indeed, failure to meet these requirements will result 
in premature destruction of the carrier through attack by the host defence systems, 
which renders the drug delivery system useless. 
PEO is found to be a promoter of cell fusion and hydration 74 as well as a 
chemical entity for reducing or controlling the antigenicity of immunogenic 
proteins 75. An earlier review article 76 stressed the conjugation of PEO to protein 
or liposome as an important tool for reducing the shortcomings encountered in 
using these therapeutic agents, namely the degradation by proteolytic enzymes, 
thermal instability, and immunogenicity. More recently it has been reported that 
the presence of PEO segments in polyelectrolyte causes complexation with 
plasmids, reducing the side effects and increases the lifetime of these complexes 
in vivo 77, 78. 
 
3.1.1.4 Chemical composition 
 
The carrier macromolecule must comprise reactive functional groups suitable for 
drug anchoring and release. These groups should be separated from the principal 
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chain by short side chains or spacers. The presence of spacers will serve to 
diminish the steric inaccessibility due to the polymeric backbone. By their nature, 
the spacers should be stable in the blood stream 79 but susceptible to either 
enzymatically catalyzed or pH-dependent hydrolysis in the lysosomal 
compartment 80. Likewise, polymeric carriers should display the ability to be 
directed to predetermined cell types. This can be achieved by the incorporation of 
targeting moieties such as cationic functions and antibodies 81. The presence of 
cationic functions, including tertiary amino groups, is required in the carrier 
backbone as this will facilitate adsorptive pinocytotic cell entry 82 and therefore 
prevent problems related to potential ionicity or polarity of the monomeric drug, 
and on the other hand, increase drug selectivity for the transformed cell, given that 
many types of cancer cell are characterized by negative surface charge. Also the 
macromolecular carrier should incorporate an interposition, between the spacer-
bearing units, of subunits lacking drug-binding abilities along the principal chain. 
This will prevent multifunctional drug binding by reducing spacer density in the 
molecule. 
 
3.1.2 Natural polymers as drug carriers. 
Natural polymers have the advantage of easy availability and biocompatibility, 
although their preparation may be restricted by the need for several purification 
steps, and their use is limited by their high immunogenicity. Many of them have 
been identified and have been or are being used as possible drugs or possess an 
intrinsic anticancer activity. Naturally occurring polymers such as Albumin, BSA, 
Chitins, and dextran have been successfully conjugated to doxorubicin 83, 84 and 
mitomycin 85, respectively. In general, these polymers being biodegradable owing 
to their natural origin, they will be excreted from the bloodstream by natural 
catabolic mechanisms. However, their use as drug carriers is often limited. 
Indeed, the substitution of natural macromolecules with covalently linked low-
molecular-weight drug molecules generally results in the hampering of the host’s 
ability to enzymatically degrade the polymeric carrier effectively 86. The loss of 
biodegradation ability into easily eliminated fragments leads to inhibition of 
elimination from the body.  
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Some synthetic macromolecules, including polylysine (PLL Mw = 5x106) 87, 
diethylaminoethyl-dextran (DEAE-dextran (Mw = 2x106), and poly (Arg-Gly-Asp) 
(Mw =10 000) 88, have shown intrinsic anticancer activity. They are termed 
polymer drugs, and their mechanism of action is either the direct action upon the 
tumor cell, or the stimulation of the host’s immune system 89. Some cytokines, 
topoisomerase inhibitors, monoclonal antibodies, thymic hormones, cell growth 
inhibitors, and enzymes 90 are among the natural and biological macromolecules 
possessing anticancer activity. The main problem associated with the 
administration of such natural macromolecules is their short intravascular half-
life, immunogenicity, and sometimes poor solubility 90. Their modification with 
synthetic macromolecules dramatically increases their therapeutic effectiveness. 
 
3.1.3 Synthetic polymers as drug carriers. 
The synthetic polymers used as drug carriers are tailor-made in accordance with 
the general requirements to be fulfilled by any polymer in an attempt to serve in a 
biological environment (section 3.1.1), especially their entire molecular-weight 
distribution must be under the kidney threshold (30 000 - 50 000) if they are not 
biodegradable. This will have the advantage of minimizing storage. Moreover, 
they must be designed in such a way as to be easily internalized by fluid-phase 
pinocytosis in order to prevent their non-specific re-uptake after being released 
into the bloodstream following cell death. Indeed, the absence of non-specific 
interactions with plasma membranes minimizes the probability of accumulation of 
the carrier in nontarget cells, and thus increases its biocompatibility. These 
synthetic polymers are categorized according to the chemical nature (e.g. 
polysaccharides, vinylic, acrylic polymers, poly(amino acids), etc.), the stability 
of the backbone, and the molecular weight. More interest was developed in the 
use of the synthetic polymers as drug carriers since Ringsdorf 91 proposed his 
model of water-soluble macromolecular prodrugs in the mid-Seventies. Ever since 
that time, numerous carrier types have been investigated including the poly(amino 
acids) and poly(amidoamines).  
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3.1.3.1 Amino acid polymers and copolymers 
 
In recent years, intensive studies of poly(amino acids) have been performed, 
motivated by the definite advantages these polymers have over other 
macromolecules generally used as drug carriers. Indeed, because of the 
proteinaceous structure imparted to them by the protein-like amide linkage, one 
assumes their easy cleavage to amino acids (in the body), which, being non-toxic, 
would be used as cellular nutrients. The first poly(amino acid) whose plasma 
expander property was investigated was poly(glutamic acid) 92. However, the 
results were not encouraging, the compound proved to be inefficient 93 and toxic 
94. The major cause of this was that at physiological pH the net charge exhibited 
was too high, and this was confirmed by the lower toxicity observed with the 
poly(glutamic acid-co-lysine) 95. Therefore, the interest for the preparation of 
uncharged poly(amino acids) as plasma expander rose. This was achieved by 
blocking the side carboxyl groups through amide linkage with an amino alcohol 
whose hydroxyl groups render the polymer water-soluble and at the same time 
eliminates the electrostatic interaction with cells and other components of the 
organism. The resulting poly([N5-(2-hydroxyethyl)-L-glutamine] (PHEG) proved 
to be more efficient, non-toxic, and non-immunogenic on animal testing 96, but 
from an economic viewpoint its large-scale production was found to be costly 97. 
In this respect, the synthesis of analogous derivatives of poly(aspartic acid) lent 
itself as an alternative. These derivatives are widely used, and exhibit special 
properties, such as biocompatibility, biodegradability, and non-toxicity. The 
potential of plasma expander properties of poly(aspartic acids) was revealed in 
1974 98 by Antoni and co-workers on their study of poly-α,β-(2-hydroxyethyl)-
DL-aspartamide (PHEA), and more recently with α, β-polyasparthydrazide 
(PAHy) 99. Many model polymeric drugs have been reported, such as PAHy-
Ofloxacin 99, and PHEA-L-dopa 100. The pulmonary absorption kinetics of a 
single molecular-weight distribution of fluorophore-labeled-PHEA, a hydrophilic 
and biocompatible synthetic polypeptide studied in isolated perfused rat lung 101, 
was also reported. Poly(aspartic acid)-derived cisplatin conjugates were prepared 
and in vitro cytotoxicity was studied 102. More recently 103, the synthesis and 
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biopharmaceutical characterization of four new PHEA-based polymers, which 
bear PEG as pendant groups, confirmed the retention of the suitable properties 
previously observed with PHEA, namely, biodegradability, solubility, 
multifunctionality, and biocompatibility. 
 
3.1.3.2 Poly(amidoamines)  
 
Poly(amidoamines) (PAAs) belong to the family of polymers characterized by the 
regular arrangement of amido groups and secondary (or/and tertiary) amines along 
the macromolecular chain. Pioneered by Ferruti 104, they are synthesized by 
polyaddition of primary monoamines or bis(secondary amines) to bisacrylamides. 
Since they bind tightly to heparin, PAAs were introduced in biomedical 
applications, initially as a heparin-adsorbing surface for medical devices (heparin 
renders the device non-thrombogenic) 105. PAAs were later proposed as 
particularly promising drug 105 and DNA 106 delivery carriers owing to their water 
solubility 105, biodegradability 107, conformation-changing ability with changing 
pH 108, and potentially low cytotoxicity compared with other synthetic polymers, 
e.g. poly-L-lysine 107. Furthermore, PAAs are also known to possess structure-
cytotoxicity relationships 107. They have both aminic and amidic sites in their 
backbones, and the polymers prepared, in general, are selected to incorporate 
several different variables to reinforce the aforementioned physicochemical 
properties. Using the pKa values of different PAAs, Ferruti demonstrated the 
basicity of the aminic nitrogen atoms of each repeating unit to be independent of 
the degree of protonation of the whole macromolecule. Thus, the main influence 
on polymer basicity is governed by the aminic moiety 105; therefore several 
different monoamines were incorporated. The purpose of monoamine 
incorporation was to ensure firstly higher basicity, as the mechanism of  a 
macromolecule cell entry, endocytosis, exposes it to pH changes, from pH 7.4 
extracellular to pH 5.5-6.5 within the endosomal-lysosomal system 109, and, 
secondly, increased water solubility. More recent review articles from Ferruti’s 
laboratory cover the synthesis of primary amine-functionalized PAAs 110, the 
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biomedical applications 111, and the correlation between physicochemical and 
biological properties 112 of the PAAs. 
3.1.4 Pharmacokinetic benefits of macromolecular prodrugs 
Ringsdorf’s model, as the possibility of drug delivery systems able to achieve 
both controlled release of the drug, through optimization of its pharmacokinetics, 
and drug targeting, through a moiety able to drive the carrier-bound drug to 
specific organs and tissues, rapidly became a primary goal, especially in cancer 
chemotherapy. Since then, polymers with varying chemical and biological 
properties have been investigated.  These included polymer carrier-bound drugs, 
where a physiologically active substance is bonded to a polymeric chain and so 
becomes a macromolecular prodrug. 
Most of the carriers utilized for drug anchoring are predominantly non-
biodegradable polymers of the polyvinyl class, dextran, antibodies and other 
proteins, as well as biodegradable synthetic polyamides and polyesters. 
Biomedical in vitro and in vivo evaluation has generally revealed a spectrum of 
promising activities against a large number of murine and human cancer lines, 
provided that the drug species are anchored via biofissionable links, preferably 
oligopeptide and other spacers. An overriding finding has been a marked 
reduction in toxicity, frequently coupled with enhanced cancer cell specificity and 
extended circulation half-lives. Selected conjugates have entered clinical trials, 
and among these, is a highly promising neocarcinostatin derivative 113. Some 
excellent review articles  114, 115, which cover the observed benefits of drug 
anchoring to polymeric carriers, the polymer-drug conjugation technology, and 
the drug anchoring concept, are available, as well as a large number of related 
reports 116-118 dealing with the polymer anchoring of doxorubicin, methotrexate, 
mitoxantrone and other “classical” anticancer agents. 
The main function of the conjugate resulting from the chemical (generally, 
reversibly covalent) bonding of bioactive agent to the carrier is seen to be a 
successful drug transport to the endoplasmic space (site of action in the 
chemotherapy of cancer), where the bioactive drug exerts its biological action 
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after release ensured either by passive hydrolysis or caused by a more specific 
mode including enzymatic or reductive or pH-controlled cleavage. Figure 3.1 
below illustrates a general scheme showing the principal configurations of a 
macromolecule-drug conjugate system. 
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A water-soluble polymer conjugate designed in full compliance with a variety of 
biomedical specifications will furnish some or all of the following 
pharmacokinetic advantages: 
 
(1) Efficacious drug distribution in the aqueous fluid system is ensured even for 
an intrinsically water-insoluble drug as the intravenously or intraperitoneally 
administered drug conjugate is carried immediately into the aqueous phase of the 
vasculature or the intraperitoneal cavity. Smooth drug dissipation serves to 
enhance bioavailability while reducing the risk of interception by the 
reticuloendothelial system. 
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(2) Easier endocytotic 119 (especially, pinocytotic) cell entry will be experienced 
by the water-soluble conjugate irrespective of the structural peculiarities of the 
drug, such as ionicity, polarity or electrical charge. Many common drug molecules 
are polar or salt-like, and thus encounter difficulties in membrane penetration and 
cell entry by the usual passive diffusion mechanism generally available to 
exogenous molecules. Unless associated with a specialized carrier-mediated 
transport system, such polar or salt-like molecules, therefore, fail to reach 
intracellular space effectively, and most of them will be wasted as medicinal 
agents. 
 
(3) Temporary protection from enzymatic attack, serum protein binding and 
other deleterious depletion mechanisms will be provided to the conjugate while 
circulating in the vascular system. As a result, premature drug losses through renal 
clearance and catabolic processes will be substantially reduced, and serum 
circulation life time will be extended with beneficial effects on the drug’s 
bioavailability. 
 
(4) In common with macromolecules in general, polymeric conjugates tend to 
accumulate in solid tumors as a consequence of the enhanced permeability and 
retention (EPR) 120effect, and thus benefit from a tumoritropic driving force. This 
effect results from enhanced intratumoral vascular permeability, which allows for 
considerable leakage of the polymeric molecules into the tumor tissue. Moreover, 
whereas in normal tissues, macromolecules in interstitial space are efficiently 
recovered by the lymphatic system, this lymphatic clearance is strongly retarded 
in tumorous tissue, adding to polymer accumulation in such tissue. 
3.1.5 Mechanism of cellular uptake of polymeric conjugates 
While low-molecular-weight drugs enter the cell interior by passive diffusion, 
macromolecules, on the other hand, get into the intracellular space by endocytosis, 
a common term encompassing phagocytosis and pinocytosis. Phagocytosis refers 
to the internalization of vesicular material by specialized cells (macrophages and 
monocytes), and pinocytosis involves the internalization of all solutes dissolved in 
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the extracellular fluid and any material adherent to the infolding cell surface 121. 
The polymer conjugate molecules are internalized by pinocytosis involving 
membrane invagination with concomitant capture of macromolecules, followed 
by transfer into the endosomal compartment of the cell. After a series of vesicle 
fusion events, most of molecules are directed into a secondary lysosomal 
compartment, thus ensuring continued exposure to acidic environment. However, 
because of its low permeability, the lysosomal membrane only allows the escape 
into the cytoplasm of low-molecular-weight compounds (including free drug) that 
are released from the polymeric conjugates as a consequence of lysosomal 
degradation. This renders the biodegradability of the spacer by lysosomal 
enzymes a prerequisite for lysosomotropic drug delivery. Endocytosis 
(pinocytosis) is macromolecule-structure-dependent. Thus, three types of 
endocytosis occur. These are:  
 
(a) Fluid-phase endocytosis. This mechanism takes place when the 
macromolecules do not interact with the cell surface; consequently, they are 
taken up slowly, depending on their concentration in the extracellular fluid. 
 
(b) Adsorptive endocytosis is specific to the macromolecule imparted with 
hydrophobic 122 and positively charged 82 moieties. Indeed, for this type of 
macromolecules, non-specific interactions with plasma membranes of 
different cells occur, resulting in concomitant increase in the rate of 
macromolecular uptake. 
 
(c) Receptor-mediated endocytosis, the rationale for the design of targetable 
polymeric carriers, occurs when moieties such antibody, antigens, and 
viruses are incorporated into the macromolecular structure. These moieties, 
which are complementary to cell surface receptors or antigens of a subset of 
cells, render the macromolecule biorecognizable 81. In the receptor-mediated 
endocytosis the macromolecule is specifically internalized by a select subset 
of cells, and the rate of uptake, as well as the body distribution, is 
substantially altered.  
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Non-biodegradable macromolecules accumulate within lysosomes, and are 
released slowly by exocytosis or as a consequence of cell death. Figure 3.2 
summarises the endocytic pathways. 
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Figure 3.2: Schematic representation of endocytic pathways and intracellular fate 
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3.1.6 Polymer-drug conjugation 
 
The drug systems submitted to investigation in the framework of this project have 
been conjugated to various polymeric carriers and the conjugation which is 
achieved by formation of either ester or amide biocleavable bond is extensively 
reported. 
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3.1.6.1 Polymer-MTX conjugation 
 
In an attempt to improve its therapeutic index, including the site-specific targeting 
or providing controlled release, MTX has been conjugated to biopolymers like 
mono- and polyclonal antibodies 123, 124, serum albumins 125, 126, neoglycoproteins 
127, chitosan 128. The conjugation of MTX to synthetic polymers has been 
extensively reported 129-131. These reports include investigation from this 
laboratory. Indeed, following Ringsdorf’s model of macromolecular prodrugs, 
MTX was conjugated to various polymeric carriers. In earlier project 130 
polyaspartamides were conjugated with MTX through tethers containing an ester 
group as the biofissionable site, and in a recent study 129 we prepared a series of 
related conjugates with biocleavable carboxamide links in the connecting spacer.  
 
3.1.6.2 Polymer-folic acid anchoring 
 
The potential use of cellular nutrients as mediators of macromolecular and 
colloidal particle uptake is appealing, since receptor-mediated endocytosis is a 
cellular process designed for transporting critical molecules across the plasma 
membrane into the cytoplasm 132. Rapidly-dividing cells express high affinities for 
folic acid because folate is an essential factor in purine, nucleotide, and DNA 
synthesis. Hence, the possibility exits of utilizing this pathway for promoting 
folate-linked molecules or colloidal particles to enter gastrointestinal (GI) 
epithelia. And, by virtue of its ability to be taken up by folate receptor 
overexpressed on certain tumor cells, folic acid has been widely investigated as a 
targeting molecule for active anticancer drug delivery. Proper synthesis 
procedures have been pointed out to link folic acid to drug carriers to produce 
targeting drug delivery systems. The folic acid molecule possesses two carboxyl 
groups, termed α- and γ-, which can act as handles for covalent attachment. 
However, according to literature, there is a stronger affinity of folate toward its 
receptor when linked via the γ-carboxyl group, whereas its α-carboxyl derivatives 
are not readily recognized 133. 
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Folate-induced receptor-mediated endocytosis has been extensively exploited to 
facilitate entry of anchored drugs 134, antibodies 135, imaging agents 136, liposomes 
137 or macromolecules 138, and proteins into cells.  Folate-conjugated proteins 
present the advantages of conceivably contacting and binding to all cells in a 
culture medium simultaneously. This avoids membrane damage or alteration as 
the macromolecular uptake occurs through a natural vitamin endocytosis pathway. 
Unlike hormone- or virus-mediated endocytosis, folate uptake occurs in all 
dividing cells, at reasonably rates, and folate is deposited into cytosolic rather than 
lysosomal compartments.  
 
3.1.6.3 Polymer-ferrocene conjugation 
 
The aforementioned considerations (Section 3.2.1.8) led to the strategy of 
conjugating the inherently hydrophobic ferrocene complex reversibly to water-
soluble macromolecular carriers. The reversible anchoring of the complex to the 
polymeric carrier can lead to considerably enhanced therapeutic effectiveness of 
the therapeutic agent, as crucially important factors combined to increase 
bioavailability at the target site while reducing toxicity and risk of resistance 
build-up. Following Ringsdorf’s model of macromolecular prodrugs, the 
ferrocene complex was conjugated to various polymeric carriers in Neuse’s 
laboratory. Conjugation was achieved with ferrocenylcarboxylic acids and either 
amine-functionalized carriers leading to amide-bonded 139 ferrocene conjugates, or 
hydroxyl-functionalized carriers affording ester-bonded 140 ferrocene conjugates. 
A more recent article from the same laboratory reported the cytotoxic activity of 
macromolecular ferrocene conjugates against Colo 320 DM human colon cancer 
line 141. In the present study, 4-ferrocenylbutanoic acid was anchored to polymers, 
using various approaches. 
 
3.1.7 Anticancer drug co-conjugation 
 
During the past decade, many research projects have focused on the sequential 
and simultaneous delivery of drug combinations to reduce the side effects 
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associated with the systemic delivery of anticancer agents 142. Several drugs have 
been found to amplify the anticancer activity of others 143. This synergistic effect 
can potentially lead to reduced doses for each drug administered 144. Hence, the 
simultaneously administration of several drugs could reduce the side effects 
caused by the high doses of single drug, and could prevent the development of 
multi-drug resistance (MDR) 145.  
An alternative approach to systemic delivery of antineoplastic agents is the 
localized release from a polymer. Various strategies can lead to the simultaneous 
and targeted delivery of a combination of anticancer drugs, and the use of 
hydrogels constitutes one of them. Bouchir et al.116 incorporated three model 
drugs, namely, methotrexate (antimetabolite), doxorubicin (anthracycline 
antibiotic), and mitoxantrone (anthracenedione antibiotic) into cross-linked 
oxidized alginate hydrogel and successfully released them from the polymer. The 
model antineoplastic agents were loaded into the hydrogel via three differents 
mechanisms. Methotrexate was incorporated within the pores of the hydrogel and 
was released by diffusion into the surrounding medium. Doxorubicin was 
covalently attached to the polymer backbone via hydrolytically labile linker and 
was released following the chemical hydrolysis of the linker. Mitoxantrone was 
ionically complexed to the polymer and was released after dissociation of the 
complex. Rao and co-worker 146 also reported the simultaneous incorporation and 
controlled release of methotrexate and cisplatin using the hydrogel approach. 
Another possible route for the simultaneous delivery of anticancer compounds is 
the co-conjugation of two or more of these agents to a single polymeric carrier via 
biofissionable linkages. Reports covering this approach are rare. However, the 
literature extensively reported the targeted delivery of a drug system in which a 
targeting moiety together with a drug is anchored to the same polymer backbone 
via biofissionable linkages 147, 148.    
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CHAPTER 4 
RESULTS AND DISCUSSION 
4.1 Polymeric Drug Carriers 
4.1.1 Introduction 
In fulfilment of the two objectives of this study, the synthesis by bioreversible 
conjugation of selected anticancer drug models with water-soluble 
macromolecular carriers and the biological activity evaluation of the resulting 
conjugates, and in accordance with the necessary prerequisites for any 
macromolecule intended to serve in the biomedical field (Section 3.1.1), an  
attempt was made to afford tailor-made drug carriers through the design and 
derivation of several synthetic polymeric structures. This was additionally 
motivated by the non-abundance of the naturally occurring counterparts and the 
possibility to impart the desired functions leading to the accomplishment of the 
goals. The polymeric carriers used for the anchoring of the selected drug models 
fell into the wide aliphatic polyamide type (schematized below) with subunits 
randomly distributed along the chain. 
CONH y
 FCONH x
 S
Figure 4.1: Structure of polyamide-type carrier
 
In this scheme, S represents an extra- or intra-chain hydrosolubilizing group 
required to impart water-solubility to the ultimate polymer-drug conjugate. S is a 
tertiary amine, hydroxyl or methoxy functionality.  
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F stands for an extra- or intra-chain functional group capable of reversible-drug 
anchoring. In this study, the primary amino group was adopted as the functional 
group of choice. This amino group leads to polymer-drug binding via amide bond 
formation. The amide bond has the ability to undergo biofission, which results in 
enzymatic activity in the intracellular lysosomal compartment, and causes drug 
release from the cytoplasmic space. Additional subunits of predetermined 
structures may be incorporated, if required, to afford tailor-made polymers that are 
equipped with all necessary functions. This allows efficacious administration and 
enhanced pharmacokinetics of the anticancer drug. 
 
All the drug systems used in the framework of this project are hydrophobic. 
Hence, the polymeric carriers were designed to provide a balance between the 
load of these inherently hydrophobic drugs and the solubilizing moieties on the 
polymer, because hydrophilic polymer-drug conjugates are required at varying 
concentration. The carriers designed were linear polyamides of different side 
chains but with similar drug anchoring capacity, the primary amino group. The 
side chains were tertiary amine-, hydroxyl- or methoxy-terminated. The choice of 
these structures was based on the following considerations: 
 
(a) The weight-average molecular weight, generally in the range of 20 000 - 30 
000, is sufficiently low to suppress (chain length-dependent) inherent 
polymer toxicity, but still high enough to retard renal clearance. The 
conjugates, therefore, enter cells easily owing to the enhanced permeability 
retention (EPR) effect.   
 
(b) The intrachain amide groups assist in gradual backbone cleavage for ease of 
catabolic elimination of the polymer in the “spent” state. The stereoisomeric 
“scrambling” of any peptide units in the backbone chain impedes unduly 
rapid α-peptidase-mediated “unzipping”, ensuring this fragmentation to be 
an appropriately retarded process. 
 
(c) Properly selected polyamides are essentially non-toxic, and immunogenicity 
of these synthetic polymers is expected to be appreciably lower in 
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comparison with that commonly occurring with high-molecular-weight 
proteinaceous biopolymers. 
 
(d) The S-modified subunits can be easily introduced as majority components (x 
> y), thus ensuring effective insulation of the F-modified subunits from each 
other. This will reduce the risk of intramolecular interaction of adjacent 
conjugated drug species. 
 
(e) Tertiary amine functions can be introduced as side groups to provide the 
special functions of adsorptive pinocytotic cell entry and target cell affinity. 
 
(f) While inherently water-soluble, with S comprising selected amine or 
hydroxyl functions, the polyamides can be made to acquire additional 
solubility in methanolic medium. This can be achieved by incorporation of 
poly(ethylene oxide) (PEO) side chains as additional solubilizing groups. 
This added solubility feature will be advantageous in follow-up reactions in 
alcoholic media. 
 
(g) When synthesized from amino acid monomers, the polyamide carrier will 
provide vitally required nutrients for the rapidly growing cell tissue, and 
hence may be preferentially taken up by the cancerous cell.  
 
The option of a polymeric carrier bearing extra-chain functional groups for drug 
species anchoring was adopted in this project. The adoption was based on a 
commonly observed phenomenon that fissionable groups as main chain 
components are generally less prone to cleavage than the same type of groups 
located more accessibly in side chains. 
  
Two classes of polyamide conforming to the basic carrier model (Figure 4.1), 
namely, polyaspartamide (PAsA) and poly(amidoamines) (PAAs) were used for 
drug conjugation by amide bond formation between the carriers and the 
carboxylic acid-functionalized drugs. The primary amine functional groups of 
these polymers were introduced as terminals in component F.  
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The subunits incorporating this binding site form 10 to 20 mol-% of the chains, 
leaving 90 and 80 mol-% of S-labelled subunits of the tert-amine, hydroxyl or 
methoxy types for hydrosolubilization. The choice of the compositional 
specification was based on the necessity to restrict drug loading to levels 
commensurate with retention of water solubility of the resulting conjugates. 
Indeed, experiments with carrier containing larger mole percentages of F-labelled 
subunits had previously demonstrated the need for utilization of a 
disproportionately large excess of drug in the feed for complete drug 
incorporation. In addition, the coupling products so obtained had displayed a 
propensity for branching and crosslinking with concomitantly decreasing 
solubility once they had been isolated in the solid state. All polymeric carriers 
were fractionated by dialysis to remove constituents with molecular weight 
substantially below 25 000.    
 
4.1.2 Polyaspartamide carriers (PAsA) 
 
The potential value of polysuccinimide-derived aspartamide polymeric carriers for 
biomedicinal agents was revealed by Drobnik 149, and his proposal was 
subsequently translated, in this laboratory, to the reality of a class of eminently 
functional carriers for a variety of antineoplastic drug systems that include those 
submitted to our investigation. The polyaspartamides were prepared from 
polysuccinimide. 
 
4.1.2.1 Synthesis of polysuccinimide (PSI) 
 
The literature reported two different methods for the synthesis of polysuccinimide 
(PSI). These are the polymerization of N-carboxyanhydride of α-amino acid in 
general (NCA method) 150 and the thermal phosphoric acid- catalyzed 
polycondensation of aspartic acid (Neri method) 151. The NCA method was found 
to be disadvantageous both in cost and production as the pendent reactive groups 
carried by the amino acid had to be protected before polymerization, and then 
deprotected under harsh conditions to give poly (amino acid). In addition, the 
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management of large amounts of phosgene, diphosgene or triphosgene, a reagent 
widely used for the synthesis of N-carboxyanhydride, raised complex safety 
problems in a large-scale plant. On contrary, the Neri method is reported to 
deliver high molecular weight PSI in one step 152. 
In light of these considerations, the Neri method was the approach adopted for the 
synthesis of poly-DL-succinimide from DL- aspartic acid as shown in Scheme 
4.1. The crude polymer was treated with dicyclohexylcarbodiimide (DCC) 
coupling agent for further chain extension purposes. A representative polymer had 
a relative viscosity of 35 mL g-1 in DMF at 30 oC, which corresponds to a weight- 
average molecular weight of 32 000. 
NH2
O
O
OH
OH
N
O
O
*
x
 
DL-aspartic acid Poly-DL-succinimide
H3PO4 (85%)
210 - 180 oC
Scheme 4.1: Synthesis of polysuccinimide (PSI)
 
The 1H NMR spectrum of PSI in DMSO-d6 showed a large resonance at 5.2 ppm 
corresponding to the methine proton (NCO-CH). The methylene protons (CH2CH) 
are seen as two peaks of roughly equal intensity at 3.3 and 2.6 ppm. 
4.1.2.2 Preparation of homopoly (α, β-DL-aspartamides) 
In general, polyaspartamides are readily prepared from poly DL-succinimide by 
an aminolytic ring-opening process in anhydrous, dipolar aprotic medium, such as 
N,N-dimethylformamide (DMF) at 0-25 oC. The product is racemic and possesses 
both α- and β-peptidic repeat units. Scheme 4.2 shows the preparation of 
homopoly(α,β-DL-aspartamides) by the poly-DL-succinimide aminolytic ring-
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opening process using one type of amine reactant. For convenience, only the α-
forms of polyaspartamide will be depicted in further schematic diagrams.  
NH
O
O
x
 
CONH
CONH R
m
 
CONH
CONH
R
n
 
R NH2
Scheme 4.2: Preparation of homopoly(α, β-DL-aspartamides)
α-peptide β-peptidePSI
DMF, 0-25 0C
 
While D-type polymers are resistant to enzymatic cleavage, L-type polymers are 
more prone to rapid enzymatic degradation. Therefore, a backbone structure of the 
DL-racemic mixture will ensure retarded enzymatic cleavage and ultimate 
backbone degradation as a result of hydrolytic cleavage.  
4.1.2.3 Preparation of copolyaspartamides (PAsA) 
Aminolytic ring-opening of polysuccinimide can lead to the generation of 
copolyaspartamides through a stepwise process which involves utilization of two 
or more different amine reactants in given stoichiometric feed ratios. Thus, H2N-R 
and H2N-R´-NH2 were used sequentially to form polyaspartamides, in which the 
subunits featured R and R´-NH2 in predetermined ratios along the chain. In the 
framework of this project, a series of random copolyaspartamides of the general 
type depicted in Scheme 4.3 were prepared as drug carriers. In this scheme and 
the subsequent schemes, the end groups (generally of the amine- and carboxyl-
types) were neglected. The methods of synthesis were adopted from the literature. 
In some cases, unpublished procedures developed previously in this laboratory 
were used. In the schematic copolyaspartamide model, the group R (tertiary 
amine, hydroxyl or methoxy) has a hydrosolubilizing function while the primary 
amino group that is covalently attached to the R´ group has a drug-anchoring 
function, and is also used as a spacer segment. 
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NH
O
O
x
 
* NH CH CO
CONH x
 NH CH CO
CONH y
 
R R'
NH2
Scheme 4.3: Preparation of copolyaspartamide (PAsA)
DMF, 0-25 0C
1.  H2N-R
2.  H2N-R'-NH2
+ y
 
The diamine (H2N-R´-NH2) could, by its nucleophilic difunctionality, lead to 
irreversible crosslinking during the aminolytic ring opening process. However, the 
operational conditions developed in this laboratory led to complete PSI ring 
opening with no evidence of irreversible crosslinking. 
The adsorptive endocytotic cell entry of a prodrug 63 is influenced deeply by its 
ability to undergo protonation in physiological conditions (pH~7.4). Therefore, 
the copolyaspartamides synthesized in this study were classified into two 
categories, based on their protonation potential. Thus, the first category comprises 
the copolyaspartamides containing tertiary amine-terminated side chains, and the 
second category those bearing hydroxyl- or methoxy-terminated side chains. 
Copolyaspartamides containing tertiary amine-terminated side chain: Their 
composition is shown in Table 4.1. The ratios in parentheses denote the molar 
percentage (x: y) of the respective constituents in the chains of these polymers and 
all subsequent carriers and conjugates. 
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Table 4.1: Composition of PAsA containing tertiary amine-terminated side chain 
* NH CH CO
CONH x
 NH CH CO
CONH y
 
R'
NH2
R
1 (90:10)-7 (90:10)
 
 
Carriers 
 
 
R 
 
R´ 
 
x/y  
 
1 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3- 
 
9 
 
2 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3- 
 
4 
 
3 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 NH(CH2)2- 
 
9 
 
4 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 NH(CH2)2- 
 
4 
 
5 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
9 
 
6 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
4 
 
7 (90:10) 
 
-(CH2)3N(CH3)2 
 
-CH2CHOHCH2- 
 
9 
 
As can be seen in Table 4.1, these copolyaspartamides are all 3-(N,N-
dimethylamino)propylamine (DMP)-based. The tertiary amine group acts as both 
hydrosolubilizing and cell-selecting group. Many considerations supported the 
choice of this group from all those investigated in this laboratory 153. First, as a 
strong base per se, it is readily protonated even under weakly basic conditions. 
Secondly, in this protonated state, the amino group, more cationic and positively 
charged, will preferentially approach surfaces of certain types of cancer cells that 
are negatively charged. This will favor the adsorptive pinocytotic cellular uptake 
of the macromolecules as reported by Shen 154. 
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In accordance with the general principle stressed in section 4.1.1, DMP was used 
as a major reactant (x > y) in the two-step preparative process of these polymers. 
The first step is the reaction in anhydrous conditions between a given amount of 
polysuccinimide and its corresponding R-NH2 counterpart. This reaction, based 
on the desired x/y feed ratio, is performed at room temperature.  
In the second step, the resulting mixture is added to a large excess of a solution 
NH2-R´-NH2, and the reaction is continued for 24h. This was a comparatively 
long enough time to ensure full reactivity of the diamine. The relative amount of 
NH2-R´-NH2 (3-fold stoichiometric amount) was necessary to achieve the desired 
percentage incorporation with complete ring opening and substitution of the 
remaining succinimide units of the substrate polymer without causing crosslinking 
through involvement of the terminal amino group. The diamine nucleophiles NH2-
R´-NH2 used throughout this project are exemplified by 1,3-propylenediamine 
(PDA); diethylenetriamine (DET); 2,2´-(ethylenedioxy)diethylamine (EDDA) and 
1,3-diamino-2-propanol (DAP). EDDA introduced a relatively long spacer 
between the main chain and the drug-anchoring site. 
In order to avoid unwanted hydrolytic ring opening resulting in the generation of 
free carboxylic acid side groups, both steps were performed under strictly 
anhydrous conditions. 
The polymeric products were isolated as completely water-soluble solids by a 
series of operations which involved precipitation with an adequate non-solvent, 
aqueous dialysis (in tubing with 25 000 molecular weight cut-off limit), and 
freeze-drying. As a consequence of the crude fractionation achieved by this 
dialysis step, yields did not exceed 75%, generally ranging from 52% to 72% 
(Table 4.2). The inherent viscosities (ŋinh) ranged from 10 to 20 mL g-1, with small 
differences when compared with each another (Table 4.3). 
 
The solid-state IR spectra of polymers 1-7 revealed a tertiary amine band at 1400-
1340 cm-1 as well as a weak methyl band at 1460 cm-1 corresponding to N(CH3)2. 
The amide I band is remarkable in the region 1680-1610 cm-1, and the band at 
1580 cm-1 corresponds to amide II. Both spectra of 5 and 6 exhibited a strong 
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asymmetric band at 1060 cm-1 corresponding to ether band of EDDA. The OH 
band of DAP is also visible as a broad band in the region 3400-3200 cm-1. 
The 1H NMR spectra of polymers 1-7 measured in D2O, and recorded at pH 10-11 
for elimination of protonation effects, showed characteristic band groups, some of 
them containing overlapping signals. Thus, the CH (methine) signal of aspartic 
appeared in the region of 4.75-4.5 ppm; CH2-O (methylene) and CH-OH 
(methine) signals were grouped in the region of 3.7-3.6 ppm. The methylene 
protons of CONH-CH2 were found in the region of 3.5-3.0 ppm. Proton signals of 
CO-CH2, CH2-N (CH3)2, CH2-NH, and CH2-NH2 groups were superposed in the 
region of 2.9-2.0 ppm. Methylene protons of CH2CH2CH2 groups were in the 1.8-
1.5 ppm region. 
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Table 4.2: Summary of preparative data for PAsA containing tertiary amine-terminated side chain      
 
 
 
 
 
Parenthetic numbers indicate the number of moles of amino compound per 100 base moles of poly-DL-succinimide.  
DMP = 3-(N, N-dimethylamino)propylamine, PDA = 1,3-propylenediamine, DET = Diethylenetriamine, EDDA = 2,2´-(ethylenedioxy)diethylamine,  
DAP = 1,3-diamino-2-propanol. 
b Mole ratio (used) of hydrosolubilizing to drug-anchoring groups. 
c RT= room temperature; reaction step sequence in parentheses. 
d Polymer yield after ultimate (25 000 molecular weight cut-off) dialysis. 
 
 
Reactants in feed (mol-%) a 
 
 
PAsA carriers 
 
R-NH2 
 
H2N-R´-NH2 
 
Mole ratio 
x/y b 
 
 
 
Reaction conditions c 
 
 
Yield 
(%) d 
 
Designation 
 
DMP (90) 
 
PDA (30) 
 
9 
 
(1) 10h, RT; (2) 4h-0oC then 24h, RT 
 
52 
 
1 (90:10) 
 
DMP (80) 
 
PDA (60) 
 
4 
 
                              ´´           
 
72 
 
2 (80:20) 
 
DMP (90) 
 
DET (30) 
 
9 
 
                              ´´           
 
52 
 
3 (90:10) 
 
DMP (80) 
 
DET (60) 
 
4 
 
                              ´´           
 
59 
 
4 (80:20) 
 
DMP (90) 
 
EDDA (30) 
 
9 
 
                              ´´           
 
61 
 
5 (90:10) 
 
DMP (80) 
 
EDDA (60) 
 
4 
 
                              ´´           
 
57 
 
6 (80:20) 
 
DMP (90) 
 
DAP (30) 
 
9 
 
                              ´´           
 
54 
 
7 (90:10) 
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Table 4.3: 1H NMR and viscometric results for PAsA containing tertiary amine-terminated side chain 
     
 
 
PAsA carriers 
 
 
Designation 
  
η inh  
(mL g-1) a 
 
x/y b
 
Base 
molecular 
weight c 
 
Number of protons counted d (expected) e 
 
chemical shift (ppm) 
  
 δ 4.75-4.4 f         δ 3.7-3.5           δ 3.5-3.0            δ 2.9-2.0          δ 1.8-1.5 
 
1 (90:10) 
 
11.61 
 
9 
 
1964.5 
     
   10(10)                                         20(20)                 94(94)             20(20)   
 
2 (80:20) 
 
14.47 
 
4 
 
968.2 
        
       5(5)                                         10(10)                 44(44)             10(10) 
 
3 (90:10) 
 
10.24 
 
9 
 
1993.5 
   
   10(10)                                         20(20)                 98(98)             18(18) 
 
4 (80:20) 
 
16.99 
 
4 
 
997.2 
        
       5(5)                                         10(10)                 48(48)                 8(8) 
 
5 (90:10) 
 
10.57 
 
9.1 
 
2038.5 
       
    9(10)                9(8)                   20(20)                 94(94)             18(18)    
 
6 (80:20) 
 
20.14 
 
4.2 
 
1042.3 
        
      4(5)                 7(8)                   11(10)                 43(44)                8(8) 
 
7 (90:10) 
 
13.25 
 
9 
 
1980.5 
 
   10(10)                1(1)                   21(20)                 95(94)             18(18)   
 
a At 30.0 ± 0.5 o C, in deionized H2O; concentration c = 2 mg/mL. 
b Mole ratio (found) of hydrosolubilizing to drug-anchoring groups after 1H NMR integration. 
c Molecular weight of the simplest recurring unit (normalized to y=1) rounded off to the nearest integer. 
d In D2O,  pH 10-11, chemical shifts, δ/ppm, referenced against internal sodium 3-trimethylsilyl-2,2,3,3-d4-propionate; integration error limits ± 12%.  
Protons are calculated (figures rounded off to the nearest integer) on basis of found x/y ratios. 
e Expected count for composition in accordance with recurring unit (see b). 
f Assignment: δ/ppm: 4.75-4.5 (CH Asp); δ 3.7-3.6 (CH2-OH; CH-OH); 3.5-3.0 (CONH-CH2); 2.9-2.0 (CO-CH2, CH2-N(CH3)2, CH2-NH, CH2-NH2), 1.8-1.5 (CH2CH2CH2). 
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From the 1H NMR data of the polymers 1-7 (compiled in Table 4.3), we deduced 
that the x/y ratios of hydrosolubilizing to drug-binding groups were in excellent in 
agreement with the proposed structures. This proves the efficacy of the 
preparative procedure. 
  
Copolyaspartamides containing hydroxyl- or methoxy-terminated side chain: 
Table 4.4 shows the composition of the copolyaspartamides with hydroxyl- or 
methoxy-terminated side chain acting as hydrosolubilizing groups.  
 
Table 4.4: Composition of PAsA containing hydroxyl- or methoxy-terminated 
side chain  
 
* NH CH CO
CONH x
 NH CH CO
CONH y
 
R'
NH2
R
8 (90:10)-20 (90:10)
 
 
 
Carriers 
 
 
R 
 
R´ 
 
x/y  
 
8 (90:10) 
 
-(CH2)2OH 
 
-(CH2)2 NH(CH2)2- 
 
9 
 
9 (80:20) 
 
-(CH2)2OH 
 
-(CH2)2 NH(CH2)2- 
 
4 
 
10 (90:10) 
 
-(CH2)2OH 
 
-CH2CHOHCH2- 
 
9 
 
11 (90:10) 
 
-(CH2)2OH 
 
-(CH2)3- 
 
9 
 
12 (90:10) 
 
-(CH2)2OH 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
9 
 
13 (90:10) 
 
-(CH2)2 O(CH2)2OH
 
-(CH2)2 NH(CH2)2- 
 
9 
 
14 (80:20) 
 
-(CH2)2 O(CH2)2OH
 
-(CH2)2 NH(CH2)2- 
 
4 
 
15 (90:10) 
 
-(CH2)2 O(CH2)2OH
 
-(CH2)3- 
 
9 
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Table 4.4 continued 
 
Carriers 
 
 
R 
 
R´ 
 
x/y  
 
16 (90:10) 
 
-(CH2)2 O(CH2)2OH
 
-CH2CHOHCH2- 
 
9 
 
17 (90:10) 
 
-(CH2)2OCH3 
 
-(CH2)2 NH(CH2)2- 
 
9 
 
18 (80:20) 
 
-(CH2)2OCH3 
 
-(CH2)2 NH(CH2)2- 
 
4 
 
19 (90:10) 
 
-(CH2)2OCH3 
 
-(CH2)3- 
 
9 
 
20 (90:10) 
 
-(CH2)2OCH3 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
9 
 
The major components of these polymers (x > y) are either hydroxyl- or methoxy-
functionalized. These components are unable to undergo protonation under 
physiological conditions, and will rather favor a fluid-phase pinocytotic cell entry 
of the macromolecules as opposed to the adsorptive-pinocytosis observed with the 
tertiary amine-terminated polymers. This enables a comparison of cytotoxic 
activity of the ultimate prodrugs via these different hydrosolubilizing groups as 
the spacer segments are identical in both categories of copolyaspartamides. 
The hydroxyl- and methoxy-terminated amines used as reactants are represented 
by ethanolamine (EA), aminoethoxyethanol (AEE), and methoxyethylamine 
(MEA), respectively.  
 
The aminolysis of polysuccinimide leading to the formation of these 
copolyaspartamides occurred in two steps as depicted in the general Scheme 4.3. 
In the first step, PSI was allowed to react with R-NH2 in a selected feed molar 
ratio (x/y) for 24h period. The longer reaction period, in comparison with that for 
DMP-based copolymers, was motivated by the influence of the basicity on the 
rate of PSI aminolysis 155. The R-NH2 reactants being weakly acidic, are expected 
to react more slowly, therefore, a longer period is required to ensure PSI ring-
opening to the desired extent. In the second step, the resulting mixture was added 
to a solution of NH2-R´-NH2 (3-fold stoichiometric amount) and the reaction was 
continued in the same conditions as for the first category of polyaspartamides. 
These copolyaspartamides, worked up similarly to preceding polymeric carriers, 
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were obtained in yields ranging from 50 to 70% and possessed inherent viscosities 
in the range of 11 to 18 mL g-1. 
 
The solid-state IR spectra of polyaspartamides 8-16 revealed a broad band in the 
region 3400-3200 cm-1, which is attributable to the OH group. Polymers 8-20 
showed a broad amide I band in the region 1680-1610 cm-1. The presence of an 
amide II band is also noticeable at 1530 cm-1. Polymers 13-20 showed a strong 
asymmetric ether band at 1060 cm-1. 
 
The 1H NMR spectra (400 MHz) of these polymers, measured in D2O solutions, 
were recorded at pH 10-11 in order to preclude any protonation effects. They 
showed several groups of bands, which were occasionally superimposed upon 
each other. Prominent band groups were in the regions of 4.75-4.5 ppm (CH Asp), 
3.7-3.6 ppm (CH2-O, CH-OH, OCH3), 3.5-3.0 ppm (CONHCH2), 2.9-2.0 ppm 
(COCH2, CH2NH, CH2NH2), 1.8-1.5 ppm (CH2CH2CH2). 
 
From 1H NMR data of the polymers 8-20 (complied in Table 4.6); we deduced 
that the x/y ratios of hydrosolubilizing to drug-binding groups correlated with the 
proposed structures.
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Table 4.5: Summary of preparative data for of PAsA containing hydroxyl- or methoxy-terminated side chain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reactants in feed (mol-%) a 
 
 
R-NH2 
 
 
H2N-R´-NH2 
 
Mole ratio 
x/y b 
 
 
Reaction conditions c 
 
 
Yield 
(%) d 
 
Designation 
 
EA (90) 
 
DET (30) 
 
9 
 
(1) 24h, RT; (2) 4 h-0oC then 24h, RT 
 
65 
 
8 (90:10) 
 
EA (80) 
 
DET (60) 
 
4 
 
´´ 
 
68 
 
9 (80:20) 
 
EA (90) 
 
DAP (30) 
 
9 
 
´´ 
 
68 
 
10 (90:10) 
 
EA (90) 
 
PDA (30) 
 
9 
 
´´ 
 
69 
 
11 (90:10) 
 
EA (90) 
 
EDDA (30) 
 
9 
 
´´ 
 
74 
 
12 (90:10) 
 
AEE (90) 
 
DET (30) 
 
9 
 
´´ 
 
68 
 
13 (90:10) 
 
AEE (80) 
 
DET (60) 
 
4 
 
´´ 
 
70 
 
14 (80:20) 
 
AEE (90) 
 
PDA(30) 
 
9 
 
´´ 
 
62 
 
15 (90:10) 
 
AEE (90) 
 
DAP (30) 
 
9 
 
´´ 
 
63 
 
16 (90:10) 
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Table 4.5 continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Parenthetic numbers indicate the number of moles of amino compound per 100 base moles of poly-DL-succinimide.  PDA = 1,3-propylenediamine,  
DET = diethylenetriamine; EA = ethanolamine, MEA = 2-methoxyethylamine, DAP = 1,3-diamino-2-propanol, EDDA = 2,2´–(ethylenedioxy)diethylamine. 
b Mole ratio (used) of hydrosolubilizing to drug-anchoring groups. 
c RT= room temperature; reaction step sequence in parentheses. 
d Polymer yield after ultimate (25 000 molecular weight cut-off) dialysis. 
 
 
 
 
 
 
Reactants in feed (mol-%) a 
 
 
R-NH2 
 
 
H2N-R´-NH2 
 
Mole ratio 
x/y b 
 
 
Reaction conditions c 
 
 
Yield 
(%) d 
 
Designation 
 
MEA (90) 
 
DET (30) 
 
9 
 
(1) 24h, RT; (2) 4 h-0oC then 24h, RT 
 
54 
 
17 (90:10) 
 
MEA (80) 
 
DET (60) 
 
4 
 
´´ 
 
66 
 
18 (80:20) 
 
MEA (90) 
 
PDA (30) 
 
9 
 
´´ 
 
71 
 
19 (90:10) 
 
MEA (90) 
 
EDDA (30) 
 
9 
 
´´ 
 
55 
 
20 (90:10) 
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Table 4.6: 1H NMR and viscometric results for PAsA containing hydroxyl- or methoxy-terminated side chain 
 
 
 
PAsA carriers 
 
 
 
Designation 
 
 
 
η inh 
(mL g-1) a 
 
 
x/y b
 
Base 
molecular 
weight c 
 
Number of protons counted d (expected) e 
 
chemical shift (ppm) 
 
 δ 4.75-4.4 f         δ 3.7-3.6           δ 3.5-3.0            δ 2.9-2.0    δ 1.8-1.5 
 
8 (90:10) 
 
16.2 
 
9 
 
1623.7 
     
      10(10)            18(18)               20(20)                 26(26)                    
 
9 (80:20) 
 
15.5 
 
4 
 
832.9 
    
         5(5)                 8(8)               10(10)                  16(16)                    
 
10 (90:10) 
 
12.75 
 
9 
 
1610.7 
 
      10(10)             20(19)              20(20)                  22(22)                    
 
11 (90:10) 
 
12.05 
 
9 
 
1594.6 
 
      10(10)             18(18)              20(20)                  22(22)          2(2) 
 
12 (90:10) 
 
13.45 
 
9 
 
1668.7 
 
      10(10)             24(24)              20(20)                  22(22) 
 
13 (90:10) 
 
14.02 
 
9 
 
2020.1 
 
      10(10)             54(54)              20(20)                  26(26) 
 
14 (80:20) 
 
12.08 
 
4 
 
1009.1 
 
          5(5)             37(36)              10(10)                  16(16) 
 
15 (90:10) 
 
11.54 
 
9 
 
1991.1 
 
         9(10)            55(54)              20(20)                  22(22)          2(2) 
 
16 (90:10) 
 
11.28 
 
9 
 
2007.7 
 
       10(10)            54(55)              20(20)                  22(22)                    
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Table 4.6 continued 
 
 
 
PAsA carriers 
 
 
 
Designation 
 
 
 
η inh  
(mLg-1) a 
 
 
x/y b 
 
Base 
molecular 
weight c 
 
Number of protons counted d (expected) e 
 
chemical shift (ppm) 
 δ 4.75-4.4 f       δ 3.7-3.6           δ 3.5-3.0          δ 2.9-2.0      δ 1.8-1.5 
 
17 (90:10) 
 
18.43 
 
9 
 
1750 
 
       10(10)          45(45)              20(20)               25(26) 
 
18 (80:20) 
 
17.31 
 
4 
 
889 
 
           5(5)          20(20)              10(10)               16(16) 
 
19 (90:10) 
 
15.45 
 
9 
 
1720.9 
 
        10(10)         45(45)              20(20)               22(22)           2(2) 
 
20 (90:10) 
 
14.85 
 
9 
 
1795 
 
        10(10)         53(53)              20(20)               22(22)                 
 
a At 30.0 ± 0.5 o C, in deionized H2O; concentration c= 2 mg/mL. 
b Mole ratio (found) of hydrosolubilizing to drug-anchoring groups after 1H NMR integration. 
c Molecular weight of the simplest recurring unit (normalized to y=1) rounded off to the nearest integer. 
d In D2O, pH 10-11, chemical shifts, δ/ppm, referenced against internal sodium 3-trimethylsilyl-2,2,3,3-d4-propionate; integration  
error limits ± 12 %.  Protons are calculated (figures rounded off to the nearest integer) on basis of found of x/y ratios. 
e Expected count for composition in accordance with recurring unit (see b). 
f Assignment: δ/ppm: 4.75-4.5 (CH Asp); 3.7-3.6 (CH2O; CHOH; OCH3 ); 3.5-3.0 (CONHCH2); 2.9-2.0 (COCH2, CH2NH, CH2NH2), 1.8-1.5 (CH2CH2CH2).
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Characterization data of a dozen of copolyaspartamide carriers by gel permeation 
chromatography (GPC) (performed generously by an outside institution) are 
compiled below.  
 
Table 4.7: Gel permeation chromatography a characteristics of PAsA 
 
 
Designation 
 
η inh 
(mL g-1) 
 
Mw c x10-3  
 
 
Mn b x10-3 
 
 
I nd 
 
1 (90:10) 
 
11.61 
 
25.28 
 
12.33 
 
2.05 
 
2 (80:20) 
 
14.47 
 
27.64 
 
12.23 
 
2.26 
 
3 (90:10) 
 
10.24 
 
22.56 
 
12.19 
 
1.85 
 
4 (80:20) 
 
16.99 
 
28.36 
 
11.34 
 
2.5 
 
5 (90:10) 
 
10.57 
 
24.48 
 
11.54 
 
2.12 
 
6 (80:20) 
 
20.14 
 
54.85 
 
30.47 
 
1.8 
 
7 (90:10) 
 
13.25 
 
17.86 
 
12.85 
 
1.39 
 
8 (90:10) 
 
16.2 
 
28.28 
 
23.56 
 
1.2 
 
9 (80:20) 
 
14.02 
 
54.0 
 
25.71 
 
2.1 
 
10 (90:10) 
 
18.43 
 
31.07 
 
20.99 
 
1.48 
 
13 (90:10) 
 
11.54 
 
54.48 
 
20.3 
 
2.71 
 
14 (80:20) 
 
17.31 
 
29.4 
 
15.55 
 
1.89 
 
a Performed using sepharose 6 gel, at a flow rate of 0.5ml/min, in a buffer solution of 0.3 
M sodium acetate and 0.5 g NaN3, pH 6.5. 
b Mw= weight-average molecular weight.  
c Mn = number-average molecular weight.  
d In= Mw/ Mn, polydispersity index. 
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These results showed that the weight-average molecular weight of the 
copolyaspartamides was, for the most part, in the 20 000 - 30 000 range. This was 
in accordance with the biomedical requirement that the average molecular weight 
of the polymeric carrier should be sufficiently low to suppress inherent polymer 
toxicity, as well as high enough to retard renal clearance (Section 4.1).  
The polydispersity indices were in the range of 1.2 to 2.7. The relation between 
inherent viscosity and molecular weight (Figure 4.2) revealed large differences in 
the stiffness of these copolyaspartamides. The trend of increasing viscosities did 
not always match an increase in Mw. Typically, polymer 7 (Mw = 17 860) 
displayed a higher viscosity (13.25 mL g-1) than polymer 13 (Mw = 54 480, and 
viscosity = 11.54 mL g-1). The difference in the stiffness could be explained either 
by hydrolytic cleavage or aggregation in the polymeric chain. However, no further 
investigation was performed to elucidate these peculiar differences. 
 
Figure 4.2: Inherent viscosity (η inh) versus Mw of PAsA
15
25
35
45
55
10 14 18 22
 η inh (mL g-1)
M
w
 1
0-
3
 
 
4.1.3 Poly(amidoamine) carriers (PAAs) 
 
Interest in the study of poly(amidoamines), pioneered by Ferruti 104, 105, 107-109, 110-
112 was prompted by the need for polymeric carriers that provide primary amino 
groups as side chain terminal for drug anchoring while possessing complete 
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solubility in both aqueous and organic media, and more critically in methanolic 
media. This led to the synthesis, by a Michael addition mechanism, of 
bisacrylamide-derived polymers that contain various solubilizing groups as side-
chain or main-chain components in addition to short side chains which possess 
primary amine functionality as the drug conjugation site.  
 
Methylenebisacrylamide (MBA), used in earlier 109, 156 and more recent 157 
investigations from this laboratory, was chosen as the bifunctional acrylic acid 
derivative, which had to be copolymerized in various feed ratios with 
functionalized monoamines and diamines mono-N-protected by tert-
butoxycarbonyl (Boc) substituent. Deprotection of the primary amino groups with 
trifluoroacetic acid afforded the target polymers. 
 
4.1.3.1 Preparation of mono-N-Boc-protected primary diamine 
 
Ethylenediamine (EDA), 1,3-propylenediamine (PDA), diethylenetriamine 
(DET), and 2,2´-(ethylenedioxy)diethylamine (EDDA) are four diamine 
derivatives selected to be mono-N-protected with tert-butoxycarbonyl substituent. 
They were chosen as short-chain aliphatic spacers designed to provide spacing 
between main chain and the drug. Moreover, the choice of the protecting group, 
Boc, was motivated by its easy removal by trifluoroacetic acid 158 in a short period 
that is enough to avoid hydrolytic cleavage of the ultimate polyamidoamine.  
 
As an example, Boc-PDA, compound 22, was prepared in a pure state by reacting 
di-tert-butyl dicarbonate, (Boc)2O, with a large excess of PDA dissolved in 
dioxan, followed by filtration of disubstitued-diamine upon addition of water. 
This was followed by extraction of the filtrate with dichloromethane, and 
evaporation of the combined extracts to dryness in vacuo. Scheme 4.4 depicts the 
preparation of the mono-N-Boc-protected primary diamines used in this study, 
and the experimental conditions are summarized in Table 4.8. The yields ranged 
from 85 to 93%. The 1H NMR data of the mono-N-Boc-protected primary 
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diamines (Table 4.9) satisfactorily confirmed the assigned structures of these 
compounds. 
 
N
H
R' NH2CH3
CH3
CH3
O
O
CH3
CH3
CH3
O O
O O
O
CH3
CH3
CH3
(Boc)2O
Scheme 4.4: Synthesis of  mono-N-Boc-protected primary diamines
21   R':   -CH2-CH2-   Boc-EDA
22   R':   -CH2-CH2-CH2-   Boc-PDA
23   R':   -CH2-CH2-NH-CH2-CH2-   Boc-DET
24   R':   -CH2-CH2-O-CH2-CH2-O-CH2-CH2-   Boc-EDDA
21-24
RT, 24h, dioxan
Boc-NH-R'-NH2
NH2-R'-NH2
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Table 4.8: Summary of preparative data for H2N-R´-NH-Boc compounds 
 
 
 
Reactants in feed (mol-%) 
 
 
H2N-R´-NH-Boc 
 
Diamine a 
 
 
(Boc)2O b 
Mole ratio 
 
diamine: (Boc)2O 
 
Medium 
 
 
Reaction 
 
conditions c 
 
 
Yield (%)  
 
 
Designation 
 
EDA 
  
(Boc)2O  
 
9 
 
dioxan 
 
24h, RT 
 
93 
 
21 
 
1,3-PDA 
 
´´ 
 
9 
 
´´ 
 
´´ 
 
85 
 
22 
 
EDDA 
 
´´ 
 
7 
 
´´ 
 
´´ 
 
92 
 
23 
 
DET 
 
´´ 
 
7 
 
´´ 
 
´´ 
 
92 
 
24 
 
 
a EDA = ethylenediamine; PDA = 1,3-propylenediamine, EDDA = 2,2´-(ethylenedioxy)diethylamine; DET = diethylenetriamine. 
b (Boc)2O = di-tert-butyl dicarbonate.  
c RT= room temperature. 
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Table 4.9: 1H NMR data for H2N-R´-NH-Boc compounds 
 
 
 
H2N-R´-NH-Boc 
 
compounds 
 
designation 
 
Number of protons counted a (expected) b 
 
chemical shift (ppm) 
 δ 3.8-3.6 c         δ 3.5-3.1             δ 3.0-2.5           δ 1.8-1.6            δ 1.5-1.3 
 
21 
     
                           2 (2)                       2 (2)                                          9 (9)   
 
22 
   
                          2 (2)                       2 (2)                 2 (2)                 9 (9)          
 
23 
    
                          2 (2)                       5 (6)                                          9 (9)          
 
24 
      
      8 (8)            2 (2)                       2 (2)                                          9 (9)          
 
a In D2O, pH 7, chemical shifts, δ/ppm, referenced against internal sodium 3-trimethylsilyl-2,2,3,3-d4-propionate,  
integration error limits ± 12 %. Protons are calculated (figures rounded off to the nearest integer). 
b Expected count for composition in accordance with recurring unit. 
c Proton assignment, δ/ppm: 3.7-3.6 (OCH2CH2O, NCH2CH2O); 3.5-3.1 (CONHCH2); 3.0-2.5 (CH2NH2); 1.8-1.6 (CH2CH2CH2);  
1.5-1.3 (CH3). 
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4.1.3.2 Synthesis of primary amine-functionalized poly(amidoamine) carriers 
 
PAAs bearing extrachain hydrosolubilizing groups: The primary amine-
functionalized poly(amidoamine) carriers containing hydrosolybilizing side chains 
were obtained by polymerization conducted in aqueous medium, performed in 
two steps. In the first, methylenebisacrylamide (MBA), served as the key 
monomer. It was allowed to react with the respective amount of proteted amine 
(H2N-R´-NH-Boc), based on the desired x/y feed ratio. Such protection was 
necessary to prevent grafting-type side reactions from proceeding during the 
propagation step. Upon the addition of the second amine comonomer (H2N-R) the 
experiments were continued. In the propagation sequence of this scheme, the 
terminal amino groups of the amine co-reactants act as bifunctional sites, 
undergoing double addition with resultant formation of tert-amine functionality in 
the main chain, precluding three-dimensional crosslinking. Therefore, 
considerably higher reactant (H2N-R) concentrations (1.5-3 M) could be used. A 
brief treatment with ethanolamine (EA) to eliminate any terminal unsaturation 
was followed by solvent removal, treatment with trifluoroacetic acid for N-
deprotection, and acid removal under reduced pressure. The crude target polymers 
were worked up by aqueous dialysis in tubing with 12 000 - 14 000 and 25 000 
molecular weight cut-off tubing, and were isolated in the solid state upon freeze-
drying. The products possessed complete solubility in water and, as required, in 
methanol. They were structurally characterized by comparison of the 
CONHCH2NHCO methylene proton resonance near 4.5 ppm with other 
prominent bands in the 1H NMR spectra. The preparation is depicted in the 
Scheme 4.5 below. 
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CONH HNCO
R x
 
R' y
 
NH2
Methylenebisacrylamide (MBA)
25-31
Scheme 4.5:Synthesis of poly(amidoamines) bearing extrachain 
                     hydrosolubilizing groups 
1. y H2N-R'-NH-Boc25-50 oC, 48h
2. x H2N-R50-60 
oC, 48h
3. CF3COOH25 
oC, 1h
x+y
CONH     NHCO     NCONH     NHCO     N
 
 
PAAs bearing intrachain hydrosolublizing groups: Contrasting with Scheme 4.5 
which shows the synthesis of poly(amidoamines) (25-31) in which the side groups 
serve as solubilizing entities, Scheme 4.6 depicts PAAs comprising the 
solubilizing units as main chain segments. The synthesis is also a two-step  
process. In the first step, MBA was reacted with 0.5 equivalents of a mono-N-
protected diamine in aqueous isopropanol medium. The bis(acrylamido)-
terminated macromonomer so generated was allowed in the second step to 
copolymerized with primary diamines of the poly(ethylene oxide)-type H2N-
CH2(CH2CH2O)n(CH2)3NH2, where n = 3 and 32, thus giving polymers 32 and 
33, respectively. The polymerization and work-up conditions were slightly 
different to those leading to 25-31. These monomers bearing two primary amino 
groups would be expected to react tetrafunctionally in the polyaddition reactions, 
as the intermediary secondary amino groups, although inherently less reactive, are 
prone to further addition. The ultimate products would come out as gels generated 
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by three-dimensional crosslinking, as already experienced earlier by Ferruti 159 
and co-workers. In our work, in order to circumvent such crosslinking, we applied 
more selective conditions, including low reactant concentrations and low initial 
temperature, were required in order to ensure monofunctional reactivity of the –
NH2 terminals in the diamine. Thus, reactions were typically carried out by 
allowing MBA and diamine, 0.2-0.4 M each, to copolymerize. The temperature 
was maintained at 0-5oC during the first 24h of the reaction and the water-soluble 
product was thoroughly purified and crudely fractionated by exhaustive aqueous 
dialysis in a membrane tubing with a molecular weight cut-off limit of 25 000. It 
was isolated in the solid state by freeze-drying, with water and methanol solubility 
retained  
 
CONH HNCO
R'
NH2
NHO
n
 
Methylenebisacrylamide (MBA)
1. x H2N-R'-NH-Boc25 oC, 72h
60 oC, 48h
3. CF3COOH25 
oC, 1h
2. x H2N-CH2(CH2CH2O)n(CH2)3NH2
32   R: -(CH2)3-   n = 3
33   R: -(CH2)3-   n = 32
Scheme 4.6: Synthesis of poly(amidoamines) bearing intrachain hydrosolubilizing groups
CONH     NHCO     N CONH     NHCO     NH
2x
x
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Table 4.10: Composition of primary amine-functionalized PAAs 
 
R'
NH2
NHO
n
 
R' y
 
NH2
R x
 
25 (80:20) - 31 (80:20)
32-33
CONH     NHCO     N CONH     NHCO     NH
CONH     NHCO     N CONH     NHCO     N
x
 
 
 
Carriers 
 
 
R 
 
R´ 
 
x/y 
 
n 
 
25 (80:20) 
 
-(CH2)2N(CH3)2 
 
-(CH2)3- 
 
4 
 
 
26 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3- 
 
4 
 
 
27 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 NH(CH2)2- 
 
4 
 
 
28 (80:20) 
 
-(CH2)2N(CH3)2 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
4 
 
 
29 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
4 
 
 
30 (80:20) 
 
-(CH2)2O(CH2)2OH 
 
-(CH2)3- 
 
4 
 
 
31 (80:20) 
 
-(CH2)2O(CH2)2OH 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
4 
 
 
32  
 
 
 
-(CH2)3- 
 
 
 
3 
 
33  
  
-(CH2)3- 
  
32 
 
 
The constituent R, represented by a dimethylaminoalkyl residue in polymers 25-
29, imparts cationic behaviour to the molecule under physiological pH conditions. 
This feature entails potential pharmacokinetic benefits which afford facilitated 
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pinocytotic cell entry of the molecule in biomedical applications 111, 159.  When 
introduced into related polyamide-based drug conjugates, the dimethylaminoalkyl 
functionality has generally been found to provide superior cytotoxic activity in 
cell culture tests against cancer lines 141, 160.  
For comparison a hydroxyl-terminated side chain incapable of adding to the 
polymers’ cationic behaviour has been incorporated in 30 and 31. The R´ segment 
represents various short-chain aliphatic spacers designed to provide spacing 
between the main chain and the drug.  
 
As already mentioned, the PEO chains were introduced into MBA by virtue of 
their numerous properties, namely, high hydrophilic character, nontoxicity, blood 
compatibility, lower immunogenicity and antigenicity. Therefore, the presence of 
the PEO segments in the chain of polyamidoamines 32 and 33 is expected to 
improve both the physico-chemical and pharmacokinetic properties of these 
polymeric carriers.  
 
Experimental variables and viscometric and 1H NMR data are summarized in 
Table 4.11 and 4.12, respectively. 
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Table 4.11: Summary of preparative data for PAA carriers 
 
 
 
Reactants in feed (mol-%) a 
 
 
PAA carriers  
 
R-NH2 
 
H2N-R´-NH-Boc 
 
 
Mole 
ratio x/y b 
 
 
 
Reaction conditions c 
 
 
Yield (%) d 
 
Designation 
 
DME (80) 
 
Boc-PDA (20) 
 
4 
 
(1) 48h, 25-500C ; (2) 48h, 60oC then 1h, RT   
 
22.1 
 
25 (80:20) 
 
DMP (80) 
 
Boc-PDA (20) 
 
4 
 
´´ 
 
16.8 
 
26 (80:20) 
 
DMP (80) 
 
Boc-DET (20) 
 
4 
 
´´ 
 
16.8 
 
27 (80:20) 
 
DME (80) 
 
Boc-EDDA (20) 
 
4 
 
´´ 
 
15.5 
 
28 (80:20) 
 
DMP (80) 
 
Boc-EDDA (20) 
 
4 
 
´´ 
 
18.4 
 
29 (80:20) 
 
AEE (80) 
 
Boc-PDA (20) 
 
4 
 
´´ 
 
15.7 
 
30 (80:20) 
 
AEE (80) 
 
Boc-EDDA (20) 
 
4 
 
´´ 
 
18.4 
 
31 (80:20) 
 
TRIA (50) 
 
Boc-PDA (50) 
  
(1) 72h, 25oC; (2) 24h, 0oC then 48h, 50oC and 1h  at RT 
 
16 
 
32  
 
PEO1500 (50) 
 
Boc-PDA (50) 
  
´´ 
 
23.19 
 
33  
 
   a Parenthetic numbers indicate the number of moles of amino compound per 100 base moles of MBA (methylenebisacrylamide).  
   DME = 3-(N,N-dimethylamino)ethylamine, TRIA = 4,7,10-trioxa-1,13-tridecanediamine; PEO = O,O´-bis(3-aminopropyl)poly(ethylene glycol) 1500. 
b Mole ratio (used) of hydrosolubilizing to drug-anchoring groups. 
c RT= room temperature; reaction step sequence in parenthesis. 
d Polymer yield after ultimate (25 000 molecular weight cut-off) dialysis. 
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Table 4.12:  1H NMR and viscometric data for PAA carriers 
 
 
 
PAA carriers 
 
 
 
Designation 
 
η inh 
 
(mL g-1) a 
 
 
x/y b 
 
 
Base molecular 
 
weight c 
 
Number of protons counted d (expected) e 
 
chemical shift (ppm) 
 
  
 δ.4.8-4.5 f     δ 3.7-3.5      δ 3.0-2.8                δ 2.7-2.0                    δ 1.8-1.5  
 
25 (80:20) 
 
24.29 
 
4 
 
1197.6 
      
   10(10)                                    21(20)                  65(66)                         2(2) 
 
26 (80:20) 
 
17.5 
 
4 
 
1253.7 
      
   10(10)                                    21(20)                  66(66)                      10(10) 
 
27 (80:20) 
 
16.86 
 
4 
 
1281.7 
    
   10(10)                                    22(20)                  68(70)                         7(8) 
 
28 (80:20) 
 
20.98 
 
4 
 
1271.7 
      
   10(10)                8(8)              22(20)                  66(66)                      
 
29 (80:20) 
 
18.45 
 
4 
 
1327.8 
     
   10(10)                8(8)              21(20)                  64(64)                         8(8) 
 
30 (80:20) 
 
20.10 
 
4 
 
1265.5 
      
   10(10)            24(24)              20(20)                  33(32)                         2(2) 
 
31 (80:20) 
 
16.98 
 
4 
 
1339.6 
 
   10(10)            31(32)              20(20)                  33(32)                          
 
32  
 
15.58 
  
602.8 
        
     4(4)              12(12)                  8(8)                  15(16)                         6(6) 
 
33  
 
14.17 
  
1880.4 
        
     4(4)           130(128)                 9(8)                  16(16)                         5(6) 
 
a At 30.0 ± 0.5 o C, in deionized H2O; concentration c= 2 mg/mL. 
b Mole ratio (found) of hydrosolubilizing to drug-anchoring groups after 1H NMR integration. 
c Molecular weight of the simplest recurring unit (normalized to y=1 for 25-31) rounded off to the nearest integer. 
d In D2O, pH 10-11, chemical shifts, δ/ppm, referenced against internal sodium 3-trimethylsilyl-2,2,3,3-d4-propionate; integration error limits ± 12 %.  
Protons are calculated (figures rounded off to the nearest integer) on basis of found x/y ratios. 
e Expected count for composition in accordance with recurring unit (see b). 
f Proton assignment, δ/ppm: 4.6-4.5 (CONHCH2HNCO), 3.8-3.5 (OCH2CH2O), 3.0-2.8 (COCH2), 2.7-2.0 (CH2N(CH3)2, CH2NH2, CH2N(CH2CH2)), 1.8-1.5 (CH2CH2CH2). 
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As indicated in Table 4.11, the experimental yields for the PAAs were quite low 
(15-23%). This was in accordance with previous reports from diverse laboratories 
104, 109, 111. Indeed, polymerization reactions involving Michael additions are 
inherently inefficient, because, while requiring an aqueous or partially aqueous 
solvent system for efficacious propagation, the growing polymer chains are 
susceptible to hydrolytic fission at the labile amide link constituents of the 
bisacrylamide monomers. Hence, the two reaction sequences militate against each 
other, and any polymerization will invariably provide a compromise between 
propagation and depropagation. As a result, the molecular weight distribution of 
the polymer products will be unduly wide. In order to collect polymers in the 
desired molecular weight range of 20 000 and higher, which are required for 
acceptably extended serum residence times, one has to resort to fractionation 
techniques, which cut off all material that is substantially below the stated limit. 
Since this material constitutes the bulk of the polymerization product, the ultimate 
yields of the desired fractions, depending critically on the relative hydrolytic 
stability of the monomers used, are generally quite low. However, these low 
yields were accepted in this study as the price to be paid for obtaining material in 
the proper molecular size. 
 
Some properties of the PAAs are compiled in Table 4.13. According to this table 
the weight-average molecular weight and the polydispersity indices are in the 11 
000 - 65 000, and 1.4-2.7 range, respectively. The inherent viscosities (Table 
4.12) for all the polymers are in the 14-24 mL g-1 range.  The average-molecular-
weights were very variable among them. In accordance with the biomedical 
requirements already mentioned (section 4.1), only polymers 25, 28, 32 and 33 
characterized (Mw = 65 360; 52 000; 28 830 and 23 000, respectively) could be 
used as drug carriers. Although the increasing molecular-weight of polymers 33, 
32, 28 and 25 corresponds to an increase in inherent viscosity, one could not 
correlate the trend of viscosity with that of the molecular-weight in general. For 
example, polymer 29 (Mw =14 880; viscosity, 18.45 mL g-1) has lower-molecular-
weight than polymer 32 (Mw = 28 830; viscosity, 15.58 mL g-1).  
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Moreover, the polymers: 26, 27, and 29, have molecular-weight of 11 000; 13 
000; and 14 880 respectively; this is well below the cut-off limit of 25 000 used in 
dialysis. These low molecular-weight could be explained by the well-established 
fact that ionic and branched polymers act as rigid, comb-like structures in 
solution, for that reason, their hydrodynamic volume is greater compared to their 
linear and neutral analogs 161. It just means that they appear bigger than their 
normal size in the dialysis tube, and therefore do not go through the membrane. 
Table 4.13: GPC characteristics of poly(amidoamine) carriers 
 
Designation 
 
 
η inh 
(mL g-1) 
 
Mw x10-3 
 
 
Mn x10-3
 
 
In 
 
25 (80:20) 
 
24.29 
 
65.36 
 
23.99 
 
2.73 
 
26 (80:20) 
 
17.5 
 
11.02 
 
6.24 
 
1.72 
 
27 (80:20) 
 
16.86 
 
13.21 
 
6.3 
 
2.09 
 
28 (80:20) 
 
20.98 
 
52.00 
 
24.76 
 
2.1 
 
29 (80:20) 
 
18.45 
 
14.88 
 
5.59 
 
2.66 
 
32 (n = 3) 
 
15.58 
 
28.83 
 
20.74 
 
1.39 
 
33 (n = 32) 
 
14.17 
 
23.44 
 
11.32 
 
2.07 
 
The solid-state IR spectra of all polymers 25-33 showed a broad amide I band in 
the region 1680-1610 cm-1, a tertiary amine band at 1400-1340 cm-1 as well as a 
strong methyl band at 1460 cm-1 corresponding to N(CH3)2. The band at 1060 cm-
1, corresponding to the ether bond was noticeable in polymers 28-33, and was 
particularly remarkable in 33 owing to the presence of the PEO segment  
(n = 32). The OH band was also visible as a broad band in the region 3400-3200 
cm-1 of the spectra of polymers 30 and 31. 
The 1H NMR spectra (400 MHz measured in D2O solutions) were recorded at pH 
10-11 (adjusted with NaOH) in order to preclude any protonation effects. These 
spectra showed several groups of bands which were occasionally superimposed 
upon each other. Thus, the methylene protons of CONHCH2HNCO group were 
prominent in the 4.6-4.5 ppm region.  The methylene protons of OCH2CH2O were 
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grouped in the 3.8-3.5 ppm region and those of COCH2 in 3.0-2.8 ppm region. 
The band appearing in the 2.7-2.0 ppm region was assigned to the methylene and 
methyl protons of CH2N (CH3)2, CH2-NH2, and CH2-N (CH2) (CH2) groups. The 
band in the 1.8-1.5 ppm region was assigned to methylene protons of the 
CH2CH2CH2 group.  
The mol-% of drug binding primary amino groups in polymers 25 and 30 was 
found to be 20% by comparing the integral of the signal in the 1.8-1.5 ppm region, 
assigned to the methylene protons of CH2CH2CH2 group originating exclusively 
from PDA monomer, with the integral of the signal near 4.5 ppm assigned to 
MBA. As indicated in Table 4.12, in a similar fashion, polymers 28 and 29 were 
found to possess 20 mol-% NH2 groups by considering the methylene protons of 
OCH2CH2O originating exclusively from the EDDA monomer. This method was 
not applicable to other PAAs, as the characteristic protons of the spacers were also 
found either in both the main chain and the side chain of the hydrosolubilizing 
group or in one of them. However, the number of protons derived from the 1H 
NMR spectra of these PAAs and those provided by the recurring units coincide. 
Thus, polymers 26, 27 and 31 were found to contain 20 mol-% NH2, while 32 and 
33 possess 100 mol -% NH2.  
 
4.2. Polymer Drug Conjugation 
  
The numerous carriers of polyaspartamide and poly(amidoamine)-type, which 
featured primary amino side groups, were used to anchor drug systems via the 
formation of biofissionable amide groups between the carrier and the drugs. 
The first drug investigated was methotrexate. Investigation of the ferrocene-type 
drug followed. Finally, each of these drugs was co-conjugated with folic acid. 
 
4.2.1 Polymer-methotrexate conjugates 
 
The literature provides numerous examples of MTX anchoring, which involves 
the covalent reversible attachment of the carrier through amide bond formation. 
Anchoring of MTX by coupling with the aid of water-soluble carbodiimides such 
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as 1-ethyl-3-(3´-dimethylaminopropyl)carbodiimide hydrochloride has been the 
preferred technique in these studies 127, 162. Proteinaceous carriers have been used 
in the coupling process and these reactions were conducted in aqueous phase. 
Coupling in anhydrous media such as N,N-dimethylformamide (DMF) has 
generally been brought about through the intermediacy of in situ presynthesized, 
active N-succinimide esters. In this laboratory, these active esters, especially if 
applied in higher mole ratios, tended to cause gradual crosslinking of the ultimate 
conjugates, presumably because of the presence of bifunctionally active drug 
molecules. The preferred method herein adopted therefore involved the direct 
acid-amine coupling, which was mediated by the HBTU coupling agent, 2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate. The coupling 
reactions were performed by treatment of the carrier with MTX, an organic base, 
and HBTU for 2 hours at ambient temperature in DMF solution. MTX: NH2 molar 
reactant ratios typically employed were 1.2 or 1.3. Under these conditions, MTX 
binding in most experiments approached the 100% level. However, in polymer-
homologous reactions, such as carrier-drug conjugation, one commonly observes 
greater variability than in analogous non-polymeric processes. Accordingly, 
coupling experiments occasionally failed to achieve an extent of conjugation 
larger than 70-90%, with corresponding proportions of the drug binding left intact 
in the conjugates. These required a retreatment with drug, base, and coupling 
agent, and in the resulting conjugates essentially complete anchoring was 
generally achieved. The actual binding site on the glutamyl constituent of the drug 
in these reactions is unknown. In the conjugate structures shown in the project, 
binding has been ascribed to the α-carboxyl group. The arbitrary choice was 
corroborated by a literature report, which gave preference to that group as the 
more reactive one in coupling reactions with polylysine 163. It may be recalled, 
parenthetically, that MTX-dihydrofolate reductase binding likewise involves the 
drug’s α-carboxyl group 164, although steric factors in the complex may contribute 
to this regiospecific binding. 
 
4.2.1.1 Preparation of polyaspartamide-MTX conjugates 
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The target conjugates 1(90:10)-MTX to 18(80:20)-MTX were prepared from 
polyaspartamides 1-18 by amide bond formation with MTX. As described above, 
the amidation reactions are depicted in Scheme 4.7.  
* NH
x
 
R
* NH CH CO
CONH x
 NH CH CO
CONH y
 
R R'
CH CO
CONH
O
NH
O
NH
HOOC
NH2
NH2
N N
NN
N
CH3
NH CH CO
CONH y
 
R'
NH2
Scheme 4.7: Preparation of polyaspartamide-MTX conjugates
MTX, HBTU, TEA
DMF, 25 oC, 2h
 
 
In the case of DAP spacer-type carriers, the hydroxyl group, by virtue of its 
position, could provoke steric hindrance, thus reducing the accessibility to the 
primary amino drug-binding group. Therefore, the reaction period was extended 
to 3h.  
The polymer-MTX conjugates, after precipitation, were isolated upon 
centrifugation, and subjected to size exclusion chromatography with Sephadex gel 
G-25. The gel has a molecular weight cut-off limit in the 1 000 - 5 000 range. 
Thus, the unreacted drug (Mw 454.45) and by-products were removed by this 
process. The resulting eluates were ultimately subjected to staged aqueous dialysis 
in 25 000 cut-off membrane tubing under carefully controlled pH conditions. The 
aim was to remove lower-molecular-weight products that are inadequate for 
biomedical applications. The ultimate product yields typically ranged from 41 to 
80%.  The efficiency of the purification process was confirmed by thin layer 
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chromatography (TLC). Indeed, TLC of an aqueous solution of conjugates 
(acidified to pH~3-4 with addition of hydrochloric acid) revealed an Rf value of 
zero (0.9 for free MTX) when eluted with methanol-water-ammonia (40:10:1, 
v/v/v).  
 
Table 4.14: Composition of PAsA-MTX conjugates   
* NH CH CO
CONH x
 NH CH CO
CONH y
 
R R'
O
NH
O
NH
HOOC
NH2
NH2
N N
NN
N
CH3
 
 
Carriers 
 
R 
 
R´ 
Conjugates 
 
designation 
 
1 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3- 
 
1 (90:10)-MTX 
 
2 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3- 
 
2 (80:20)-MTX 
 
3 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 NH(CH2)2- 
 
3 (90:10)-MTX 
 
4 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 NH(CH2)2- 
 
4 (80:20)-MTX 
 
5 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
5 (90:10)-MTX 
 
6 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
6 (80:20)-MTX 
 
7 (90:10) 
 
-(CH2)3N(CH3)2 
 
-CH2CHOHCH2- 
 
7 (90:10)-MTX 
 
8 (90:10) 
 
-(CH2)2OH 
 
-(CH2)2 NH(CH2)2- 
 
8 (90:10)-MTX 
 
9 (80:20) 
 
-(CH2)2OH 
 
-(CH2)2 NH(CH2)2- 
 
9 (80:20)-MTX 
 
10 (90:10) 
 
-(CH2)2OH 
 
-CH2CHOHCH2- 
 
10 (90:10)-MTX 
 
13 (90:10) 
 
-(CH2)2 O(CH2)2OH 
 
-(CH2)2 NH(CH2)2- 
 
13 (90:10)-MTX 
 
15 (90:10) 
 
-(CH2)2 O(CH2)2OH 
 
-(CH2)3- 
 
15 (90:10)-MTX 
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Table 4.14 continued 
 
Carriers 
 
R 
 
R´ 
Conjugates 
 
designation 
 
16 (90:10) 
 
-(CH2)2 O(CH2)2OH 
 
-CH2CHOHCH2- 
 
16 (90:10)-MTX 
 
17 (90:10) 
 
-(CH2)2OCH3 
 
-(CH2)2 NH(CH2)2- 
 
17 (90:10)-MTX 
 
18 (80:20) 
 
-(CH2)2OCH3 
 
-(CH2)2 NH(CH2)2- 
 
18 (80:20)-MTX 
 
Pertinent reaction variables and conjugate yields are summarized in Table 4.15, 
while the 1H NMR and viscometric results of the PAsA-MTX conjugates are 
shown in Table 4.16. The MTX contents (mass percentage) were determined by 
1H NMR spectroscopy by assessing the relative intensities of the aromatic 
resonances in the 8.5-6.5 ppm region against prominent bands in the spectra. 
Table 4.17 summarizes all analytical results including GPC characteristics of 
these conjugates. 
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Table 4.15: Reaction variables for PAsA-MTX conjugates 
 
  
Reactants in feed  
 
 
PAsA-MTX conjugates 
 
Carriers 
 
Coupling 
agent 
Carrier : drug :
coupling agent 
ratio (mol-%) a
 
Medium 
 
 
Reaction 
 
conditions b 
 
Yield (%) c 
 
Designation 
 
1 (90:10) 
 
HBTU  
 
1:1.2:1.1 
 
DMF 
 
2h, RT 
 
61 
 
1 (90:10)-MTX 
 
2 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
53 
 
2 (80:20)-MTX 
 
3 (90:10) 
 
´´ 
 
1:1.2:1.1 then 1:0.8:0.5 
 
´´ 
 
2h then 4h, RT 
 
41 
 
3 (90:10)-MTX 
 
4 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
48 
 
4 (80:20)-MTX 
 
5 (90:10) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
43 
 
5 (90:10)-MTX 
 
6 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
42 
 
6 (80:20)-MTX 
 
7 (90:10) 
 
´´ 
 
1:1.2:1.1 
 
´´ 
 
3h, RT 
 
73 
 
7 (90:10)-MTX 
 
8 (90:10) 
 
´´ 
 
´´ 
 
´´ 
 
2h, RT 
 
63 
 
8 (90:10)-MTX 
 
9 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
55 
 
9 (80:20)-MTX 
 
10 (90:10) 
 
´´ 
 
´´ 
 
´´ 
 
3h, RT 
 
74 
 
10 (90:10)-MTX 
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Table 4.15 continued 
 
 
 
a Molar ratio of carrier repeating unit to MTX  to coupling agent. 
b RT= room temperature. 
c Conjugate yield after size exclusion chromatography and ultimate (25 000 molecular weight cut-off) dialysis. 
 
 
 
 
 
 
Reactants in feed  
 
 
PAsA-MTX conjugates 
 
Carriers 
 
Coupling 
agent 
Carrier : drug :
coupling agent 
ratio (mol-%) a
 
Medium 
 
 
Reaction 
conditions b 
 
 
Yield (%) c 
 
Designation 
 
13 (90:10) 
 
HBTU 
 
1:1.2:1.1 
 
DMF 
 
2h, RT 
 
71 
 
13 (90:10)-MTX 
 
14 (80:20) 
 
´´ 
 
1:1.2:1.1 then 1:0.8:0.5 
 
´´ 
 
2h then 4h, RT 
 
54 
 
14 (80:20)-MTX 
 
15 (90:10) 
 
´´ 
 
1:1.2:1.1 
 
´´ 
 
2h, RT 
 
67 
 
15 (90:10)-MTX 
 
16 (90:10) 
 
´´ 
 
´´ 
 
´´ 
 
3h, RT 
 
80 
 
16 (90:10)-MTX 
 
17 (90:10) 
 
´´ 
 
´´ 
 
´´ 
 
2h, RT 
 
77 
 
17 (90:10)-MTX 
 
18 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
66 
 
18 (80:20)-MTX 
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Table 4.16: 1H NMR and viscometric results for the PAsA-MTX conjugates 
 
 
 
 
 
Conjugates 
 
designation 
 
 
 
η inh  
(mL g-1) a
 
 
 
 
x/y b 
 
 
 
Base molecular  
 
weight c 
 
 
 
% MTX 
 
Calcd d 
 
 
 
% MTX 
 
NMR e 
 
Protons counted g (expected) h  
 
chemical shift (ppm) 
 δ 8.5-6.5 f       δ 3.7-3.6      δ 1.8-1.5 
 
1 (90:10)-MTX 
 
16.15 
 
9.2 
 
2392.2 (2400.9) 
 
18.93 
 
18.6 
  
   4.90 (5)                             20 (20)    
 
2 (80:20)-MTX 
 
19.95 
 
4.2 
 
1391.6 (1404.6) 
 
32.36 
 
31.68 
 
   4.85 (5)                             10 (10) 
 
3 (90:10)-MTX 
 
16.75 
 
9 
 
2429.9 (2429.9) 
 
18.7 
 
18.7 
   
        5 (5)                             18 (18) 
 
4 (80:20)-MTX 
 
20.18 
 
4.2 
 
1416.3 (1433.7) 
 
31.7 
 
30.81 
 
   4.80 (5)                                 8 (8) 
 
5 (90:10)-MTX 
 
15.42 
 
9.2 
 
2461.9 (2475) 
 
18.36 
 
17.91 
 
   4.85 (5)                              18 (18) 
 
6 (80:20)-MTX 
 
21.08 
 
4.1 
 
1465.7 (1478.8) 
 
30.7 
 
30.08 
 
   4.85 (5)                                  8 (8) 
 
7 (90:10)-MTX 
 
15.94 
 
9.2 
 
2408.2 (2416.9) 
 
18.8 
 
18.5 
 
   4.90 (5)                              18 (18) 
 
8 (90:10)-MTX 
 
18.66 
 
9.4 
 
2042.7 (2060.1) 
 
22.06 
 
21.36 
 
   4.80 (5)            18 (18) 
 
9 (80:20)-MTX 
 
17.5 
 
4.2 
 
1247.6 (1269.3) 
 
35.8 
 
34.61 
 
   4.75 (5)               8 (8) 
 
10 (90:10)-MTX 
 
16.5 
 
9.4 
 
2025.3 (2047.0) 
 
22.2 
 
21.31 
 
   4.75 (5)            19 (19) 
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  Table 4.16 continued 
 
 
 
Conjugates 
 
designation 
 
 
 
η inh  
(mL g-1) a 
 
 
 
 
x/y b 
 
 
 
Base molecular 
 
weight c 
 
 
 
% MTX 
 
Calcd d 
 
 
 
% MTX 
 
NMR e 
 
Protons counted g (expected) h 
 
chemical shift (ppm) 
 δ 8.5-6.5f                 δ 3.7-3.6 
 
13 (90:10)-MTX 
 
16.25 
 
9 
 
2456.6 (2456.5) 
 
18.5 
 
18.5 
 
     5 (5)                      54 (54) 
 
14 (80:20)-MTX 
 
15.95 
 
4 
 
1445.6 (1445.5) 
 
31.4 
 
31.4 
 
     5 (5)                      24 (24) 
 
15 (90:10)-MTX 
 
12.35 
 
9.5 
 
2405.8 (2427.5) 
 
18.72 
 
17.95 
 
4.75 (5)                      54 (54) 
 
16 (90:10)-MTX 
 
14.87 
 
9.1 
 
2439.2 (2443.5) 
 
18.6 
 
18.45 
 
4.95 (5)                      55 (55) 
 
17 (90:10)-MTX 
 
19.85 
 
9.4 
 
2169.0 (2186.3) 
 
20.79 
 
20.12 
 
4.80 (5)                      45 (45) 
 
18 (80:20)-MTX 
 
21.98 
 
4 
 
1321.1 (1325.4) 
 
34.3 
 
34.06 
 
4.95 (5)                      20 (20)       
 
a At 30.0 ± 0.5 o C, in deionized H2O; concentration c = 2 mg/mL. 
b Mole ratio (found) of hydrosolubilizing to drug-anchoring groups after 1H NMR integration. 
c Molecular weight, actual (in parenthesis, calculated for 100% acylation). 
d Derived from 100% acylation. 
e Derived from 1H NMR spectrum (error limit ± 12%). 
f In D2O, pH 10-11, chemical shifts, δ/ppm, referenced against internal sodium 3-trimethylsilyl-2,2,3,3-d4-propionate; integration error limits ± 12 %.  
Protons are calculated for the structural representations in Table 4.14. 
g Expected count for composition in accordance with recurring unit (see b). 
h Assignment: δ/ppm: 8.6-6.6 (aromatic and heteroaromatic CH of MTX); 3.8-3.5 (CH2O; CH-OH; OCH3); 1.8-1.5 (CH2CH2CH2). 
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Table 4.17: Summary of analytical results for all PAsA-MTX conjugates 
 
 
 
Conjugates 
 
designation 
 
 
η inh 
 (mL g-1) 
 
 
Mwx10-3 
 
 
Mnx10-3 
 
 
 
In 
 
% MTX 
 
Calcd a 
 
% MTX 
 
UV-ε370 b 
 
% MTX 
 
NMR c 
 
NH2 acylation  (%) 
 
UV d 
 
NH2 acylation (%) 
 
NMR e 
 
1 (90:10)-MTX 
 
16.15 
 
26.35 
 
17.0 
 
1.55 
 
18.93 
 
18.30 
 
18.6 
 
97 
 
98 
 
2 (80:20)-MTX 
 
19.95 
 
32.2 
 
18.68 
 
1.74 
 
32.36 
 
30.75 
 
31.68 
 
95 
 
97 
 
3 (90:10)-MTX 
 
16.75 
 
28.25 
 
14.49 
 
1.95 
 
18.7 
 
18.36 
 
18.7 
 
98 
 
100 f 
 
4 (80:20)-MTX 
 
20.18 
 
33.03 
 
15.3 
 
2.17 
 
31.7 
 
29.8 
 
30.81 
 
94 
 
96 f 
 
5 (90:10)-MTX 
 
15.42 
 
25.2 
 
15.27 
 
1.65 
 
18.36 
 
18.05 
 
17.91 
 
98 
 
98 f 
 
6 (80:20)-MTX 
 
21.08 
 
35.03 
 
18.07 
 
1.94 
 
30.7 
 
29.75 
 
30.08 
 
97 
 
97 f 
 
7 (90:10)-MTX 
 
15.94 
 
* g 
 
* 
 
* 
 
18.8 
 
18.2 
 
18.5 
 
~97 
 
98 
 
8 (90:10)-MTX 
 
18.66 
 
31.86 
 
18.21 
 
1.75 
 
22.06 
 
20.85 
 
21.36 
 
95 
 
96 
 
9 (80:20)-MTX 
 
17.5 
 
*  
 
* 
 
* 
 
35.8 
 
33.02 
 
34.61 
 
92 
 
95 f 
 
10 (90:10)-MTX 
 
16.5 
 
* 
 
* 
 
* 
 
22.2 
 
20.65 
 
21.31 
 
93 
 
95 
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Table 4.17 continued 
 
 
 
Conjugates 
 
designation 
 
 
 
η inh 
 (mL g-1) 
 
 
Mwx10-3 
 
 
Mnx10-3 
 
 
 
In 
 
 
% MTX 
 
Calcd a 
 
 
% MTX 
 
UV-ε370 b 
 
 
% MTX 
 
NMR c 
 
 
NH2 acylation (%) 
 
UV d 
 
 
NH2 acylation (%) 
 
NMR e 
 
13 (90:10)-MTX 
 
16.25 
 
* 
 
* 
 
* 
 
18.5 
 
18.25 
 
18.5 
 
99 
 
100 
 
14 (80:20)-MTX 
 
15.95 
 
* 
 
* 
 
* 
 
31.14 
 
30.95 
 
31.4 
 
99 
 
100 f 
 
15 (90:10)-MTX 
 
12.35 
 
* 
 
* 
 
* 
 
18.72 
 
17.65 
 
17.95 
 
94 
 
95 
 
16 (90:10)-MTX 
 
14.87 
 
* 
 
* 
 
* 
 
18.6 
 
18.04 
 
18.45 
 
97 
 
99 
 
17 (90:10)-MTX 
 
19.85 
 
31.9 
 
17.06 
 
1.87 
 
20.79 
 
19.65 
 
20.12 
 
95 
 
96 
 
18 (80:20)-MTX 
 
21.98 
 
66.17 
 
31.88 
 
2.08 
 
34.3 
 
33.6 
 
34.06 
 
98 
 
99 
 
a Mass percentage calculated for 100% acylation. 
b From UV-vis absorbance of bound MTX in H2O at 370 nm using ε = 6500 cm-1M-1. 
c Derived from 1H NMR spectrum (error limit ± 12%). 
d Ratio of b to a. 
e Ratio of c to a. 
f In parallel experiments conducted under identical or modified conditions, percentage acylation ranged from 66-85%, requiring retreatment.      
g Non-determined. 
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As can be seen from Table 4.16, the inherent viscosities of the polyaspartamide-
MTX conjugates are in the 14-22 mL g-1 range. For those determined, the average 
molecular weights range from 25 000 to 66 000, and the polydispersity indices are 
in the 1.5-2 range. These conjugates show an increase in both molecular weights 
and inherent viscosities compared to the derived polymeric carriers, thus 
indicating incorporation of drug molecules into the polymer chain to proceed 
without major chain cleavage during the conjugation process. There is a fair 
match between the trend of molecular weight and inherent viscosity, the 
molecular weight increasing with increase in the inherent viscosity for these 
conjugates. One could speculate that since such relation was not observed in the 
parent carriers, the ultimate dialysis process of the conjugates in the 25 000 cut-
off membrane tubing might have eliminated lower-molecular-weight fractions 
However, these results should be considered cautiously since the observations 
were made on small numbers of conjugates.   
The solid-state IR spectra of polyaspartamide-MTX conjugates commonly 
revealed a broad amide I band in the region 1680-1610 cm-1, and the band at 1580 
cm-1 is attributable to amide II band. The spectra of conjugates 1(90:10)-MTX to 
7(90:10)-MTX retained the majority of bands present in the spectra of the parent 
polymeric carriers 1-7. Thus, the tertiary amine band as well as the weak methyl 
band assigned to N(CH3)2 were present in the region 1400-1340 cm-1 and at 1460 
cm-1, respectively. The spectra of conjugates 5(90:10)-MTX and 6(80:20)-MTX 
exhibited a strong asymmetric band at 1060 cm-1, which is attributable to –CH2-
O-CH2- of EDDA. The OH band of DAP was also visible as a broad band in the 
region 3400-3200 cm-1 of the spectrum of 7(90:10)-MTX conjugate. 
The spectra of conjugates 8(90:10)-MTX to 16(90:10)-MTX showed a broad OH 
band in the 3400-3200 cm-1 region. The ether CH-O-CH stretching mode to which 
the band at 1060 cm-1 is attributable was also seen in the spectra of conjugates 
13(90:10)-MTX to 18(80:20)-MTX. 
 
MTX contents (mass percentage) were determined from the 1H NMR spectra of 
the conjugates. This was achieved by assessing the relative intensities of the 
aromatic resonances in the 8.5-6.5 ppm region, characteristic of the drug, against 
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other prominent bands assigned to the polymeric carriers. Thus, in spectra of 
conjugates 1(90:10)-MTX to 7(90:10)-MTX, the methylene CH2CH2CH2 proton 
peak was chosen as it did not overlap with other signals. The MTX contents were 
in the range of 18-31% by mass. UV-visible spectroscopy was also used to assess 
MTX content in these conjugates. This was achieved using the molar extinction 
coefficient, ε = 6500 mol-1cm-1 and the absorbance at λ = 370 nm in H2O. The 
determined values also ranged from 18 to 31%. These drug contents indicated the 
extent of primary amino group acylation, calculated either by 1H NMR or UV 
spectroscopy, to be in the range of 94-100%. Conjugates 3(90:10)-MTX to 
6(80:20)-MTX, having initially achieved an extent of conjugation lower than 
90%, were retreated with 0.8 equivalents of the drug, 0.5 equivalents of HBTU 
coupling agent, and 1 equivalent of the organic base. The reaction was conducted 
at room temperature for a period of 4h.  A 96-100% extent of conjugation was 
attained as shown in Table 4.17.  
For conjugates 8(90:10)-MTX to 18(80:20)-MTX, the drug contents were 
assessed by using the integral of the signals in the 3.7-3.6 ppm region. The signals 
in this region are assigned to methine (CH-OH), methylene (CH2O) and methyl 
(OCH3) protons, and are characteristic of the polymeric carriers with hydroxyl- or 
methoxy-terminated side groups.  The drug contents were in the range of 17 to 
34% by mass. This corresponds to an extent of conjugation of 92-100%. These 
values were in a fair agreement with those found by UV spectroscopy. 
 
On balance, for the polyaspartmide-MTX conjugates, the drug contents 
determined either by 1H NMR or UV spectroscopy wa in excellent agreement 
with those provided by the proposed structures. This led to two pertinent 
deductions:  Firstly, the purification process (combination of size exclusion 
chromatography and exhaustive dialysis) was efficient as it afforded conjugates 
devoid of free drug. The presence of free drug in the conjugates would distort the 
biological evaluation of these conjugates, resulting in erroneous data. Secondly, 
the conjugates did not undergo molecular association in aqueous solution under 
the conditions of NMR experiments; such self-assembly would cause MTX signal 
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attenuation in the NMR spectra as observed with MTX conjugates based on 
poly(ethylene oxide)-terminated block-copolymers 165. 
 
4.2.1.2 Preparation of poly(amidoamine)-MTX conjugates 
 
The method of synthesis was the same as that for polyaspartamide-MTX 
conjugates. The coupling reactions were performed by treatment of the 
poly(amidoamine)-type carriers with MTX, an organic base, and HBTU as shown 
in Scheme 4.8. MTX: NH2 molar reactant ratios typically employed were 1.2 or 
1.3. 
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Scheme 4.8: Preparation of poly(amidoamine)-MTX conjugates
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Table 4.18: Composition of PAA-MTX conjugates 
*
CONH
R
HNCO N
x
 
NHNCOCONH
R'
y
 
O
NH
O
NH
HOOC
NH2
N N
NN
N
CH3
NH2
25 (80:20)-MTX - 29 (80:20)-MTX
CONH N CONH HNCO NH NHO
n
 
HNCO
O
NH
O
NH
HOOC
R'
NH2
NH2
N N
NN
N
CH3
32-MTX - 33-MTX
x
 
 
Carriers 
 
 
R 
 
R´ 
Conjugate 
 
designation 
 
25 (80:20) 
 
-(CH2)2N(CH3)2 
 
-(CH2)3- 
 
25 (80:20)-MTX 
 
26 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3- 
 
26 (80:20)-MTX 
 
27 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 NH(CH2)2- 
 
27 (80:20)-MTX 
 
28 (80:20) 
 
-(CH2)2N(CH3)2 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
28 (80:20)-MTX 
 
29 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
29 (80:20)-MTX 
 
32 (n = 3) 
  
-(CH2)3- 
 
32-MTX 
 
33 (n = 32) 
  
-(CH2)3- 
 
33-MTX 
The conjugates, after precipitation from solution by adding non-solvent and 
isolation by centrifugation, were subjected to purification by both size exclusion 
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chromatography on Sephadex gel G-25 and exhaustive dialysis in ultimate 25 000 
cut-off membrane tubing. Yields of the conjugates isolated in the solid state by 
freeze-drying of the dialysis retentates were in the 44-60% range.  
Tables 4.19, 4.20, and 4.21 show the experimental variables, the viscometric and 
1H NMR data, and the summary of analytical data, respectively.  
Solid-state IR spectra of all conjugates retained the prominent bands of the parent 
polymeric carriers. Thus, these conjugates showed a broad amide I band in the 
1680-1610 cm-1 region. The spectra of conjugates 25(80:20)-MTX to 29(80:20)-
MTX retained the tertiary amine band at 1400-1340 cm-1 as well as a strong 
methyl band at 1460 cm-1, which corresponds to N(CH3)2. The band at 1060 cm-1, 
corresponding to CH2-O-CH2, was noticeable in conjugates 25(80:20)-MTX, 
29(80:20)-MTX, and 32-MTX. This band is particularly strong in 33-MTX due 
to the presence of the PEO segment (n = 32).  
 
These conjugates were characterized by weight-average molecular weights 
ranging from 15 000 to 86 000. The polydispersity indices were in the range of 
1.3 to 2.5. An increase in molecular weight of conjugates was observed as 
compared to those of the parent polymeric carriers. The inherent viscosities, found 
in the range of 20 - 25 mL g-1, were increased compared to those of the carriers. In 
overall, the trend of increasing molecular weight matched the increase in 
viscosity, thus confirming the incorporation of drug molecules into the polymeric 
carrier chains. 
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Table 4.19: Experimental variables for all PAA-MTX conjugates  
 
 
 
Reactants in feed 
 
 
PAA-MTX Conjugates 
 
Carriers 
 
Coupling 
agent 
 
Medium 
Carrier : drug : 
coupling agent 
ratio (mol-%) a 
 
 
 
Reaction  
 
conditions b 
 
Yield  
(%)  c 
 
Designation 
 
25 (80:20) 
 
HBTU 
 
DMF 
 
1:1.2:1.1 
 
2h, RT 
 
45 
 
25 (80:20)-MTX 
 
26 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
50 
 
26 (80:20)-MTX 
 
27 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
49 
 
27 (80:20)-MTX 
 
28 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
44 
 
28 (80:20)-MTX 
 
29 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
48 
 
29 (80:20)-MTX 
 
32 (n = 3) 
 
´´ 
 
´´ 
 
´´ 
 
3h, RT 
 
47 
 
32-MTX 
 
33 (n = 32) 
 
´´ 
 
´´ 
 
1:1.2:1.1 then 1:0.8:0.5 
 
3h then 4h, RT 
 
60 
 
33-MTX 
 
a Molar ratio of carrier repeating unit to MTX  to coupling agent. 
b RT= room temperature. 
c Conjugate yield after size exclusion chromatography and ultimate (25 000 molecular weight cut-off) dialysis. 
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Table 4.20: 1H NMR and viscometric results for the PAA- MTX conjugates  
 
 
 
 
 
Conjugates 
 
designation 
 
 
 
η inh  
 
(mL g-1) a 
 
 
 
x/y b 
 
 
 
Base molecular 
 
mass c 
 
 
 
% MTX 
 
Calcd. d 
 
 
 
%  MTX 
 
NMR e 
 
Protons counted f (expected) g
 
chemical shift (ppm) 
 δ 8.5-6.5 h                  δ 4.8-4.5 
 
25 (80:20)-MTX 
 
25.09 
 
4 
 
1634.1 (1634).1 
 
27.8 
 
27. 8 
 
      5 (5 )                       10 (10)  
 
26 (80:20)-MTX 
 
19.35 
 
4.1 
 
1681.5 (1690.2) 
 
26.89 
 
26.35 
 
   4.9 (5)                        10 (10) 
 
27 (80:20)-MTX 
 
20.65 
 
4 
 
1713.9 (1719.2) 
 
26.4 
 
26.17 
 
 4.95 (5)                        10 (10) 
 
28 (80:20)-MTX 
 
22.05 
 
4.2 
 
1683.8 (1708.2) 
 
26.6 
 
25.38 
 
 4.77 (5)                        10 (10) 
 
29 (80:20)-MTX 
 
21.08 
 
4 
 
1764.3 (1764.3) 
 
25.76 
 
25.76 
 
      5 (5)                        10 (10) 
 
32-MTX 
 
21.95 
 
 
 
1004.4 (1039.3) 
 
43.73 
 
40.24 
 
   4.6 (5)                           4 (4)  
 
33-MTX 
 
21.8 
 
 
 
2229.5 (2316.8) 
 
19.62 
 
15.69 
 
      4 (5)                           4 (4)  
 
a At 30.0 ± 0.5 o C, in deionized H2O; concentration c = 2 mg/mL. 
b Mole ratio (found) of hydrosolubilizing to drug-anchoring groups after 1H NMR integration. 
c Molecular weight, actual. (in parenthesis, calculated for 100% acylation). 
d Derived from 100% acylation. 
e Derived from 1H NMR spectrum (error limit ± 12%). 
f In D2O, pH 10-11, chemical shifts, δ/ppm, referenced against internal sodium 3-trimethylsilyl-2,2,3,3-d4-propionate; integration error limits ± 12 %.  
Protons are calculated for the structural representations in Table 4.20.  
g Expected count for composition in accordance with recurring unit (see b). 
h Proton assignment, δ/ppm: 8.6-6.6 (aromatic and heteroaromatic CH of MTX); 4.8-4.5 (CONHCH2HNCO). 
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Table 4.21: Analytical results of PAA-MTX conjugates  
 
 
Conjugates 
 
designation 
 
 
η inh  
(mL g-1)  
 
 
Mw x10-3 
 
 
 
Mn x10-3 
 
 
 
In 
 
% MTX 
 
Calcd. a 
 
% MTX 
 
UV- ε370 b 
 
% MTX 
 
NMR c 
 
NH2 acylation 
(%)  
UV d 
 
NH2 acylation 
(%)  
NMR e 
 
25 (80:20)-MTX 
 
25.09 
 
86.6 
 
67.1 
 
1.3 
 
27.8 
 
27.74 
 
27.8 
 
~100 
 
100 
 
26 (80:20)-MTX 
 
19.35 
 
15.05 
 
9.33 
 
1.6 
 
26.89 
 
26.09 
 
26.35 
 
97 
 
98 
 
27 (80:20)-MTX 
 
20.65 
 
15.52 
 
10.25 
 
1.5 
 
26.4 
 
26.16 
 
26.17 
 
~100 
 
99 
 
28 (80:20)-MTX 
 
22.05 
 
60.8 
 
45.8 
 
1.3 
 
26.6 
 
25.27 
 
25.38 
 
95 
 
95 
 
29 (80:20)-MTX 
 
21.08 
 
18.66 
 
13.61 
 
1.4 
 
25.76 
 
25.28 
 
25.76 
 
98 
 
100 
 
32-MTX 
 
21.95 
 
26.09 
 
13.44 
 
2.5 
 
43.73 
 
40.1 
 
40.24 
 
91 
 
92 
 
33-MTX 
 
21.8 
 
33.02 
 
14.49 
 
1.8 
 
19.62 
 
15.3 
 
15.69 
 
78 
 
80 f 
 
a Mass percentage calculated for 100% acylation. 
b Mass percentage found from UV absorbance of bound MTX in H2O at 370 nm using ε = 6500 M-1cm-1. 
c Mass percentage derived from 1H NMR spectrum (error limit ± 12%). 
d Ratio of b to a. 
e Ratio of c to a . 
f In parallel experiments conducted under identical or modified conditions, percentage acylation ranged from 66-85%, requiring retreatment. 
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The MTX content (percent by mass using 1H NMR spectroscopy) were 
determined by assessing the relative intensities of the aromatic resonances in the 
8.5-6.5 ppm region characteristic of the drug against that of the methylene signal 
CONHCH2HNCO near 4.5 ppm. Thus, the conjugates 25(80:20)-MTX to 
29(80:20)-MTX show drug contents in the range of 25 to 28%. This corresponds 
to primary amino group acylation in the 95-100% range. These results were 
confirmed by quantitative UV spectroscopy of polymer solutions using the molar 
extinction coefficient value (ε = 6500 mol-1cm-1) and the absorbance at λ = 370 
nm in H2O. No excess drug was revealed in comparison with the content derived 
from theoretical structures. This fact confirms the efficiency of the purification 
procedure, as free drug was used in 20% excess.  
The MTX content of conjugate 32-MTX was found to be 40.24% and 40.1% by 
NMR and UV spectroscopy, respectively. This corresponds to 91% and 92% NH2 
acylation. The found drug content, hence, was lower than to the theoretical value 
of 43.73 %. NMR and UV spectroscopy gave MTX mass loading of 15.69% and 
15.3%, respectively, for conjugate 33-MTX, which was below the expected value 
of 19.62%. Therefore, the conjugate was retreated with 0.8, 0.5, and 1 equivalent 
of free drug, HBTU coupling agent, and organic base respectively, with an 
extended reaction period of 4h. The ultimate conjugate was characterized by 
15.68% of drug content as determined by NMR spectroscopy. This corresponds to 
80% NH2 acylation, which is still lower than expected. 32-MTX and 33-MTX 
were derived from polymeric carriers containing intrachain hydrosolubilizing 
groups (PEO segment). While carrier 32 contained a short PEO segment (n = 3), 
polymer 33 comprised a long PEO segment (n = 32). The extent of conjugation of 
32-MTX ranged from 91 to 92%, while the acylation of drug binding sites was 
observed to be 80% in the case of 33-MTX, even under optimal conditions. The 
difference in drug conjugation extent observed with both carriers could be due to 
less accessibility of the drug binding site as a result of coil formation of PEO 
chain around the site. This could be more pronounced in polymer 33, which is 
characterized by a long and highly flexible PEO chain of 32 units compared with 
carrier 32 in which the PEO chain length contains only 3 units.    
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4.2.1.3 Cell culture testing  
 
The conjugates of both classes were evaluated in cell culture tests against various 
human cancer cell lines. The parenthetic attributes denoting mol-% composition 
in the conjugate designations will be omitted in the following text. 
 
(a) CEM/S and CEM/E cell lines  
 
Selected PAsA-MTX conjugates were tested in vitro by established procedure 166 
against human CEM/S leukemic lymphoblasts, a drug-sensitive cell line and, in 
parallel, against the derived multidrug-resistant CEM/E subline. Free MTX was 
tested under the same conditions for comparison. The cytotoxic activities 
determined for the individual samples are listed in Table 4.22, expressed in terms 
of IC50 values, (drug concentration required to retain 50% cell viability relative to 
drug-free control). The table also contains entries for the resistance factor, RF, 
defined here as the ratio of IC50 [CEM/E] over IC50 [CEM/S]. 
A cursory comparison of the results tabulated in the two CEM columns 
immediately reveals the expected trend of lowered activity on going from CEM/S 
to CEM/E, with the resistance factors generally in the vicinity of 15-20, and the 
same trend obtains for free MTX (RF = 20.5). Against the two CEM lines, then, 
the carrier-bound drug, on balance, exhibits no selective ability to circumvent 
resistance. For conjugates 2-MTX and 7-MTX resistance factors below 5 are 
apparent from the tabulation. These are exceptional, however, and a larger number 
of repetitively synthesized conjugates will be required to confirm and rationalize 
this deviating behaviour.  
Comparing now performance data of individual conjugate structures, we detect 
only minor differences on going from type to type. Significantly, against CEM/S, 
the overall IC50 range (~0.02 – 0.2) for polymers with tertiary amine side 
functionalities (1-MTX to 7-MTX) does not substantially differ from that (~0.01 
– 0.3) determined for the conjugates featuring hydroxyl-terminated side groups 
(8-MTX to 15-MTX). The same argument holds for IC50 data determined against 
CEM/E. (The only outstanding case is conjugate 17-MTX, which shows poor 
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performance relative to all other samples; this may be an artefact, however, which 
will be reinvestigated). Evidently, realistic structure-performance relationships 
can only be derived on the basis of an increased sample number for each structural 
type, and future investigations will focus on this topic. 
The most striking aspect of the here described series of tests emerges as we 
compare for each CEM column the data derived for the carrier-drug conjugates 
with those pertaining to unconjugated MTX. With just one exception (conjugate 
17-MTX), the conjugate-derived IC50 values are considerably lower than the 
respective values for the free drug. This indicates the cytotoxic activities of the 
polymer-bound drug to exceed monomeric MTX activity by a large factor (40- to 
50-fold in about one-third of all tested samples). The tabulated figures in the 
activity factor column (AF = IC50 [MTX] /IC50 [conjugate]) provide the details.  
 
In summary: methotrexate, both conjugated and unconjugated, shows essentially 
the same trend of decreasing antiproliferative activity on going from the sensitive 
to the resistant CEM lines. Conjugation thus provides no panacea for 
circumvention of drug resistance interests against CEM. On the other hand, vastly 
superior activities, up to 50-fold and higher, against both CEM/S and CEM/E are 
observed for the carrier-anchored MTX derivatives in relation to the unbound 
drug. In view of the common experience that realistic pharmacological benefits, as 
they arise from drug binding to carrier polymer, will manifest themselves 
predominantly, if not solely, in the living organism 167, 168, these findings are 
highly significant and warrant ongoing studies involving further synthetic work 
and extensive in vitro/in vivo screens.       
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  Table 4.22: Antiproliferative activity of polyaspartamide-MTX conjugates against CEM/E and CEM/S cell lines 
 
 
Polyaspartamide-MTX Conjugates 
 
 
CEM/S  
 
CEM/E  
 
 
 
Designation 
Base molecular 
weight 
% MTX 
by mass 
IC50 
(µg MTX/mL) 
AF a IC50 
(µg MTX/mL) 
AF RF b 
1-MTX 2392.2 18.6 0.107 7.8 1.556 11.0 14.5 
2-MTX 1391.6 31.68 0.137 6.1 0.542  4.0 
3-MTX 2429.9 18.7 0.121 6.9 1.773 9.6 14.7 
4-MTX 1416.3 31.7 0.02 41.7 0.467 36.5 23.4 
5-MTX 2461.9 18.36 0.163 5.1 2.12 8.1 13.0 
7-MTX 2408.2 18.8 0.145 5.8 0.633 27.0 4.4 
8-MTX 2042.7 22.06 0.273 3.1 6.433 2.7 23.6 
13-MTX 2456.6 18.5 0.013 64.1 0.281 60.7 21.6 
15-MTX 2405.8 18.72 0.011 75.8 0.228 74.9 20.7 
17-MTX 2169.0 20.79 >20 - >20 - - 
MTX - - 0.834 - 17.07 - 20.5 
 
a Activity factor defined here as IC50 [free MTX] : IC50 [conjugate]. 
b Resistance factor defined as IC50 [CEM/E] : IC50 [CEM/S]. 
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(b) HeLa and Colo cell lines   
 
The conjugates of both classes were evaluated in cell culture tests for 
antiproliferative activity against a refractory .i.e. less drug-responsive cell line 
derived from the Colo 320 DM human colorectal adenocarcinoma. For 
comparison, the samples of both classes were separately screened for activity 
against the HeLa human cervical epitheloid adenocarcinoma line generally found 
to be drug-sensitive and frequently used as a standard. Activities were determined 
in triplicate by the earlier described procedure, and the findings, expressed as IC50 
values were averaged for each sample. In order to obtain a measure of the drug 
activity of the conjugates relative to unconjugated drug, free MTX was also 
included in these test series, and the results derived from five determinations 
against each cell line, averaged for each line, were used for this comparison. It is 
convenient to present and discuss the test results separately for the two classes of 
conjugates.   
 
Polyaspartamide-MTX conjugates 
 
For the polyaspartamide-based conjugates 1-MTX to 18-MTX, the IC50 values 
were derived from plots of cell growth relative to control versus conjugate 
concentration (Fig. 4.3 and 4.4). They are expressed in terms of µg MTX/mL and 
are listed in Table 4.23 for the tests against both cell lines. The table also contains 
the averaged results shown by free MTX for each cell line. Also included are the 
activity factors, AF, here defined as the ratio of conjugate activities over MTX 
activity and expressed in terms of IC50 (MTX)/ IC50 (conjugate). 
It is instructive to consider first the data in the HeLa column. A superficial 
examination reveals that IC50 values for the first one-half of the listed conjugates 
are lower than that for MTX. For these first 4 tested samples (conjugates 1-MTX, 
3-MTX, 5-MTX, and 7-MTX) an averaged activity factor of 4.15 can be 
calculated from the averaged IC50 value (0.0123 µg MTX/mL). These conjugates 
as a group, hence, are some 4-fold more active than the free drug. It must be 
  
108
recalled that these samples are characterized by tert-amine side chain terminals in 
the hydrosolubilizing groups R. 
The situation is different for the second one-half of the tabulated samples 
(conjugates 8-MTX to 16-MTX) identified by hydroxyl chain terminals in R. For 
the first 5 tested samples, the averaged IC50 value, 2.0176 µg MTX/mL, suggests 
an average activity factor of 0.025, thus reflecting a reverse behavior, with free 
MTX now some forty-times more active than the samples as a group. Conjugate 
18-MTX identified by methoxy side chain terminal in R, with IC50 value, 8.414 
µg MTX/mL corresponding to an activity factor of 0.006, is 167-fold less active 
than free MTX. It is clear that, against the HeLa line, the tert-amine functionality 
in conjugates 1-MTX to 7-MTX exerts a positive influence on the in vitro 
cytotoxic data. In the biological environment, this functionality is partially 
protonated, which renders the polymer moderately basic and may thus facilitate 
pinocytic cell entry with resultant activity enhancement. Larger sample numbers 
will be required, however, to corroborate this explanation.      
 
Let us proceed now to the Colo column. To the unconjugated drug, the Colo line 
proves to be some 50-times more refractory than HeLa, which clearly identifies 
that Colo variant as a strongly drug-resistant line. Here, for the first four samples 
listed in this column (conjugates 1-MTX, 3-MTX, 5-MTX and 7-MTX) the 
averaged IC50 value (0.2875 µg MTX/mL) leads to an average activity factor of 
9.61, showing these tert-amine functionalized polymers as a group to be over 10-
fold more active than free MTX. In this first one-half of samples, conjugates 5-
MTX and 3-MTX, which show a reverse behavior, can possibly be artifacts. The 
lower performance observed can be due to poor solubility. Indeed, poor solubility 
would result in aggregation, and ultimately in the delivery of a small portion of 
the drug in the intracellular compartment. Among the seven samples in the 
category of hydroxyl-functionalized, the conjugates 10-MTX, 14-MTX and 16-
MTX are distinctly less active as a group against this strongly resistant line. With 
an activity ratio of 0.34, derived from the averaged IC50 value (8.1253 µg 
MTX/mL), the hydroxyl-functionalized conjugates are even less active than the 
free drug. This average AF value is misleading, however, being strongly affected 
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by the three outsiders (possibly artifacts), the conjugates 10-MTX, 14-MTX and 
16-MTX. If these are omitted from the calculations, an activity factor of 3.18 
results from the averaged IC50 value (0.8693 µg MTX/mL). This indicates that 
even these hydroxyl-functionalized conjugates for the most part are three-times as 
active as the unconjugated drug. 
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Table 4.23: Antiproliferative activity of polyaspartamide-MTX conjugates against HeLa and Colo cell lines  
 
 
Polyaspartamide-MTX conjugates 
 
 
HeLa  
 
CoLo  
Designation Base molecular 
weight 
% MTX by 
mass 
IC50 
(µg MTX/mL) 
AF d IC50 
(µg MTX/mL) 
AF RF 
1-MTX 2392.2 18.6 0.013 3.9 0.196 14 15.08 
2-MTX 1391.6 31.68 - - 2.82 0.98 - 
3-MTX 2429.9 18.7 0.0075 6.8 0.032 86.4 4.27 
4-MTX 1411.9 30.81 - - 2.872 0.96 - 
5-MTX 2466.3 17.91 0.0037 13.8 0.432 6.4 11.68 
7-MTX 2408.2 18.5 0.025 2.0 0.49 5.6 19.6 
8-MTX 2042.7 21.36 0.379 0.14 1.214 2.3 3.2 
9-MTX 1234.5 34.61 - - 0.044 62.8 - 
10-MTX 2025.3 21.31 4.918 0.01 12.965 0.21 2.64 
13-MTX 2456.6 18.5 0.536 0.1 1.712 1.6 3.19 
14-MTX 1445.6 31.4 - - 24.069 0.12 - 
15-MTX 2401.4 17.95 0.027 1.9  0.507 5.5 18.78 
16-MTX 2439.4 18.45 4.228 0.01 16.366 0.17 3.87 
17-MTX 2168.4 20.12 8.414 0.006 >50 > 0.06 5.94 > 
18-MTX 1321.1 34.06 - - 46.286 0.06  - 
MTX - - 0.051 - 2.764 - 54 
 
a Activity factor defined here as IC50 [free MTX] : IC50 [conjugate] 
b Resistance factor defined as IC50 [Colo] : IC50 [HeLa]. 
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Figure 4.3: Antiproliferative activity of PAsA-MTX and free MTX against HeLa cells 
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Figure 4.4: Antiproliferative activity of PAsA-MTX and free MTX against Colo cells 
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Poly(amidoamine)-MTX conjugates 
 
This class comprises a small number of conjugates (25-MTX to 33-MTX; one 
sample per conjugate) made available for a very preliminary evaluation of 
activities against the HeLa and Colo lines. The results in terms of IC50 values 
derived from plots (Figures 4.5 and 4.6) and activity factor are presented in Table 
4.24, which includes data obtained in this test series for unconjugated MTX. 
 
Let us first inspect the data in the HeLa column. For the first five conjugates 25-
MTX to 29-MTX; characterized by the presence of tert-amine terminals on short 
side chains functioning as hydrosolubilizing moieties, the IC50 values approximate 
that of free MTX. The average activity factor, 1.34, derived from the averaged 
IC50 data (0.053 µg MTX/mL), identifies this group of conjugates as slightly more 
active than MTX proper. Conjugates 32-MTX and 33-MTX, in contrast, 
containing a solubilizing intrachain oligo(ethylene oxide) segment, provide AF of 
0.05 and 0.03, respectively. The activities of these two conjugates are thus 
considerably lower than that of MTX. 
The same basic trend is apparent for all conjugates from the Colo data. While 
conjugates 25-MTX to 29-MTX as a group are four-times more active than free 
MTX, with averaged IC50 = 1.2266 µg MTX/mL and resultant AF: 3.67, the 
remaining two conjugates turn out to be less active than free MTX, with activity 
factors of 0.47 and 0.29, respectively. The oligo(ethylene oxide) segment in 32-
MTX and 33-MTX possesses protein-repellent characteristics, and this may lead 
to inhibition of intracellular enzymatic cleavage of the drug-binding carboxamide 
links and resultant lower bioavailability.     
Based on the IC50 values, 27-MTX is more effective than 25-MTX. However, the 
cell-killing efficaciousness is more pronounced with 25-MTX than it is with 27-
MTX. Indeed, Fig. 4.6 (a) shows 25-MTX to maintain its trend of cell growth 
inhibitory activity at the concentration of 0.75 µg MTX/mL, while at the same 
concentration 27-MTX forms a plateau with about 25% of cells surviving. The 
same phenomenon was observed with conjugates 26-MTX (Fig. 4.6 (b)) and 32-
MTX (Fig. 4.6 (c)). The plateau formation, which corresponds to gently enhanced 
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cell resistance with increasing drug concentration can be due to decreased 
intracellular drug levels resulting from increased drug efflux or decreased inward 
transport. More experiments and extended numbers of conjugates will be required 
for elucidation of this behavior in these cases. 
Moreover, using the Tables 4.13, 4.21, and 4.23, it appears that the polydispersity 
indexes of polymer 25(80:20) to 33 are relatively high: 2.73; 1.72; 2.09; 2.1; 2.66; 
1.39; and 2.07 respectively.  
Fortunately, these values have sensibly improved after conjugation with 
Methotrexate. The lowest values are for conjugates 25(80:20)-MTX to 29(80:20)-
MTX: 1.3; 1.6; 1.5; 1.3; and 1.4 respectively. The highest are for 32-MTX and 
33-MTX with 2.5 and 1.8 respectively.  
However, the narrow polydispersity (around 1.2) of conjugates has been 
associated biological 169. If we look at the results compiled in Table 4.23, the 
conjugates 25(80:20)-MTX to 29(80:20)-MTX are more effective than 32-MTX 
and 33-MTX. Even the conjugate 17(90:10)-MTX with polydispersity of 1.87 
(Tables 4.17 and 4.22) showed no cytotoxicity at all. This study may have 
demonstrated once again that polydispersity plays a certain role in the 
effectiveness of drug conjugates.  
 
In conclusion, cell culture tests performed against the drug-sensitive HeLa and the 
strongly resistant Colo lines reveal a vastly superior cell-killing potential for 
polymer-bound MTX as a class in relation to the unconjugated drug. Best 
performers belong to the group of polyaspartamide-based conjugates featuring 
tert-amine side chain terminals as hydrosolubilizing entities, with selected 
compounds some 4- to 10-times more active than free MTX. The superiority of 
this group of conjugates is particularly apparent in tests against the resistant Colo 
line. While in tests against this line all compounds show lowered cytotoxic 
performance, this loss of activity is much less severe with the polymeric than the 
monomeric drug. Polyaspartamide-bound MTX derivatives, notably those 
containing tert-amine side chain terminals, thus stand out as eminently promising 
candidates for further bio-evaluation work in tests against both sensitive and 
multidrug-resistant cancer cells.  
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Table 4.24: Antiproliferative activity of PAA-MTX conjugates against HeLa and CoLo cell lines. 
 
 
PAA-MTX conjugates 
 
 
HeLa  
 
Colo 
 
Designation 
 
Mw x 10-3 
 
 
% MTX 
by mass 
 
IC50  
(µg MTX/mL)  
 
AF a 
 
IC50  
(µg MTX/mL)  
 
AF a 
 
RF b 
 
25-MTX 
 
86.6 
 
27.8 
 
0.086 
 
0.83 
 
0.675 
 
6.7 
 
7.48 
 
26-MTX 
 
15.05 
 
26.35 
 
0.134 
 
0.53  
 
1.348 
 
3.3  
 
10.1 
 
27-MTX 
 
15.52 
 
26.17 
 
0.014 
 
5.1  
 
0.087 
 
51.7  
 
6.2 
 
28-MTX 
 
60.8 
 
25.38 
 
0.025 
 
2.8  
 
3.179 
 
1.4 
 
127.2
 
29-MTX 
 
18.66 
 
25.76 
 
0.0058 
 
12.24 
 
0.844 
 
5.3 
 
145.5
 
32-MTX 
 
26.09 
 
40.24 
 
1.324 
 
0.05  
 
9.58 
 
0.47  
 
7.24 
 
33-MTX 
 
33.02 
 
15.69 
 
2.659 
 
0.03 
 
15.625 
 
0.29  
 
5.9 
 
MTX 
 
- 
 
- 
 
0.071 
 
- 
 
4.5 
 
- 
 
63.4 
 
a Activity factor defined here as IC50 [free MTX] : IC50 [conjugate]. 
b Resistance factor defined as IC50 [Colo] : IC50 [HeLa]. 
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Figure 4.5: Antiproliferative activity of PAA-MTX conjugates and free MTX against HeLa cells 
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Figure 4.6: Antiproliferative activity of PAA-MTX conjugates and free MTX against Colo cells 
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4.2.2 Preparation of polymer-ferrocene conjugates 
 
The ferrocene derivative involved in this study was 4-ferrocenylbutanoic acid, 
whose choice was motivated by its conveniently low reduction potential as 
reported by Swarts et al. 170. It was synthesized as described in the literature 171. 
Various polymers of both polyaspartamide and poly(amidoamine) types, which 
feature primary amino side chain terminals, were anchored to the ferrocene unit 
through the formation of biofissionable amide links. Two ferrocene anchoring 
methods have extensively been investigated in this laboratory. The first method 
involves direct acid-amine coupling, which is mediated by 2(1H-benzotriazol-1-
yl)-1,1,3,3-tetramethyluronium fluorophosphate (HBTU), while the second 
involves coupling via the active N-succinimide ester of the ferrocene compound, 
N-succinimidyl 4-ferrocenylbutanoate. The active ester was prepared from the 4-
ferrocenylbutanoic acid and N-hydroxysuccinimide (HSU) in the presence of 
dicyclohexylcarbodiimide in ethyl acetate medium. In order to assess the extent of 
drug conjugation of each coupling method, a series of screening experiments were 
performed.  In these experiments, the ratio of Ferrocene/polymer repeat unit 
varied in the 1.3-2.5 range. In some cases, where the extent of conjugation was 
unsatisfactory (< 90%), the conjugates were treated with additional amount of 
drug and the reaction period was extended in order to achieve greater degrees of 
acylation ranging from 95 to 100%. The results of screening experiments 
indicated that the two coupling methods are essentially equivalent in efficiency 
172. The HBTU-mediated acylation, while reported in one case 170 to cause main 
chain fragmentation, offers the benefit of originating directly from the free 
butanoic acid without requiring the active ester intermediacy. The HSU ester 
method, on the other hand, offers the advantage of retaining main chain integrity, 
thus permitting long reaction periods as may be required for coupling processes 
involving reactants of low reactivity. 
 
In the present project, the coupling efficiency of another type of 
ferrocenylbutanoic acid-based active ester was investigated for comparison with 
the preceding methods.  
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This active ester, para-nitrophenyl 4-ferrocenylbutanoate, was synthesized using a 
method adapted from literature 173 as depicted in Scheme 4.9.   
 
OH NO2
NO2O
OFeFe
OH
O +
HONp Fc-ONp
DCC, 0-25oC, 3h
Etac
Scheme 4.9: Synthesis of para-nitrophenyl 4-ferrocenylbutanoate (Fc-ONp)
 
 
Thus, the two main drug conjugation methods herein used were the HBTU-
mediated and the para-nitrophenyl active ester methods. However, in order to 
demonstrate the drug-anchoring potential of poly(amidoamine), an exemplifying 
polymer was allowed to react with the HSU-derived active ester of 
ferrocenylbutanoic acid in methanolic solution. 
4.2.2.1 Polymer-ferrocene conjugation by HBTU-mediated coupling method 
These conjugates were obtained by treating the primary amine-functionalized 
polymeric carriers of both polyaspartamide and poly(amidoamine) types with 1.2-
1.4 molar equivalents of the ferrocenylbutanoic acid in the presence of 1.1-1.3 
equivalents of HBTU and 2 equivalents of organic base (triethylamine, TEA) at 
pH of 7 or higher as shown in Scheme 4.10. The carriers were converted into 
conjugates in which complete acylation of available primary amine functions were 
achieved after typically 3h. The water-soluble product conjugates were 
precipitated from the reaction solution and, after purification by size exclusion 
chromatography and exhaustive dialysis, were isolated by freeze-drying in the 
solid state.  
Table 4.25 shows the composition of these conjugates, and the reaction conditions 
leading to these conjugates are summarized in Table 4.26, whereas the 
spectroscopic and viscometric results are compiled in Table 4.27. For 
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convenience, the ferrocene conjugates in this section and the forthcomings will be 
reported without the molar percentage in parenthesis. 
R'
NH2
R
NH
O Fe
* *
y
 
x
 
R
x
 
R'
y
 
NH CH CO
CONH y
 
R'
NH2
* NH
x
 
R
CH CO
CONH
NH
O Fe
* NH CH CO
CONH x
 
NH CH CO
CONH y
 
R R'
Scheme 4.10: Preparation of ferrocene-conjugates by HBTU-mediated coupling method  
1 (90:10)-5 (90:10)
25 (80:20)-28 (80:20)
1-Fc (HBTU) - 5-Fc (HBTU)
25-Fc (HBTU) - 28-Fc (HBTU)
Fc(CH2)3COOH, HBTU, TEA
DMF, RT, 3h
CONH     NHCO     N CONH     NHCO     N
CONH     NHCO     N CONH     NHCO     N
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Fc(CH2)3COOH, HBTU, TEA
DMF, RT, 3h
NH
O Fe
*
NHO n
 
R'
x
 
R'
NH2
NHO n
 
x
 
Scheme 4.10 continued  
32-Fc (HBTU) - 33-Fc (HBTU)
CONH     NHCO     N CONH     NHCO     NH
CONH     NHCO     N CONH     NHCO     NH
32-33
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Table 4.25: Compostion of polymer-ferrocene conjugates prepared by HBTU–
mediated coupling method 
R' y
 
*
R
x
 
NHO n
 
R'
x
 
NH
O Fe
* NH CH CO
CONH x
 
NH CH CO
CONH y
 
R R'
NH
O Fe
NH
O Fe
1-Fc (HBTU) - 5-Fc (HBTU)
25-Fc (HBTU) - 28-Fc (HBTU)
32-Fc (HBTU) - 33-Fc (HBTU)
CONH     NHCO     N CONH     NHCO     N
CONH     NHCO     N CONH     NHCO     NH
 
 
Carriers 
 
R 
 
R´ 
Conjugates 
 
designation 
 
1 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3- 
 
1-Fc (HBTU) 
 
3 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 NH(CH2)2- 
 
3-Fc (HBTU) 
 
5 (90:10)  
 
-(CH2)3N(CH3)2 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
5-Fc (HBTU)  
 
25 (80:20) 
 
-(CH2)2N(CH3)2 
 
-(CH2)3- 
 
25-Fc (HBTU) 
 
26(80:20)  
 
-(CH2)3N(CH3)2 
 
-(CH2)3- 
 
26-Fc (HBTU) 
 
27 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 NH(CH2)2- 
 
27-Fc (HBTU) 
 
28 (80:20) 
 
-(CH2)2N(CH3)2 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
28-Fc (HBTU) 
 
32 (n = 3) 
  
-(CH2)3- 
 
32-Fc (HBTU) 
 
33 (n = 32) 
  
-(CH2)3- 
 
33-Fc (HBTU) 
  
123
Table 4.26: Reaction conditions for ferrocene conjugates prepared by HBTU-mediated coupling method 
 
Reactants in feed  
 
 
  Fc (HBTU) conjugates 
Carriers 
 
designation 
Coupling 
 
agent 
 
Medium 
Carrier : drug : 
coupling agent 
ratio (mol-%) a 
 
 
Reaction  
 
conditions b 
 
 
Yield 
(%) c 
 
Designation 
 
1 (90:10) 
 
HBTU 
 
DMF 
 
1:1.2:1.1 
 
3 h at RT 
 
53 
 
1-Fc (HBTU) 
 
3 (90:10) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
56 
 
3-Fc (HBTU) 
 
5 (90:10)  
 
´´ 
 
´´ 
 
1:1.4:1.3 
 
´´ 
 
64 
 
5-Fc (HBTU)  
 
25 (80:20) 
 
´´ 
 
´´ 
 
1:1.2:1.1 
 
´´ 
 
39 
 
25-Fc (HBTU) 
 
26 (80:20)  
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
42 
 
26-Fc (HBTU) 
 
27 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
43 
 
27-Fc (HBTU) 
 
28 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
46 
 
28-Fc (HBTU) 
 
32 (n = 3) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
72 
 
32-Fc (HBTU) 
 
33 (n = 32) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
41 
 
33-Fc (HBTU) 
 
a Molar ratio of carrier repeating unit to ferrocenylbutanoic acid to coupling agent. 
b RT= room temperature. 
c Conjugate yield after size exclusion chromatography and ultimate (25 000 molecular  weight-cut-off) dialysis. 
  
124
Table 4.27: 1H NMR and viscometric results for Fc (HBTU) conjugates  
 
 
 
Conjugates 
 
designation 
 
 
η inh  
 
(mL g-1)  
 
 
x/y a 
 
 
Base molecular  
 
mass b 
 
 
% Fe 
 
Calcd c 
 
 
% Fe 
 
NMR d 
Protons counted e (expected) f 
 
chemical shift (ppm) 
 
 δ 4.8-4.5 g   δ 4.3-4.25   δ 3.8-3.5    δ 1.8-1.5    
 
1-Fc (HBTU) 
 
15.96 
 
9 
 
 2218.6 (2218.6) 
 
2.52 
 
2.52 
 
                         9 (9)                            22 (22) 
 
3-Fc (HBTU) 
 
13.7 
 
9 
 
 2247.6 (2247.6) 
 
2.49 
 
2.49 
 
                         9 (9)                            20 (20) 
 
5-Fc (HBTU)  
 
12.5 
 
9.1 
 
2290.1 (2292.7) 
 
2.44 
 
2.41 
 
                    8.91 (9)                            20 (20) 
 
25-Fc (HBTU) 
 
16.25 
 
4 
 
1451.6 (1451.7) 
 
3.85 
 
3.85 
 
 10 (10)            9 (9)                                4 (4) 
 
26-Fc (HBTU) 
 
19.79 
 
4 
 
1507.8 (1507.8) 
 
3.7 
 
3.7 
 
 10 (10)            9 (9)                             12 (12) 
 
27-Fc (HBTU) 
 
18.5 
 
4 
 
1535.8 (1535.8) 
 
3.64 
 
3.64 
  
 10 (10)            9 (9)                             10 (10) 
 
28-Fc (HBTU) 
 
21.2 
 
4 
 
1525.8 (1525.8) 
 
3.66 
 
3.66 
 
 10 (10)            9 (9)               9 (8)          2 (2) 
 
32-Fc (HBTU) 
 
16.3 
  
849.3 (856.9) 
 
6.52   
 
6.3 
  
     4 (4)         8.7 (9)            14 (12)         8 (8) 
 
33-Fc (HBTU) 
 
16.34 
 
 
 
2109.0 (2134.4) 
 
2.62 
 
2.33 
 
     4 (4)            8 (9)        130 (128)         7 (8) 
 
a Mole ratio  of hydrosolubilizing to drug-anchoring groups after 1H NMR integration. 
b Molecular weight, actual. (in parenthesis, calculated for 100% acylation.) 
c Mass percentage derived from 100% acylation. 
d Mass percentage derived from 1H NMR spectrum of conjugate (error limit ± 12%). 
e In D2O, pH 10-11, chemical shifts, δ/ppm, referenced against internal sodium 3-trimethylsilyl-2,2,3,3-d4-propionate; integration error limits ± 12 %. Protons are calculated for structural 
representations in Table 4.25. 
f Expected count for composition in accordance with recurring unit (see b). 
g Proton assignment, δ/ppm: 4.8-4.5 (CONHCH2HNCO); 4.3-4.25 (CH of ferrocenyl); 3.8-3.5 (OCH2CH2O); 1.8-1.5 (CH2CH2CH2). 
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   Table 4.28: Summary of analytical data for Fc (HBTU) conjugates 
 
 
Conjugates 
 
designation 
 
η inh 
 
(mL g-1) 
 
% Fe 
 
Calcd a 
 
% Fe 
 
UV- ε440 b 
 
% Fe 
 
NMR c 
 
NH2 acylation 
(%) 
UV d 
 
NH2 acylation 
(%) 
NMR e 
 
1-Fc (HBTU) 
 
15.96 
 
2.52 
 
2.45 
 
2.52 
 
98 
 
100 
 
3-Fc (HBTU) 
 
13.7 
 
2.49 
 
2.48 
 
2.49 
 
100 
 
100 
 
5-Fc (HBTU)  
 
12.5 
 
2.44 
 
2.39 
 
2.41 
 
98 
 
99 
 
25-Fc (HBTU) 
 
16.25 
 
3.85 
 
3.82 
 
3.85 
 
~100 
 
100 
 
26-Fc (HBTU) 
 
19.79 
 
3.7 
 
3.63 
 
3.7 
 
98 
 
100 
 
27-Fc (HBTU) 
 
18.5 
 
3.64 
 
3.58 
 
3.64 
 
99 
 
100 
 
28-Fc (HBTU) 
 
21.2 
 
3.66 
 
3.61 
 
3.66 
 
99 
 
100 
 
32-Fc (HBTU) 
 
16.3 
 
6.52   
 
6.25 
 
6.3 
 
96 
 
97 
 
33-Fc (HBTU) 
 
16.34 
 
2.62 
 
2.3 
 
2.33 
 
88 
 
89 
 
a Mass percentage calculated for 100% acylation. 
b Mass percentage derived from UV-absorbance of bound Fc in H2O at 440 nm  using ε = 100 cm-1M-1. 
c Mass percentage derived from 1H NMR spectrum of conjugate (error limit ± 12%). 
d Ratio of b to a. 
e Ratio of c to a. 
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The HBTU-mediated coupling method afforded ferrocene conjugates in yields of 
39-72%, with inherent viscosities varying from 12 to 21 mL g-1. These viscosities 
were higher when compared with those of the precursor carriers, in accordance 
with presence of drug molecules in the chains. 
The solid-state IR spectra of these ferrocene conjugates retained the bands of the 
precursor carriers, notably the amide I band, in the 1680-1620 cm-1 region. The 
typical bands of the ferrocene system were buried in the underlying carrier bands. 
 
The 1H NMR spectra of the conjugates displayed the signals of the respective 
carriers and those of the incorporated ferrocenylation agent, especially the 
ferrocenyl (C-H) protons whose signal (4.3-4.25 ppm) was used for the 
assessment of the drug content in comparison with other prominent signals.   For 
ferrocene conjugates 1-Fc (HBTU), 3-Fc (HBTU) and 5-Fc (HBTU) the 
prominent signal was that in the 1.8-1.5 ppm region, assigned to methylene 
(CH2CH2CH2) protons. Thus, these conjugates were found to contain of 2.52, 
2.49 and 2.41% of Fe by mass, respectively. This corresponds to 100, 100, and 
99% of NH2 acylation, respectively. Independent determination by UV 
spectroscopy using the molar extinction coefficient (ε = 100 mol-1cm-1) and the 
absorbance at λ = 440 nm in H2O showed that these conjugates contain 2.45, 
2.48, and 2.39% of Fe by mass, corresponding to 98, 100, and 98% extent of 
conjugation.  
The assessment using the signal of methylene (CONHCH2NHCO) protons (4.8-
4.5 ppm) which belongs exclusively to the poly(amidoamine)-type carriers, 
showed the conjugates 25-Fc (HBTU) to 32-Fc (HBTU) to possess Fe contents 
in the 3.8-6.3% range, corresponding to conjugation extents in the range of 97 to 
100%. This was confirmed by the UV spectroscopic analysis (see Table 4.28). 
These high degrees of conjugation, which were obtained in one step, proved the 
sufficiency of the molar feed ratio drug/polymer, which was in the 1.2-1.4 range. 
This finding contrasts somewhat with a reported investigation 170 where high 
conjugation (95-100%) was achieved by using a drug/polymer molar feed ratio of 
1.8. In the present project, the high extent of conjugation could be due to the 
mode of reactant addition. Indeed, when the drug is allowed to react alone with 
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the coupling agent (HBTU) for an hour, this could favor the formation of active 
species which, when added to the predissolved polymer, could readily interact 
with the primary amino groups for a period of 2h. This finding requires re-
investigation as it results from a small number of conjugates. 
 
32-Fc (HBTU) (characterized by the presence of a short PEO segment with n = 
3) was found to contain 6.4 and 6.25% of Fe by mass, which were determined by 
NMR and UV spectroscopy, respectively. These iron contents correspond to 
extents of conjugation of 95-97%. Conjugate 33-Fc (HBTU) contains 2.38% of 
Fe (determined by NMR). This corresponds to drug incorporation of 89% level, 
and indicates low ferrocenylation of polymer 33. The undersubstitution of this 
polymer could be due to lesser accessibility to the drug-anchoring site (possibly) 
caused by the long and flexible backbone (PEO, n = 32). However, more 
investigation will be required to elucidate this question. 
4.2.2.2 Polymer-ferrocene conjugation by active ester coupling method 
A series of 32 screening experiments were performed in order to assess the 
coupling efficiency of the new active ester, para-nitrophenyl 4-
ferrocenylbutanoate (Fc-ONp). This active ester was intended to act as an 
alternative to the extensively used N-succinimidyl 4-ferrocenylbutanoate (Fc-
OSU) in this laboratory. These experiments involved the treatment of the Fc-ONp 
ester with selected carriers of polyaspartamide and poly(amidoamine) types in 
molar ester/carrier ratios of 1.2 as. Scheme 4.11 depicts their preparation. 
The resulting water-soluble conjugates were purified by size exclusion 
chromatography and aqueous dialysis in a buffer medium as described for 
preceding ferrocene conjugates. The products were isolated in the solid state by 
freeze-drying.  
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Scheme 4.11: Preparation of ferrocene-conjugates by ONp active ester coupling method  
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Polymer 32, which features a short PEO solubilizing segment in the main chain, 
was treated with 1.3 equivalent of the active HSU ester (Fc-OSU) in methanolic 
medium. This was to test the coupling efficaciousness on replacing DMF with 
methanol. The resulting ferrocene conjugate was treated and isolated in a similar 
manner as described for the preceding conjugates.  
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Scheme 4.12: Preparation of poly(amidoamine)-ferrocene conjugate in methanol  
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Table 4.29: Composition of ferrocene conjugates prepared by the ONp active 
ester method 
R' y
 
*
R
x
 
NHO n
 
R'
x
 
NH
O Fe
* NH CH CO
CONH x
 
NH CH CO
CONH y
 
R R'
NH
O Fe
NH
O Fe
1-Fc (ONp) - 20-Fc (ONp)
25-Fc (ONp) - 28-Fc (ONp)
32-Fc (ONp) - 33-Fc (ONp)
CONH     NHCO     N CONH     NHCO     N
CONH     NHCO     N CONH     NHCO     NH
 
 
Carriers 
 
R 
 
R´ 
Conjugates 
designation 
 
1 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3- 
 
1-Fc (ONp) 
 
2 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3- 
 
2-Fc (ONp) 
 
3 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 NH(CH2)2- 
 
3-Fc (ONp) 
 
4 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 NH(CH2)2- 
 
4-Fc (ONp) 
 
5 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
5-Fc (ONp) 
 
7 (90:10) 
 
-(CH2)3N(CH3)2 
 
-CH2CHOHCH2- 
 
7-Fc (ONp) 
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Table 4.29 continued 
 
Carriers 
 
R 
 
R´ 
Conjugates 
designation 
 
8 (90:10) 
 
-(CH2)2OH 
 
-(CH2)2 NH(CH2)2- 
 
8-Fc (ONp) 
 
10 (90:10) 
 
-(CH2)2OH 
 
-CH2CHOHCH2- 
 
10-Fc (ONp) 
 
11 (90:10) 
 
-(CH2)2OH 
 
-(CH2)3- 
 
11-Fc (ONp) 
 
12 (90:10) 
 
-(CH2)2OH 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
12-Fc (ONp) 
 
13 (90:10) 
 
-(CH2)2 O(CH2)2OH 
 
-(CH2)2 NH(CH2)2- 
 
13-Fc (ONp) 
 
14 (80:20) 
 
-(CH2)2 O(CH2)2OH 
 
-(CH2)2 NH(CH2)2- 
 
14-Fc (ONp) 
 
16 (90:10) 
 
-(CH2)2 O(CH2)2OH 
 
-CH2CHOHCH2- 
 
16-Fc (ONp) 
 
17 (90:10) 
 
-(CH2)2OCH3 
 
-(CH2)2 NH(CH2)2- 
 
17-Fc (ONp) 
 
19 (90:10) 
 
-(CH2)2OCH3 
 
-(CH2)3- 
 
19-Fc (ONp) 
 
20 (90:10) 
 
-(CH2)2OCH3 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
20-Fc (ONp) 
 
25 (80:20) 
 
  -(CH2)2N(CH3)2 
 
-(CH2)3- 
 
25-Fc (ONp) 
 
27 (80:20) 
 
-(CH2)3N(CH3)2 
 
-(CH2)2 NH(CH2)2- 
 
27-Fc (ONp) 
 
28 (80:20) 
 
-(CH2)2N(CH3)2 
 
-(CH2)2 O(CH2)2O(CH2)2- 
 
28-Fc (ONp) 
 
32 (n = 3) 
  
-(CH2)3- 
 
32-Fc (ONp) 
 
33 (n = 32) 
  
-(CH2)3- 
 
33-Fc (ONp) 
 
32 (n = 3) 
  
-(CH2)3- 
 
32-Fc (OSU) 
 
Tables 4.30 and 4.31 summarize the reaction conditions and 1H NMR and 
viscometric results, respectively, while Table 4.32 shows the summary of all the 
analytical data. 
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Table 4.30: Reaction conditions for ferrocene conjugates prepared by the ONp active ester method 
 
 
Reactants in feed  
 
 
Fc (ONp)  conjugates 
 
Carriers  
 
Drug active 
ester 
 
Medium 
 
Carrier :  
active ester a (mol-%) 
 
 
 
Reaction 
 
 conditions  
 
Yield 
(%) b 
 
Designation 
 
1 (90:10)  
 
Fc-ONp 
 
DMSO 
 
1:1.2 
 
12h, RT 
 
55 
 
1-Fc (ONp) c 
 
2 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
55 
 
2-Fc (ONp)  
 
3 (90:10)  
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
58 
 
3-Fc (ONp) d 
 
4 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
58 
 
4-Fc (ONp) 
 
5 (90:10)  
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
55 
 
5-Fc (ONp) d 
 
7 (90:10) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
59 
 
7-Fc (ONp) 
 
8 (90:10)  
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
69 
 
8-Fc (ONp) c 
 
10 (90:10) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
71 
 
10-Fc (ONp) 
 
11 (90:10)  
 
´´ 
 
´´ 
 
´´ 
 
8h, RT 
 
73 
 
11-Fc (ONp) d 
 
12 (90:10)  
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
75 
 
12-Fc (ONp) d 
 
13 (90:10)  
 
´´ 
 
´´ 
 
´´ 
 
10h, RT 
 
75 
 
13-Fc (ONp) c 
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Table 4.30 continued 
 
Reactants in feed 
 
Fc (ONp)  conjugates  
 
 
Carriers 
 
Drug active 
ester 
 
Medium 
 
Carrier : 
active ester (mol-%) a 
 
 
Reaction  
 
conditions  
 
Yield (%) b 
 
Designation 
 
14 (80:20) 
 
Fc-ONp 
 
DMSO 
 
1:1.2 
 
10h, RT 
 
57 
 
14-Fc (ONp) 
 
16 (90:10) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
46 
 
16-Fc (ONp) d 
 
17 (90:10) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
74 
 
17-Fc (ONp) d 
 
19 (90:10) 
 
´´ 
 
´´ 
 
´´ 
 
8h, RT 
 
78 
 
19-Fc (ONp) 
 
20 (90:10) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
50 
 
20-Fc (ONp) 
 
25 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
10h, RT 
 
51 
 
25-Fc (ONp) 
 
27 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
42 
 
27-Fc (ONp) 
 
28 (80:20) 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
42 
 
28-Fc (ONp) 
 
32 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
48 
 
32-Fc (ONp) 
 
33 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
44 
 
33-Fc (ONp) 
 
32 
 
Fc-OSU 
 
MeOH 
 
1:1.3 
 
72h, RT 
 
40 
 
32-Fc (OSU) 
 
a Molar ratio of carrier repeating unit to Ferrocenylbutanoic acid active ester. 
b Conjugate yield after size exclusion chromatography and ultimate (25 000 molecular weight cut-off) dialysis. 
c Reaction performed in duplicate and data averaged. 
d Reaction performed in triplicate and data averaged.
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Table 4.31: 1H NMR and viscometric results for all Fc (ONp) conjugates  
 
 
 
 
Conjugates 
 
designation 
 
 
 
η inh 
 
(mL g-1) a 
 
 
 
x/y b 
 
 
 
Base molecular  
 
mass c 
 
 
 
% Fe 
 
Calcd. d 
 
 
 
% Fe 
 
NMR e 
 
Protons counted  f (expected) g 
 
chemical shift (ppm) 
 δ 4.8-4.5 h      δ 4.3-4.25       δ 3.8-3.5      δ 1.8-1.5 
 
1-Fc (ONp) 
 
15.92 
 
9 
 
2218.5 (2218.5) 
 
2.52 
 
2.52 
 
                              9 (9)                                 22 (22) 
 
2-Fc (ONp) 
 
13.15 
 
4.1 
 
1214.7 (1222.3) 
 
4.57 
 
4.45 
 
                         8.73 (9)                                12 (12) 
 
3-Fc (ONp) 
 
13.25 
 
9 
 
 2247.6 (2247.6) 
 
2.49 
 
2.49 
 
                              9 (9)                                20 (20) 
 
4-Fc (ONp) 
 
12.85 
 
4 
 
1251.4 (1251.4) 
 
4.46 
 
4.46 
 
                              9 (9)                                10 (10) 
 
5-Fc (ONp) 
 
11.95 
 
9.3 
 
2285.1 (2292.7) 
 
2.44 
 
2.37 
 
                           8.7 (9)                                20 (20) 
 
7-Fc (ONp) 
 
14.5 
 
9.5 
 
2221.9 (2234.6) 
 
2.5 
 
2.39 
 
                         8.51 (9)                                20 (20) 
 
8-Fc (ONp) 
 
17.75 
 
9 
 
1877.8 (1877.8) 
 
2.97 
 
2.97 
 
                              9 (9)               18 (18) 
 
10-Fc (ONp) 
 
13.75 
 
9.3 
 
1857.2 (1864.8) 
 
3.0 
 
2.92 
                            
                         8.73 (9)               19 (19) 
 
11-Fc (ONp) 
 
13.5 
 
9.2 
 
 1843.7 (1848.8) 
 
3.02 
 
2.97 
                             
                         8.79 (9)               18 (18) 
 
12-Fc (ONp) 
 
14.28 
 
9.3 
 
 1915.2 (1922.9) 
 
2.9 
 
2.83 
                             
                          8.75 (9)              26 (26) 
 
13-Fc (ONp) 
 
15.25 
 
9 
 
2274.3 (2274.3) 
 
2.46 
 
2.46 
 
                               9 (9)              54 (54) 
 
14-Fc (ONp) 
 
13.50 
 
4.2 
 
1258.1 (1263.2) 
 
4.42 
 
4.35 
 
                          8.82 (9)              24 (24) 
 
16-Fc (ONp) 
 
12.86 
 
9.2 
 
2256.2 (2261.3) 
 
2.47 
 
2.43 
 
      8.82 (9)              55 (55) 
 
17-Fc (ONp) 
 
18.5 
 
9 
 
2004.1 (2004.1) 
 
2.79 
 
2.79 
 
           9 (9)              45 (45) 
 
19-Fc (ONp) 
 
16.89 
 
9 
 
1975.1 (1975.1) 
 
2.83 
 
2.83 
 
                               9 (9)               45 (45)        2 (2) 
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Table 4.31 continued 
 
 
 
Conjugates 
 
 
designation 
 
 
 
η inh 
 
(mL g-1) 
 
 
 
x/y a 
 
 
 
Base molecular  
 
mass b 
 
 
 
% Fe 
 
Calcd c 
 
 
 
% Fe 
 
NMR d 
 
Protons counted e (expected) f 
 
chemical shift (ppm) 
 δ 4.8-4.5 g      δ 4.3-4.25       δ 3.8-3.5      δ 1.8-1.5       
 
20-Fc (ONp) 
 
15.45 
 
9.2 
 
2044.1 (2049.1) 
 
2.73 
 
2.68 
 
                           8.82 (9)          53 (53) 
 
25-Fc (ONp) 
 
14.5 
 
4 
 
1451.7 (1451.7) 
 
3.85 
 
3.85 
 
 10 (10)                   9 (9)                                    4 (4) 
 
27-Fc (ONp) 
 
17.05 
 
4 
 
1535.9 (1535.9) 
 
3.64 
 
3.64 
  
 10 (10)                   9 (9)                                 10 (10) 
 
28-Fc (ONp) 
 
22.05 
 
4 
 
1525.8 (1525.8) 
 
3.66 
 
3.66 
 
 10 (10)                   9 (9)              9 (8)               2 (2) 
 
32-Fc (ONp) 
 
15.75 
  
854.4 (856.9) 
 
6.52 
 
6.45 
  
    4 ( 4)                8.9 (9)           13 (12)              9 (8) 
 
33-Fc (ONp) 
 
16.85 
 
 
 
2126.8 (2134.4) 
 
2.62 
 
2.53 
 
     4 (4)                8.7 (9)       130 (128)              7 (8) 
 
32-Fc (OSU) 
 
15.05 
  
839.1 (856.9) 
 
6.52 
 
6.08 
  
     4 (4)                8.4 (9)           14 (12)            10 (8) 
 
a Mole ratio of hydrosolubilizing to drug-anchoring groups after 1H NMR integration, given by the carrier. 
b Molecular weight, actual. (in parenthesis, calculated for 100% acylation). 
c Mass percentage of Fe calculated for 100% acylation. 
d Mass percentage of Fe derived from 1H NMR spectrum (error limit ± 15%). 
e In D2O, pH 10-11, chemical shifts, δ/ppm, referenced against internal sodium 3-trimethylsilyl-2,2,3,3-d4-propionate; integration error limits ± 12 %.  
Protons are calculated for structural representations in Table 4.29.   
f Expected count for composition in accordance with recurring unit (see b). 
g Proton assignment, δ/ppm: 4.8-4.5 (CONHCH2HNCO); 4.3-4.25 (CH of ferrocenyl); 3.8-3.5 (OCH2CH2O); 1.8-1.5 (CH2CH2CH2). 
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Table 4.32: Summary of analytical results for all Fc (ONp) conjugates  
 
 
Conjugates 
 
designation 
 
η inh  
 
(mL g-1) 
 
% Fe 
 
Calcd a 
 
% Fe 
 
UV- ε440 b 
 
% Fe 
 
NMR c 
 
NH2 acylation (%) 
 
UV d 
 
NH2 acylation (%) 
 
NMR e 
 
1-Fc (ONp) 
 
15.92 
 
2.52 
 
2.48 
 
2.52 
 
99 
 
100 
 
2-Fc (ONp) 
 
13.15 
 
4.57 
 
4.48 
 
4.45 
 
98 
 
97 
 
3-Fc (ONp) 
 
13.25 
 
2.49 
 
2.46 
 
2.49 
 
99 
 
100 
 
4-Fc (ONp) 
 
12.85 
 
4.46 
 
4.42 
 
4.46 
 
99 
 
100 
 
5-Fc (ONp) 
 
11.95 
 
2.44 
 
2.39 
 
2.37 
 
99 
 
97 
 
7-Fc (ONp) 
 
14.5 
 
2.5 
 
2.45 
 
2.39 
 
97 
 
95 
 
8-Fc (ONp) 
 
17.75 
 
2.97 
 
2.94 
 
2.97 
 
99 
 
100 
 
10-Fc (ONp) 
 
13.75 
 
3.0 
 
2.88 
 
2.92 
 
96 
 
97 
 
11-Fc (ONp) 
 
13.5 
 
3.02 
 
2.98 
 
2.97 
 
99 
 
98 
 
12-Fc (ONp) 
 
14.28 
 
2.9 
 
2.85 
 
2.82 
 
98 
 
97 
 
13-Fc (ONp) 
 
15.25 
 
2.46 
 
2.41 
 
2.46 
 
98 
 
100 
 
14-Fc (ONp) 
 
13.50 
 
4.42 
 
4.3 
 
4.35 
 
97 
 
98 
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Table 4.32 continued  
 
Conjugates 
 
designation 
 
η inh  
 
(mL g-1) 
 
% Fe 
 
Calcd a 
 
% Fe 
 
UV- ε440 b 
 
% Fe 
 
NMR c 
 
NH2 acylation (%) 
 
UV d 
 
NH2 acylation (%) 
 
NMR e 
 
16-Fc (ONp) 
 
12.86 
 
2.47 
 
2.45 
 
2.43 
 
99 
 
98 
 
17-Fc (ONp) 
 
18.5 
 
2.79 
 
2.73 
 
2.79 
 
98 
 
100 
 
19-Fc (ONp) 
 
16.89 
 
2.83 
 
2.75 
 
2.83 
 
97 
 
100 
 
20-Fc (ONp) 
 
15.45 
 
2.73 
 
2.70 
 
2.68 
 
99 
 
98 
 
25-Fc (ONp) 
 
14.5 
 
3.85 
 
3.8 
 
2.85 
 
99 
 
100 
 
27-Fc (ONp) 
 
17.05 
 
3.64 
 
3.57 
 
3.64 
 
98 
 
100 
 
28-Fc (ONp) 
 
22.05 
 
3.66 
 
3.60 
 
3.66 
 
98 
 
100 
 
32-Fc (ONp) 
 
15.75 
 
6.52 
 
6.54 
 
6.45 
 
100 
 
99 
 
33-Fc (ONp) 
 
16.85 
 
2.62 
 
2.58 
 
2.53 
 
99 
 
97 
 
32-Fc (OSU) 
 
15.05 
 
6.52 
 
6.01 
 
6.08 
 
92 
 
93 
 
a Mass percentage calculated for 100% acylation. 
b Mass percentage derived from UV absorbance of bound Fc in  H2O at 440 nm; ε =100 cm-1M-1. 
c Derived from 1H NMR spectrum (error limit ± 12%). 
d Ratio of b to a. 
e Ratio of c to a.  
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The Fc (ONp) conjugates were obtained in yields that varied from 42 to 78%, and 
were characterized by inherent viscosities in the 12-22 mL g-1 range. The Fe 
content, which was calculated from the percentage of ferrocene incorporation, was 
found to be in the range of 2.4-6.5% by mass. Independent analysis by UV-vis 
absorption spectroscopy performed on these conjugates confirmed the above 
results of Fe content (see Table 4.32). These results show that under the 
experimental conditions, acylation of primary amines available in the carriers 
were achieved in the 97-100% range. The highest extent of undersubstitution was 
3%.  This allows the inference that the coupling method was efficient, and the 
molar feed ester/carrier ratio of 1.2 was sufficient to ensure high extent of drug 
incorporation. In light of the polyhomologous nature of the ferrocenylation 
reactions, the extent of ferrocene incorporation in the individual runs was not 
expected to be strictly reproducible. Therefore, some experiments were performed 
in duplicate or triplicate, and the tabulated data represent averages of the parallel 
runs.  
The ONp ester coupling method affords high extents of conjugation without 
recourse to additional treatment. The active Fc-OSU ester provides acylation of 
same the magnitude upon forcing conditions, which include molar feed 
ester/carrier ratios of 1.8, a reaction period of 48h at room temperature and 
another 3h at 65oC, and in some cases additional treatment with 0.5 equivalent of 
the ester 172. These facts allow for preference of the active ONp ester over the 
active OSU ester coupling technique.    
With the HBTU-mediated coupling, ferrocenylation levels in the order of 97-
100% were achieved upon use of drug/carrier molar feed ratios of 1.2-1.4 and 1.1-
1.3 equivalents of HBTU agent for a reaction period of 3h. The results of these 
screening experiments suggest active ONp ester and HBTU-mediated methods to 
be essentially of equivalent efficiency. However, in co-conjugation studies, the 
active ONp ester method would be preferred to the HBTU-mediated one, the latter 
being reported to cause main chain fragmentation 170, although such fragmentation 
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was not observed in the framework of this project for the nitrophenyl ester 
method.  
The efficacy of the active ONp ester method was also shown with the 
poly(amidoamine) carriers 32 and 33. The resulting ferrocene conjugates 32-Fc 
(ONp) and 33-Fc (ONp) were obtained in extents of ferrocenylation of 99 and 
97% determined by NMR spectroscopy. These correspond to 6.45 and 2.53% of 
Fe by mass, respectively. UV-vis analysis confirmed these results (refer Table, 
4.31 rows 9 and 10).  
The active OSU ester method used in methanolic medium showed the treatment of 
poly(amidoamine) carrier 32 with the ester in molar feed ratio of ester/polymer 
repeat unit of 1.3 at RT for 72h to afford conjugate 32-Fc (OSU) in yield of 40% 
with inherent viscosity 15.05 mL g-1. The acylation of available primary amino 
groups was found by NMR spectroscopy to be 93%, corresponding to 6.08% Fe 
by mass. As this ferrocenylation experiment was intended to demonstrate the 
drug-binding potential of poly(amidoamine) carriers in media other than DMF, 
namely in alcoholic, no further attempt was made to achieve complete substitution 
of NH2 groups by retreatment of the conjugate. 
4.2.3 Polymer multidrug conjugation   
As one of the tasks assigned to this project, the two anticancer compounds, MTX 
and ferrocene, were anchored to the same polymeric carrier backbone. The two 
drug systems operate by different cell killing mechanisms, and it was of interest 
here to establish potentiating or additive effects, if any, in subsequent bio-
evaluation work. The conjugation was achieved by amide bond formation, 
resulting from reaction of acid group of the drugs with the amine function of the 
carriers. Also co-conjugated were the pairs MTX-folic acid and ferrocene-folic 
acid by the same method. 
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4.2.3.1 Synthesis of polyaspartamide-co-drug conjugates  
The polyaspartamides 1(90:10) and 3(90:10), featuring tertiary amine- 
functionalized units as hydrosolubilizing and targeting moieties, were chosen to 
demonstrate the co-drug binding ability of these polymers. The choice was based 
on the report of cytotoxic activity performance of ferrocene conjugates against 
Colo 320 DM human colon cancer line 141 and current results (Section 4.2.1.4). 
Each carrier was conjugated to a pair of drug systems (MTX, Fc and FA), in a 
two-step procedure. Thus, the co-drug systems were symbolized by FA/MTX; 
FA/Fc and MTX/Fc, in reference to the following pairs; folic acid-methotrexate, 
folic acid-ferrocene, and methotrexate-ferrocene, respectively.  
In the first two pairs, folic acid was used as an additional targeting moiety, given 
that the folate cellular uptake occurs by a natural endocytosis pathway mediated 
by folate receptor (FR), the latter being overexpressed on the surface of a variety 
of cancer cells including colon cancer 43. Furthermore, since folate is an essential 
vitamin required in substantial quantities by virtually all dividing cells for purine, 
nucleotide, and DNA synthesis, one might speculate that folic acid would be 
avidly consumed, and hence required, by cancer cells. Consequently, the resulting 
co-conjugates, owing to the presence of the two targeting moieties i.e. the tertiary 
amine and folic acid, are expected to be more efficiently cell-selective in 
comparison with the conjugates possessing only the tertiary amine. Moreover, the 
presence of these entities suggests competitive mechanisms of cellular uptake, 
namely, folate receptor-mediated (folic acid) and adsorptive (tertiary amine) 
endocytosis. However, the fact that tertiary amine accounts for 90 mo-l% and 
folate at most 10 mol-% in the recurring unit, allows for speculation that the 
mechanism of cellular uptake of these co-conjugates would predominantly depend 
on cancer cell surface characteristics. In other words, since the FR is not a 
common characteristic of all cancerous cells, for those carrying negative surface 
charges, adsorptive endocytosis is expected to be the indicated mechanism of cell 
entry, while for others characterized by overexpressed FR, folate-mediated 
endocytosis would be the mechanism of cellular entry. 
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The simultaneous incorporation of MTX and ferrocene in these polymeric 
carriers, apart from exemplifying the co-drug conjugation ability, represents a tool 
for the delivery of two anticancer drugs with different mechanisms of biological 
activity. MTX is an antimetabolite and Ferrocene, an agent purportedly causing 
oxidative DNA damage. The MTX/Fc co-conjugates could be to be more efficient 
in cancer-cell killing than the individual drugs. The advantages of synergistic 
effects were reported by Buzdar and co-workers 144. 
The first step leading to the formation of homoconjugate with desired 50% NH2 
acylation was generally HBTU-mediated. It involved the treatment of the carrier 
with 0.7-0.8 equivalents of the first drug and 0.6 equivalent of HBTU. After 
conventional work-up and isolation, the drug content was determined by 
spectroscopic analysis. In the second step, the homoconjugate was allowed to 
react with the second drug through either a second HBTU coupling or by the 
active ester method. Scheme 4.16 exemplifies the preparation of FA/MTX co-
conjugate. Moreover, in all cases, either MTX or FA was anchored as the first 
drug to ensure incorporation i.e. 50% NH2 acylation. With MTX or FA acid-
bifunctionalized, there will be competitive reaction of the α and γ carboxylic 
groups of the glutamic moiety. Therefore, during the first step, characterized by 
more primary amino groups available for drug binding, the probability of MTX or 
FA drug loading up to the expected level will be increased.  
In the cases of co-conjugation involving the ferrocene system, generally as the 
second drug, the active ester coupling was preferred over HBTU-mediated 
coupling to avoid main chain fragmentation.  
The water-soluble co-conjugates were precipitated from solution and, after 
fractionation and purification by size exclusion chromatography and aqueous 
dialysis, were isolated by freeze-drying. Drug contents, in percent by mass, were 
determined by various analytical methods, with inductively coupled plasma-
optical emission spectroscopy (ICP-OES) used exclusively for iron. In cases of 
undersubstitution (i.e. below 95% of available primary amino groups), the co-
conjugates were retreated with 0.8 equivalent of the second drug.   
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Scheme 4.13: Preparation of polyaspartamide FA/MTX co-conjugates
1. FA, HBTU, DMF, 2h, RT
 y-z
2. MTX, HBTU, DMF-HMP, 3h, RT
y-z
 
Tables 4.33 and 4.34 show the composition of these co-conjugates and the 
reaction conditions, respectively, whereas Table 4.35 reports the viscometric and 
1H NMR results, and Table 4.36 gives a summary of all analytical results. 
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Table 4.33: Composition of PAsA co-conjugates 
 
* NH
x
 
NH CH CO
CONH z
 
R R'
CH CO
CONH
R'
NH CH CO
CONH
D1: drug 1 D2: drug 2D2D1
y-z
 
 
Carriers 
 
 
R 
 
R’ 
 
x/y 
 
D1 
 
D2 
 
Co-conjugates 
designation 
 
1 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3- 
 
9 
 
FA 
 
MTX 
 
1 (90:10)-FA/MTX 
 
3 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3N(CH2)2- 
 
9 
 
FA 
 
MTX 
 
3 (90:10)-FA/MTX 
 
1 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3- 
 
9 
 
FA 
 
Fc 
 
1 (90:10)-FA/Fc 
 
3 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3N(CH2)2- 
 
9 
 
FA 
 
Fc 
 
3 (90:10)-FA/Fc 
 
1 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3- 
 
9 
 
MTX 
 
Fc 
 
1 (90:10)-MTX/Fc 
 
3 (90:10) 
 
-(CH2)3N(CH3)2 
 
-(CH2)3N(CH2)2- 
 
9 
 
MTX 
 
Fc 
 
3 (90:10)-MTX/Fc 
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Table 4.34: Reaction conditions for all PAsA co-conjugates 
 
 
Reactants in feed  
 
 
PAsA co-conjugates 
 
 
Carriers  
 
Drug (or) active 
ester /(coupling 
agent) 
 
Carrier : drug (or active 
ester) : coupling agent 
ratio (mol-%) a 
 
 
Medium 
 
 
 
Reaction 
 
conditions b 
 
 
Yield 
 
(%) c 
 
 
Designation 
 
1 (90:10) 
 
 
Step 1: FA/HBTU 
Step 2: MTX/HBTU 
 
Step 1: 1:0.7:0.6  
Step 2: 1:0.8:0.5 
 
Step 1: DMF 
Step 2: DMF-HMP 
 
Step 1: 2h, RT 
Step 2: 3h, RT 
 
53 d 
 
1 (90:10)-FA/MTX
 
3 (90:10) 
 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
65 d 
 
3 (90:10)-FA/MTX
 
1 (90:10) 
 
 
Step 1: FA/HBTU 
Step 2: Fc-ONp 
 
Step 1: 1:0.7:0.6  
Step 2: 1:0.8 
 
Step 1: DMF 
Step 2: DMSO 
 
Step 1: 2h, RT 
Step 2: 10h, RT 
 
75 
 
1 (90:10)-FA/Fc 
 
3 (90:10) 
 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
62 
 
3 (90:10)-FA/Fc 
 
1 (90:10) 
 
 
Step 1: MTX/HBTU 
Step 2: Fc-ONp 
 
Step 1: 1:0.8:0.7 
Step 2: 1:0.8 
 
´´ 
 
´´ 
 
75 
 
1 (90:10)-MTX/Fc 
 
3 (90:10) 
 
 
´´ 
 
´´ 
 
´´ 
 
´´ 
 
63 
 
3 (90:10)-MTX/Fc 
 
a Molar ratio of carrier repeating unit to drug to coupling agent in step 1, and molar ratio of homoconjugate to drug (or active ester)  (to coupling agent)  in step 2. 
b RT= room temperature. 
c Co-conjugate yield ( based on starting homoconjugate) after size exclusion chromatography and ultimate (25 000 molecular weight cut-off) dialysis. 
d Yield (based on starting co-conjugate) after posttreatment. 
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  Table 4.35: 1H NMR and viscometric results for PAsA co-conjugates 
 
 
Co-conjugates 
 
designation 
 
 
 
x 
 
 
 
z a 
 
 
 
y b 
 
 
 
y-z c 
 
 
% MTX 
 
Found d 
 
 
% FA 
 
Found d 
 
 
% Fe 
 
Found d 
Protons counted e (expected) f 
 
chemical shift (ppm) 
 
δ 8.5-6.5 g       δ 4.25-4.0      δ 3.5-3.0         δ 1.8-1.5 
 
1 (90:10)-FA/MTX 
 
90 
 
5.8 
 
9.7 
 
 
 
 
 
 
 
 
 
 4.83 (5)                       -            23 (22)          20 (20) 
 
3 (90:10)-FA/MTX 
 
´´ 
 
4.3 
 
9.6 
 
 
 
 
 
 
 
 
 
   4.8 (5)                   -                22 (22)         18 (18)        
 
1 (90:10)-FA/Fc 
 
´´ 
 
5.8 
 
10 
 
4.9 
 
 
 
9.38 
 
1.2 
 
   2.6 (5)            4.4 (9)           21.7 (22)         21 (21) 
 
3 (90:10)-FA/Fc 
 
´´ 
 
4.6 
 
9.8 
 
5.3 
 
 
 
8.57 
 
1.28 
 
   2.3 (5)            4.8 (9)           21.5 (22)         19 (19)        
 
1 (90:10)-MTX/Fc 
 
´´ 
 
4.8 
 
9.9 
 
5.5 
 
8.7 
 
 
 
1.3 
 
   2.2 (5)          4.95 (9)              22 (22)      20.6 (21) 
 
3 (90:10)-MTX/Fc 
 
´´ 
 
4.3 
 
9.8 
 
5.6 
 
8.23 
 
 
 
1.35 
 
   2.1 (5)            5.1 (9)              22 (22)         19 (19)        
 
a Mol-% of first drug derived from 1H NMR after step 1.  
b Total mol-% of drugs derived from 1H NMR after step 2. 
c Mol-% of second drug derived from 1H NMR after step 2. 
d Mass percentage of drug derived from 1H NMR after step 2. 
e In D2O, pH 10-11, chemical shifts, δ/ppm, referenced against internal sodium 3-trimethylsilyl-2,2,3,3-d4-propionate; integration error limits ± 12 %.  
Protons are calculated for conjugate composition (Scheme 4.13). 
f Expected count for composition in accordance with recurring unit (see b). 
g Proton assignment, δ/ppm: 8.6-6.6 (aromatic and heteroaromatic CH of MTX and (or) FA); 4.3-4.25 (CH of ferrocenyl); 3.5-3.0 (CONHCH2); 1.8-1.5 (CH2CH2CH2). 
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   Table 4.36: Summary of analytical data for all PAsA co-conjugates 
η inh 
(mL g-1) a 
 
Carriers 
 
designation 
 
Homoconjugate 
(step 1) 
 
Co-conjugate 
 
 
 
y b 
 
 
% MTX 
 
UV c 
 
 
% MTX 
 
NMR d 
 
 
% Fe 
 
OES e 
 
 
% Fe 
 
NMR d 
 
 
% FA 
 
UV c 
 
 
% FA 
 
NMR d 
 
 
NH2 acylation 
 
(%) f 
 
1 (90:10)-FA/MTX 
 
15.05 
 
16.01 
 
9.7 
 
8 
 
7.45 
 
- 
 
- 
 
- 
 
11.58 
 
97 g 
 
3 (90:10)-FA/MTX 
 
13.25 
 
14.5 
 
9.6 
 
10.58 
 
10.0 
 
- 
 
- 
 
- 
 
8.7 
 
96 g 
 
1 (90:10)-FA/Fc 
 
18.0 
 
19.75 
 
10 
 
- 
 
- 
 
1.25 
 
1.2 
 
9.55 
 
9.8 
 
100 
 
3 (90:10)-FA/Fc 
 
14.05 
 
15.5 
 
9.8 
 
- 
 
- 
 
1.12 
 
1.28 
 
8.75 
 
9.0 
 
98 
 
1 (90:10)-MTX/Fc 
 
16.5 
 
17.05 
 
9.9 
 
8.37 
 
8.7 
 
1.24 
 
1.34 
 
- 
 
- 
 
99 
 
3 (90:10)-MTX/Fc 
 
14.25 
 
15.3 
 
9.8 
 
8.23 
 
8.66 
 
1.28 
 
1.35 
 
- 
 
- 
 
98 
 
a At 30.0 ± 0.5 o C, in deionized H2O; concentration c = 2 mg/mL. 
b Total mol-% of drugs derived from 1H NMR after step 2. 
c Mass percentage calculated from UV absorbance of MTX and FA in H2O at 370 nm using ε = 6500 M-1cm-1 and 6200 M-1cm-1,  respectively. 
d Mass percentage derived from 1H NMR spectrum (error limit ± 12%) assuming  no loss of first drug  during step 2. 
e Mass percentage of Fe obtained by ICP-OES. 
f Derived from  co-conjugate composition after step 2.  
g In parallel experiments conducted under identical or modified conditions, percentage acylation ranged from 74-92%, requiring retreatment.
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As can be seen in Table 4.33, the polyaspartamide co-drug conjugates were 
obtained in yields of 53-75%. They were characterized by inherent viscosities in 
the range of 16-20 mL g-1. These were higher than those of the precursor carriers 
(11-12 mLg-1) and the derived homoconjugates (13-18 mL g-1). The FA/Fc and 
MTX/Fc co-drugs were incorporated into polymer in overall extents of 98-100% 
NH2 whereas for FA/MTX, a posttreatment was required to achieve an extent of 
conjugation of 96-97%. The homoconjugates 1(90:10)-FA and 3(90:10)-FA 
resulting from the first step of the synthesis of FA/MTX co-conjugates showed 
extents of conjugation of 58 and 43%, respectively. These correspond to folate 
incorporation of 11.58 and 8.7 % FA by mass, respectively, determined by NMR 
spectroscopy (see Section 5.3.3.3). On balance, the undersubstitution observed 
with the co-conjugates 1(90:10)-FA/MTX and 3(90:10)-FA/MTX could 
reasonably be traced to the bifunctionality of MTX. Indeed, MTX being 
bifunctionlized doubles the probability of competitive reaction of the α and γ 
carboxylic groups of the glutamic moiety to the remaining free amino groups 
during the second step. The almost complete acylation observed with the FA/Fc 
and MTX/Fc co-conjugates involving Fc as second drug supports this argument 
because the ferrocene is monofunctionalized, and therefore no competitive 
reactivity occurs. For the FA/MTX co-conjugates, the exact MTX content by 
mass could not be assessed by NMR spectroscopy.  This, because the spectra of 
FA and MTX are identical especially in the aromatic and heteroaromatic of 8.5-
6.5 ppm region, of which peak integrals are commonly used for such 
determination (see Section 4.2.1.1). Thus, one had recourse to UV-vis 
spectroscopic analysis. The procedure is amply described in Section 5.3.4 (page 
204). This analytical technique revealed the co-conjugates 1(90:10)-FA/MTX and 
3(90:10)-FA/MTX to contain 8 and 10.58% MTX by mass, respectively. These 
MTX contents were in fair correspondence with those provided by NMR 
spectroscopy (i.e. 7.45 and 10%, respectively). The latter were obtained on 
assumption that no major loss of FA by cleavage occurred during the second step 
of this preparation.  
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For the determination of the exact Fe content by mass in the co-conjugates 
1(90:10)-FA/Fc to 3(90:10)-MTX/Fc, the ICP-OES method was used as an 
alternative to NMR spectroscopy. Thus, the co-conjugates 1(90:10)-FA/Fc and 
3(90:10)-FA/Fc were found to contain 1.25 and 1.12% Fe by mass, respectively. 
The co-conjugates 1(90:10)-MTX/Fc and 3(90:10)-MTX/Fc contained 1.24 and 
1.28 % Fe by mass, respectively. On assumption that the homoconjugates were 
stable enough to survive the second step, the NMR spectroscopy confirmed these 
Fe contents.  
Furthermore, the UV-vis spectra of Fc conjugates (Section 4.2.2.1) in H2O 
revealed almost no Fc absorption in the region 370-380nm which occurred with 
MTX. Therefore, it appears reasonable to attribute the absorption at 370nm to 
bound MTX in the spectra of MTX/Fc co-conjugates. The UV-vis determination 
of MTX content using the molar extinction coefficient value, ε = 6500 mol-1cm-1 
and the absorbance at λ = 370 nm in H2O, showed the co-conjugates 1(90:10)-
MTX/Fc and 3(90:10)-MTX/Fc to contain 8.37 and 8.23% MTX by mass, 
respectively. On assumption of homoconjuagte stablility retained during the 
second step, one finds the co-conjugates to be loaded with 8.7 and 8.66% MTX by 
mass, determined by 1H NMR.  
 
The clear correspondence of drug contents in the co-conjugates determined by the 
different analytical methods demonstrates that the polyaspartamide-type polymers 
were effective co-drug carriers, although only a small number of carriers were 
investigated. These results also show that there was no major loss of either MTX 
or folic acid during the two steps of the co-conjugation process.  
 
The IR spectra of these co-conjugates were dominated by the strong amide I and 
II bands at 1650 and 1540 cm-1. 
4.2.3.2 Cell culture testing 
The antiproliferative activity of the polyaspartamide co-conjugates was also 
evaluated against HeLa (drug-sensitive) and Colo (strongly drug-resistant) cell 
lines. The procedure was identical to that employed in previous cell culture testing 
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experiments. The performance of the Fe containing conjugates was referenced 
against that of free cisplatin used as control, while the activity of free MTX served 
as reference for the MTX co-conjugates. The IC50 values derived from plots of 
cell growth relative to untreated control versus conjugate concentration (Figures 
4.7 and 4.8), are compiled in Table 4.37 for both cell types. The table also 
comprises the IC50 data determined under the same conditions for free drugs 
(MTX and cisplatin) as well as the activity factors of the conjugates expressed in 
terms of IC50 (free drug)/ IC50 (co-conjugate). For comparison, data are also 
included for homoconjugates of MTX or ferrocene. 
Let us first inspect the data for folate-MTX conjugates. An averaged activity 
factor of 1.09 derives from an averaged IC50 value (0.047 µg MTX/mL) against 
HeLa cells. Against the resistant cells, an averaged factor of 3.14 is found, which 
derives from an averaged IC50 value (0.7955 µg MTX/mL). Thus, these co-
conjugates as a group are as active as free MTX against the sensitive line, and 
some 3-fold more active than the free drug against the strongly resistant cells.  
When comparing the activity factors of the homoconjugates with those of the 
folate-MTX co-conjugates, it can be seen that the folate by its presence reduces 
the cell-killing efficaciousness of the homoconjugates. Thus, these co-conjugates 
as group possess some 7- and 5-fold lower activity than homoconjugates as a 
group against HeLa and Colo cells, respectively. On comparing the performance 
of folate-MTX co-conjugates with their folic acid contents, there also appears a 
trend of decreasing activity with increased folate incorporation. Thus, by being 
less cytotoxic than the homoconjugates, the folate-MTX co-conjugates did not 
much improve the performance of MTX against the tested cells; hence, they do 
not represent an improvement of therapeutic effectiveness. This limits the utility 
of the simultaneous delivery of folic acid and its antagonist MTX.   
Let us now proceed with Fe containing conjugates.  The AF values reveal, on 
balance, all ferrocene samples to be less active than cisplatin as growth inhibitors 
against both cell lines. Averaged activity factors of 0.09 (from averaged IC50 
value, 0.852 µg Fe/mL) and 0.2 (from averaged IC50 value, 0.5988 µg Fe/mL) are 
found against HeLa and Colo cells, respectively. Thus, as a group the ferrocene 
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samples are some 11- and 5-fold less effective than free cisplatin in killing the 
sensitive and resistant cells, respectively. However, the IC50 values in the range of 
0.1-1.6 µg Fe/ml, are lower than previously reported values of 2-5 µg Fe/ml 
against HeLa cells 139 and 0.2-2 µg Fe/ml against Colo cells 141. 
Moreover, the decrease of antiproliferative activity upon folic acid incorporation, 
encountered with MTX-homoconjugates, is also apparent with those of the 
ferrocene-type. Thus, the folate-Fc co-conjugates as group experience 3- and 10-
times lower activity against the sensitive and resistant cells, respectively, in 
comparison to the homoconjugates. This loss of activity also increases with 
increasing incorporated folate.  
When considering the IC50 values, one finds co-conjugate 1-FA/Fc to be less 
active than 1-Fc against Colo cells. However, the cell-killing efficacy is more 
pronounced with 1-FA/Fc insofar as the ultimate extent of cell viability is 
concerned, with only 8% of cells surviving, whereas 1-Fc forms an unexpected, 
even slightly increasing plateau at the concentration of ~0.2 µg Fe/mL 
corresponding to about 30% cells surviving (Fig. 4.8(d)). Thus, the folate 
incorporation had a beneficial effect in this case.  
As folic acid incorporation did not improve significantly the cytotoxic activity of 
ferrocene against the sensitive cell line, the folate-ferrocene approach is not 
beneficial from a cancer therapeutic point of view. However, this approach could 
be an interesting route where the simultaneous delivery of folic acid and iron is 
needed. For pregnancy, where iron deficiency anaemia and folate deficiency 
macrocytic anaemia are the most encountered anaemias 174, there would be an 
appropriate case for the exploration of this approach. 
 
In summary: the data indicated that the incorporation of folic acid, contrary to 
expectation, profoundly reduces the efficacy in killing cancer cells of the 
polymer-drug conjugate of both MTX and ferrocene types. One could speculate 
that since folate is a cellular nutrient, once within the cell, it induces cancer cell 
proliferation.  However, the limited number of compounds investigated did not 
allow for drawing realistic conclusions. Therefore, more in vitro experiments will 
be required to elucidate the question of the reduction of cytotoxicity associated 
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with the folate-drug co-conjugates. As it stands, these preliminary results do not 
support the use of folic acid as a targeting moiety for the delivery of the drug 
systems herein investigated. 
  
153
Table 4.37: Antiproliferative activity of polyaspartamide co-conjugates 
 
Polyaspartamide co-conjugates 
 
 
HeLa  
 
CoLo 
 
Designation 
 
% MTX 
by mass 
 
% Fe 
by mass 
 
% FA 
by mass 
 
IC50 
(µg MTX/mL) 
 
AF a 
 
IC50 
(µg MTX/mL) 
 
AF 
 
1-MTX 
 
18.52 
 
- 
 
- 
 
0.013 
 
3.92 
 
0.196 
 
12.4 
 
3-MTX 
 
18.7 
 
- 
 
- 
 
0.0013 
 
39.2 
 
0.149 
 
16.2 
 
1-FA/MTX 
 
7.45 
 
- 
 
11.58 
 
0.054 
 
0.94 
 
1.426 
 
1.7 
 
3-FA/MTX 
 
10.0 
 
- 
 
8.7 
 
0.04 
 
1.3 
 
0.165 
 
14.7 
 
MTX 
 
- 
 
- 
 
- 
 
0.051 
 
- 
 
2.42 
 
-          
   
 
  
IC50 
(µg Fe/mL)  
 
AF c 
 
IC50 
(µg Fe/mL) 
 
AF 
 
1-Fc 
 
- 
 
2.5 
 
- 
 
0.124 
 
0.64 
 
0.032 
 
3.78 
 
3-Fc 
 
- 
 
2.49 
 
- 
 
0.741 
 
0.11 
 
0.171 
 
0.68 
 
1-FA/Fc 
 
- 
 
1.2 
 
9.8 
 
1.648 
 
0.05 
 
1.5 
 
0.08 
 
3-FA/Fc 
 
- 
 
1.28 
 
9.0 
 
0.895 
 
0.09 
 
0.692 
 
0.18 
 
Cisplatin 
 
- 
 
- 
 
- 
 
0.079 
 
- 
 
0.121 
 
- 
 
a Activity factor defined as IC50 [fre MTX] : IC50 [conjugate]. 
b Resistance factor defined as IC50 [Colo] : IC50 [HeLa].c Activity factor defined as IC50 [ free Cisp] : IC50 [conjugate]. 
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Figure 4.7: Antiproliferative activity of PAsA co-conjugates, free MTX, and free cisplatin against HeLa cells 
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Figure 4.8: Antiproliferative activity of PAsA co-conjugates, free MTX, and free cisplatin against Colo cells 
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CHAPTER 5 
 
EXPERIMENTAL SECTION 
5.1 General Procedures 
 
Solid-state Infrared (IR) spectra were recorded on KBr pellets over the region of 
4000-600 cm-1. However, only significant bands were cited in this thesis. 1H-
NMR spectra (in D2O solutions) were obtained using BRUKER AVANCE 300 
operating at 300 MHz; chemical shifts,δ in ppm, were referenced against sodium 
3-(trimethylsilyl)-2,2,3,3-d4-propionate (δHOD ≈ 4.83 ppm; integration error limit ± 
12%). Immediately prior to recording, the pH was adjusted to 10 (NaOH) in order 
to eliminate potential protonation effects. The spectra of conjugates were scanned 
in duplo and the derived intensities averaged for proton count determination. 
Inherent viscosities, ηinh, were determined at 30.0 ± 0.5oC in Cannon-Fenske 
tubes. Deionized water and DMF were the solvents (c = 0.2 g/100 mL), and the 
results, obtained as the mean of triplicate determinations, were given in units of 
mL g-1. Prior to dialysis, purification was performed by size exclusion 
chromatography on a 2.5 x 25 cm column loaded with Sephadex G-25 gel, eluted 
with distilled water. 
Dialysis operations were performed against deionized water in cellulose tubing, 
Spectra/Por 4 and Spectra/Por 6 (Spectrum Industries, Los Angeles, CA), with 
weight-average molecular weight cut-off limits of 12000 - 14000, and 25000, 
respectively.  
Aqueous polymer and conjugate solutions were freeze-dried in a VIRTIS Bench 
Top 3 freeze-drier operating at -30oC, 10-15 Pa. The freeze-dried polymers were 
routinely post-dried in a SARTORIUS Thermo Control infrared drying system. 
Iron determinations were made by inductively coupled plasma-optical emission 
spectroscopy (ICP-OES) using a multi-standard solution calibrated at 0.5 ppm in 
water. UV spectroscopy was done on a HITACHI 2000 spectrophotometer, scan 
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speed 400nm/min; both analytical methods were performed in the School of 
Chemistry of this University.  
The weight-average molecular weight (Mw) and number-average molecular 
weight (Mn) of final polymers and polymer-drug conjugates were determined by 
gel permeation chromatography (GPC) on Akta Explorer (Amersham, Pharmacia, 
Sweden) equipped with a 1.5 x 100 cm column packed with Sepharose 6 gel, at a 
flow rate of 0.5ml/min, refraction index detectors (7-15), using a buffer solution 
of 0.3 M sodium acetate containing 0.5 g NaN3, pH 6.5., as mobile phase. These 
determinations were generously performed in the laboratory of medicinal 
chemistry, Institute of Macromolecular Chemistry, Academy of Science of the 
Czech Republic, Prague, and data forwarded back. Therefore no GPC 
chromatograms were available to be included in this thesis. Carbon, hydrogen, 
and nitrogen analyses (in triplicate, data averaged) were performed in the same 
institution. 
 
5.2 Reagents, Reactants, and Solvents 
 
The aprotic solvent, N,N-Dimethylformamide (DMF), was refluxed over 
phosphoric anhydride (P2O5), distilled under reduced pressure in a faint stream of 
N2, and kept over molecular sieves 4A. All reactions involving its use were 
performed under anhydrous conditions. N-methylpyrrolidone (NMP) and 
hexamethylphosphoramide (HMP) were predried over molecular sieves 4A prior 
use. Dimethylsulfoxide (DMSO) was used as delivered. Deionized H2O was used 
also for dialysis operations. 
The hydroxyamines, mono- and diamines, and methoxyamine were commercial 
grades (Fluka Chemie AG, Aldrich Chemie G.m.b.H), and used as received. 
These included: 1, 3-propylenediamine (PDA); 2, 2'-(ethylenedioxy) diethylamine 
(EDDA); diethylenetriamine (DET), ethylenediamine (EDA), 2-
methoxyethylamine (MEA); 1, 3-diamino-2-propanol (DAP). ethanolamine (EA), 
2-(2-aminoethoxy)ethanol (AEE); 3-(N,N-dimethylamino)propylamine (DMP) 
and 3-(N,N-dimethylamino)ethylamine (DME) were also commercial grades 
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(Across Organics) and where used as received, and  so was glacial acetic acid 
(Merck). 
D,L-aspartic acid, N,N'-dicyclohexylcarbodiimide (DCC); 2-(1H-benzotriazol-1-
yl)-1,1,3,3-tetramethyluronium fluorophosphate (HBTU); triethylamine (TEA),  
4,7,10-trioxa-1,13-tridecanediamine(TRIA), O,O´-Bis(aminopropyl)poly(ethylene 
glycol) 1500, di-tert-butyldicarbonate (Boc)2O, (Fluka Chemie AG, Aldrich 
Chemie G.m.b.H) were also used as delivered. The solid methylenebisacrylamide 
(MBA) was recrystallized from isopropanol in the presence of 2,6-di-tert-butyl-p-
cresol (Fluka Chemie AG) prior to use. p-Nitrophenol was purchased from BDH 
Laboratory Reagents and used as delivered. 
The following solvents, diethyl ether (Et2O), acetone (Me2CO), hexane (Hex.) 
were used as supplied. Ethyl acetate (EtAc) was distilled and dried over calcium 
chloride (CaCl2) before use. Dioxan was distilled and kept over potassium 
hydroxide. Dichloromethane (DCM) was dried, distilled, and kept over calcium 
chloride (CaCl2).  
Methotrexate, MTX (Sigma), which contains 2.5 mol of water per mol of drug, 
and folic acid dihydrate, FA, purchased from Across Organics, were pre-dried in 
an Aberhalden tube for 24h at 50oC before use for conjugation.  
5.3  Experimental Procedures 
5.3.1   Preparation of polymeric carriers 
 
5.3.1.1 Polyaspartamide (PAsA) carriers 
 
Poly-DL-succinimide (PSI): PSI was prepared by the method of Neri and Antoni 
151; products of approximately equal viscosity were pooled from several runs and 
thoroughly mixed to give a master batch with ηinh (determined in DMF) of 35 mL 
g-1. 
 
Polyaspartamide carriers (PAsA): These carriers were prepared according to a 
general procedure, which, has been amply used in this laboratory. However, a 
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major modification was introduced. This concerns the reaction time in each step, 
the sequence and methods of addition of the different reactants, as well as the 
work-up. 
 
Polyaspartamide 1 (90:10) 
Polysuccinimide (PSI) (6g, 60mmol) was dissolved in 60 mL of freshly distilled 
DMF with stirring. 3-(N,N-Dimethylamino)propylamine (DMP) (5.52g, 54mmol) 
was dissolved in 15 mL of DMF, and added in one dash to the stirred PSI stirring 
solution. The resulting solution was saturated with N2, the flask tightly stoppered 
to preclude any moisture penetration, and stirring continued at room temperature 
for 10 h.  
To 1,3-propylenediamine (PDA) (1.33g, 18mmol, 3-fold excess) predissolved in 
25 mL of DMF and cooled in an ice bath, was added dropwise the PSI-DMP 
solution over 1h. The overall solution was N2-resaturated, stirred in the ice bath 
for 4h, then at room temperature for 24h at RT. The solution volume was reduced 
to ¼ by rotatory evaporation under reduced pressure (bath temperature not 
exceeding 70 o C). The polymeric product was precipitated out with 150 mL of 
Et2O-Me2CO (2:1), thoroughly washed with precipitant to eliminate any unreacted 
diamine, dissolved in 100 mL of distilled water, and purified in a two-step dialysis 
process. Firstly, the solution was dialysed in Spectra/Por 4 tubing for 48h against 
distilled water, the outer batches being changed several times, and secondly, in 
Spectra/Por 6 tubing for another 48h. The retentate, pH~8, was free-dried to 
afford 6.25g (52%) of beige, water-soluble material; ηinh, 11.61 mL g-1. Analysis 
by GPC revealed the following characteristics: Mw = 25 280; Mn = 12 330; In = 
2.05 (Table 4.7 row 2).  
1H NMR (D2O), δ/ppm: 4.75-4.5, 10H (expected: 10H, CH Asp); 3.5-3.0, 20H 
(expected: 20H, CONH-CH2-); 2.9-2.0, 94H (expected: 94H, -CO-CH2,  
CH2N(CH3)2, CH2NH2); 1.8-1.5, 20H (expected: 20H, CH2CH2CH2). 
 
Polyaspartamide 2 (80:20) 
Polymer 2 (a variant of 1, see Table 4.2 row 4), was prepared analogously to 1. 
Thus, PSI (2g, 20mmol), DMP (1.64g, 16mmol) and PDA (0.9g, 12mmol) 
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afforded polymer 2 in a yield of 2.85g (72%) as beige, water-soluble material; 
ηinh, 14.47 mL g-1. Analysis of 2 by GPC revealed the following characteristics: 
Mw = 27 640; Mn = 12 230; In = 2.26 (Table 4.7 row 3). 
1H NMR (D2O), δ/ppm: 4.75-4.5, 5H (expected: 5H, CH Asp); 3.5-3.0, 10H 
(expected: 10H, CONHCH2); 2.9-2.0, 44H (expected: 44H, -CO-CH2,  
CH2N (CH3)2, CH2NH2); 1.8-1.5, 10H (expected: 10H, CH2CH2CH2);  
 
Polyaspartamides 3 (90:10) and 4 (80:20)  
Polyaspartamides 3 and 4 were prepared by the procedure used to afford 1 and 2 
respectively, 1, 3-propylenediamine (PDA) being replaced by diethylenetriamine 
(DET); the reactions conditions as well as molar ratio of reactants were 
maintained. 
Polymer 3 was obtained as beige, water-soluble, and hygroscopic material in a 
yield of 52%; ηinh, 10.24 mL g-1; it possessed the following characteristics: Mw = 
22 560; Mn = 12 190; In = 1.85 (Table 4.7 row 4). 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 10H (expected: 10H, CH Asp); 3.5-3.0, 20H 
(expected: 20H, CONHCH2); 2.9-2.0, 98H (expected: 98H, -CO-CH2,  
CH2N (CH3)2, CH2NH-); 1.8-1.5, 18H (expected: 18H, CH2CH2CH2). 
 
Polymer 4, obtained in a yield of 59%, was also beige, showed water solubility 
and hygroscopicity; ηinh, 16.99 mL g-1; Mw = 28 360; Mn = 11 340; In = 2.5 (Table 
4.7 row 5). 
 
1H-NMR (D2O), δ/ppm: 4.75-4.5, 5H (expected: 5H, CH Asp); 3.5-3.0, 10H 
(expected: 10H, CONHCH2); 2.9-2.0, 48H (expected: 48H, -CO-CH2,  
CH2N (CH3)2, CH2NH-); 1.8-1.5, 8H (expected: 8H, CH2CH2CH2). 
 
Polyaspartamide 5 (90:10) 
The preparation procedure is similar to that leading to 1. However, minor l 
modifications concerning the second step reaction time and in the work-up were 
introduced.  
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Thus, PSI (6g, 60mmol) was dissolved in 60 mL of freshly distilled DMF with 
stirring. DMP (5.52g, 54mmol) dissolved in 15 mL of DMF, was added in one 
dash to the stirred PSI solution. The resulting solution was saturated with N2, the 
flask tightly stoppered to preclude any moisture penetration, and stirring was 
continued for 10 h at RT.  
To 2,2'-(ethylenedioxy)diethylamine (EDDA) (2.68g, 18mmol, 3-fold excess), 
predissolved in 25 mL of DMF and cooled in an ice bath, was added dropwise the 
PSI-DMP solution over a period of 1h. The resulting solution was N2-resaturated, 
stirred in the ice bath for 4h, and then at room temperature for 24h. The solution 
volume was reduced to ¼ by rotatory evaporation under reduced pressure (bath 
temperature not exceeding 70oC). The polymeric product was precipitated out 
with 150 mL of Et2O- Me2CO (2:1), thoroughly washed with 3x15 mL of boiling 
toluene to remove efficiently the excess diamine (in previous experiments from 
this laboratory, washing with the precipitant showed inefficacy to remove the 
unreacted EDDA), dissolved in 100 mL of distilled water, and purified in a two-
step dialysis process. Firstly, the solution was dialysed in Spectra/Por 4 tubing for 
48h against distilled water, the outer batches being changed several times, and 
secondly, in Spectra/Por 6 tubing for another 48h. The retentate, pH~8.5, was 
free-dried to afford 7.85g (61%) of beige, water-soluble material; ηinh, 10.57 mL 
g-1, it was characterized as follows: Mw = 24 480; Mn = 11 540; In = 2.12 (Table 
4.7 row 6). 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 9H (expected: 10H, CH Asp); 3.7-3.6, 9H 
(expected: 8H, CH2O), 3.5-3.0, 20H (expected: 20H, CONHCH2); 2.9-2.0, 94H 
(expected: 94H, -CO-CH2, CH2N (CH3)2, CH2NH2); 1.8-1.5, 18H (expected: 18H, 
CH2CH2CH2); (Table 4.3 row 7). 
 
Polyaspartamide 6 (80:20) 
Polymer 6 (a variant of 5, see Table 4.2 row 8), was prepared and worked up 
similarly to 5. Thus, PSI (2g, 20mmol), DMP (1.64g, 16mmol) and EDDA (1.78g, 
12mmol, 3-fold excess) afforded 2.41g (61%) of polymer 6 as beige, water-
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soluble material, ηinh, 20.14 mL g-1; with the following characteristics: Mw = 54 
850; Mn = 30 470; I n = 1.8 (see Table 4.7 row 7). 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 4H (expected: 5H, CH Asp); 3.7-3.6, 7H 
(expected: 8H, CH2O), 3.5-3.0, 11H (expected: 10H, CONHCH2); 2.9-2.0, 43H 
(expected: 44H, -CO-CH2, CH2N(CH3)2, CH2NH2); 1.8-1.5, 8H (expected: 8H, 
CH2CH2CH2); (Table 4.3 row 9). 
 
Polyaspartamide 7 (90:10) 
This polymer was prepared analogously to 1 (90:10) with a change in the amount 
polysuccinimide, and PDA being replaced by 1, 3-diamino-2-propanol (DAP). 
Thus, from PSI (3g, 30mmol), DMP (2.76g, 27mmol) and DAP (0.81g, 9mmol), it 
was obtained 3.19g (54%) of Polymer 7 as beige, fully water-soluble material. 
ηinh, 13.25 mL g-1, Mw = 17 860; Mn = 12 850; In =1.39 (Table 4.7 row 8). 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 10H (expected: 10H, CH Asp); 3.7-3.6, 1H 
(expected: 1H, CH-OH), 3.5-3.0, 21H (expected: 20H, CONHCH2); 2.9-2.0, 95H 
(expected: 94H, -CO-CH2, CH2-N(CH3)2, CH2NH2); 1.8-1.5, 18H (expected: 18H, 
CH2CH2CH2). 
 
Polyaspartamide 8 (90:10) 
Polymer 8 was prepared in a two-step reaction procedure similarly to 1. However, 
3-(N,N-dimethylamino)propylamine (DMP) was substituted by ethanoamine 
(EA), and the first step consequently proceeded at a longer reaction time of 24h. 
PSI (3g, 30mmol) was used for the preparation and polymer 8 was obtained in a 
yield of 65%, and was characterized as follows: ηinh, 16.2 mL g-1; M w = 23 560; 
Mn = 28 280; I n = 1.2 (Table 4.7 row 9) 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 10H (expected: 10H, CH Asp); 3.7-3.6, 18H 
(expected: 18H, CH2O), 3.5-3.0, 20H (expected: 20H, CONHCH2); 2.9-2.0, 26H 
(expected: 26H, -CO-CH2, CH2NH-); (Table 4.6 row 3). 
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Polyaspartamide 9 (80:20)  
Polymer 9 was obtained in an analogous procedure to the preparation of 8. The 
reactants were the same. The only change concerned the molar ratios (refer to 
Table 4.5. row 4).  
Polymer 9 was afforded as beige and water-soluble material in a yield of 68%, 
and possessed the following characteristics: ηinh, 14.02 mL g-1; M w = 54 000; Mn 
= 25 710; In = 2.1 (Table 4.7 row 10). 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 5H (expected: 5H, CH Asp); 3.7-3.6, 8H 
(expected: 8H, CH2O), 3.5-3.0, 10H (expected: 10H, CONHCH2); 2.9-2.0, 16H 
(expected: 16H, -CO-CH2, CH2-NH-). 
 
Polyaspartamide 10 (90:10)  
Polymer 10 was obtained in a two-step reaction procedure similarly to 1. 
However, 3-(N,N-dimethylamino)propylamine (DMP) was substituted by 
ethanoamine (EA), and the first step consequently proceeded at a longer reaction 
time of 24h. Diethylenetriamine (DET) in the second step was replaced by 1, 3-
diamino-2-propanol (DAP).  
Polymer 3 was obtained as beige, water-soluble, and hygroscopic material in a 
yield of 3.29g (68%) of as beige, and water-soluble material, ηinh, 18.43 mL g-1; 
Mw = 31 070; Mn = 20 990; In  = 1.48 (Table 4.7 row 11). 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 10H (expected: 10H, CH Asp); 3.7-3.6, 55H 
(expected: 54H, CH-OH, CH2O), 3.5-3.0, 20H (expected: 20H, CONHCH2); 2.9-
2.0, 22H (expected: 26H, -CO-CH2, CH2NH-); refer to Table 4.6 row 5. 
 
Polyaspartamides 11 (90:10) and 12 (90:10) 
These polymers were prepared similarly to the procedure that leading to polymer 
10 with the exception that the diamine, DAP, in the second step, was replaced by 
PDA and EDDA for 11 and 12, respectively.  
Polymer 11 was also obtained as beige and fully water-soluble solid, in a yield of 
2.5 g (74%), ηinh, 12.05 mL g-1. 
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1H NMR (D2O), δ/ppm: 4.75-4.5, 10H (expected: 10H, CH Asp); 3.7-3.6, 18H 
(expected: 18H, CH2O), 3.5-3.0, 20H (expected: 20H, CONH-CH2); 2.9-2.0, 22H 
(expected: 26H, -CO-CH2, CH2NH); 1.8-1.5, 2H (expected: 2H, CH2CH2CH2). 
 
Polyaspartamide 12 obtained in yield of 2.25g (69%), was also found fully water -
soluble, ηinh, 13.45 mL g-1. 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 10H (expected: 10H, CH Asp); 3.7-3.6, 24H 
(expected: 24H, CH2O), 3.5-3.0, 20H (expected: 20H, CONHCH2); 2.9-2.0, 22H 
(expected: 26H, -CO-CH2, CH2NH-); (Table 4.6 row 7). 
 
Polyaspartamides 13 (90:10) and 14 (80:20) 
The polyaspartamides 13 and 14 were obtained using a procedure analogous to 
that leading to polymers 8 and 9. A minor modification was introduced by 
replacing ethanolamine (EA) by 2-(2-aminoethoxy)ethanol (AEE).  
Comparatively, polymer 14 is a variant of 13, therefore, only the molar ratio of 
the reactants changes during the preparation. 
 
Polymer 13 was afforded in a yield of 68% and possessed the following 
characteristics: ηinh, 11.54 mL g-1; Mw = 54 480; Mn = 20 300; In = 2.71 (Table 4.7 
row 12). 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 10H (expected: 10H, CH Asp); 3.7-3.6, 54H 
(expected: 54H, CH2O), 3.5-3.0, 20H (expected: 20H, CONHCH2); 2.9-2.0, 26H 
(expected: 26H, -CO-CH2, CH2NH-); (Table 4.6 row 8). 
 
Polymer 14 was afforded in a yield of 70%, and was characterized as follows: 
ηinh, 17.31 mL g-1; Mw = 29 400; Mn = 15 550; In = 1.89 (Table 4.7 row 13). 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 5H (expected: 10H, CH Asp); 3.7-3.6, 37H 
(expected: 36H, CH2O), 3.5-3.0, 10H (expected: 10H, CONHCH2); 2.9-2.0, 16H 
(expected: 16H, -CO-CH2, CH2-NH-); (Table 4.6 row 9). 
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Polyaspartamides 15 (90:10) and 16 (90:10) 
The same experimental procedure leading to polymer 13 (90:10) was applied. 
However, the last diamine reactant, diethylenetriamine (DET) was replaced by 1, 
3-propylenediamine (PDA) and 1,3-diamino-2-propanol (DAP) to afford 15 
(90:10) and 16 (90:10) respectively. All the other variables were maintained (refer 
to Table 4.5 rows 10 and 11).  
 
Polyaspartamide 15 (90:10) was obtained as beige, water-soluble and hygroscopic 
material in a yield of 62%, ηinh, 11.54 mL g-1. 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 9H (expected: 10H, CH Asp); 3.7-3.6, 55H 
(expected: 54H, CH2O), 3.5-3.0, 20H (expected: 20H, CONHCH2); 2.9-2.0, 24H 
(expected: 24H, -CO-CH2, CH2NH-); 1.8-1.5, 2H (expected: 2H, CH2CH2CH2). 
 
Polymer 16 (90:10) was also afforded as beige and possessed the water solubility 
property. The yield was 63% and the inherent viscosity, ηinh, 11.28 mL g-1. 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 10H (expected: 10H, CH Asp); 3.7-3.6, 54H 
(expected: 55H, CH2O, CH-OH), 3.5-3.0, 20H (expected: 20H, CONHCH2); 2.9-
2.0, 22H (expected: 22H, -CO-CH2, CH2-NH-); (Table 4.6 row 11). 
 
Polyaspartamide 17 (90:10) 
Polymer 17 was prepared in a two-step reaction procedure similarly to 1. 
However, 3-(N,N-Dimethylamino)propylamine (DMP) was substituted by 
ethanoamine (MEA), and the first step consequently proceeded at a longer 
reaction time of 24h.  
PSI (3g, 30mmol) afforded 2.9g (54%) polymer 17 of as beige, and water-soluble 
product, ηinh; 18.43 mL g-1. 
1H NMR (D2O), δ/ppm: 4.75-4.5, 10H (expected: 10H, CH Asp); 3.7-3.6, 45H 
(expected: 45H, CH2O, OCH3), 3.5-3.0, 20H (expected: 20H, CONHCH2); 2.9-
2.0, 25H (expected: 26H, -CO-CH2, CH2NH-); (Table 4.6 continued row 3). 
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Polyaspartamide 18 (80:20) 
Polymer 18 (a variant of 17, refer to Table 4.2…) was prepared analogously to 17.   
From PSI (1g, 10mmol), it was obtained after work-up 1.2g (66%) polymer 18 of 
as beige, fluffy and water-soluble product, ηinh; 17.31 mL g-1. 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 5H (expected: 5H, CH Asp); 3.7-3.6, 20H 
(expected: 20H, CH2O, OCH3), 3.5-3.0, 10H (expected: 10H, CONHCH2); 2.9-
2.0, 16H (expected: 16H, -CO-CH2, CH2NH-); (Table 4.6 continued row 4). 
 
Polyaspartamides 19 (90:10) and 20 (90:10) 
Both polyaspartamides were prepared in an analogous fashion to polymer 17 
(90:10) with minor modification. This concerns the replacement of diamine, DET, 
in the second step by PDA and EDDA, respectively. 
Thus, polyaspartamide 19 (90:10) was isolated after work-up as beige and water-
soluble solid in a yield of 71% with inherent viscosity, ηinh; 15.45 mL g-1. 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 10H (expected: 10H, CH Asp); 3.7-3.6, 45H 
(expected: 45H, CH2O, OCH3), 3.5-3.0, 20H (expected: 20H, CONHCH2); 2.9-
2.0, 22H (expected: 22H, -CO-CH2, CH2NH-); 1.8-1.5, 2H (expected: 2H, 
CH2CH2CH2); see Table 4.6 continued row 5. 
 
Polyaspartamide 20 (90:10) was obtained in yield of 55% as water-soluble 
material with inherent viscosity, ηinh; 14.85 mL g-1. 
 
1H NMR (D2O), δ/ppm: 4.75-4.5, 10H (expected: 10H, CH Asp); 3.7-3.6, 53H 
(expected: 53H, CH2O, OCH3), 3.5-3.0, 20H (expected: 20H, CONHCH2); 2.9-
2.0, 22H (expected: 22H, -CO-CH2, CH2NH-); refer to Table 4.6 row 6. 
 
5.3.1.2 Poly(amidoamine) (PAA) Carriers 
 
Mono-N-Boc-protected primary diamines 
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Compound 21, N-(tert-butoxycarbonyl)1,2-diaminoethane (N-Boc-EDA) 
Di-tert-butyl dicarbonate, (Boc)2O (10.9g, 50mmol) was dissolved in 70 mL of 
dioxin and added dropwise over a period of 2h to 1,2-diaminoethane (EDA) (21g, 
350mmol), predissolved in 60 mL of the same solvent. The mixture was stirred at 
ambient temperature for another 24h period, and the solvent, together with excess 
EDA, was distilled off by rotary evaporation at 50oC bath temperature. Upon 
addition of 50 mL of H2O, a small portion of insoluble N,N´-bisprotected amine 
was removed by filtration, and the filtrate was extracted with several 40-mL 
portions of methylene chloride, leaving any residual unreacted diaminoethane as 
the most hydrophilic constituent in the aqueous phase. The combined extracts, 
dried over anhydrous MgSO4 afforded N-Boc-EDA, 21, after solvent removal as a 
yellow, oily liquid in a yield of 6.72g (93%). The compound gave a clean 1H 
NMR spectrum.   
 
1H-NMR (D2O), δ/ppm: 3.1 t, 2H (expected: 2H, CONHCH2); 2.7 t, 2H 
(Expected: 2H, CH2NH2), 1.4 s, 9H (Expected: 9H, CH3); see Table 4.9 row 3. 
 
Compound 22, N-(tert-butoxycarbonyl)1,3-diaminopropane (N-Boc-PDA): In an 
analogous fashion to the above described procedure, N-(tert-butoxycarbonyl)1, 3-
diaminopropane, N-Boc-PDA, 22, was prepared from di-tert-butyl dicarbonate, 
(Boc)2O, (10g, 45.8mmol) and, 1, 3-diaminopropane (PDA) (30.4g, 410mmol) in 
a total of 130 mL of dioxan. Work-up as in the preceding experiment afforded the 
crude mono-Boc-protected diamine 22 as an oily liquid in a yield of 7.05g (85%). 
 
1H-NMR (D2O), δ/ppm: 3.1 t, 2H (expected: 2H, CONHCH2); 2.65 t, 2H 
(Expected: 2H, CH2NH2), 1.6 m, 2H (Expected: 2H, CH2CH2CH2); 1.45 s, 9H 
(Expected: 9H, CH3); Table 4.9 row 4. 
 
Compound 23, N-(tert-butoxycarbonyl)-1,4,7-triaza-heptane (N-Boc-DET): Di-
tert-butyl dicarbonate, (Boc)2O, (10g, 45.8mmol), and diethylenetriamine (DET) 
(32g, 310mmol), in 130 mL of dioxan, treated as in preceding experiments, gave 
8.8g (92%) of N-Boc-DET, 23 as an oily liquid. 
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1H-NMR (D2O), δ/ppm: 3.2 t, 2H (expected: 2H, CONHCH2); 2.6 m, 6H 
(Expected: 6H, remaining CH2); 1.45 t, 9H (Expected: 9H, CH3). 
 
Compound 24, N-(tert-butoxycarbony)-4,7-dioxa-1,10-diaza-decane (N-Boc- 
EDDA): The preparation of N-(tert-butoxycarbonyl)-4,7-dioxa-1,10-diaza-decane, 
N-Boc-EDDA, 24, from di-tert-butyl dicarbonate, (Boc)2O, (15g, 68.7mmol), and 
2,2'-(ethylenedioxy)diethylamine (EDDA) (69.3g, 468mmol) in 260 mL of dioxan 
follows the same basic procedure employed in preceding experiments. The mono-
Boc-protected diamine, 24 was obtained in a yield of 15.6g (92%), and the 1H 
NMR spectrum was very clean. 
 
1H-NMR (D2O), δ/ppm: 3.7 s, 4H (Expected: 4H, OCH2CH2O); 3.6 m, 4H 
(Expected: 4H, N-CH2CH2O); 3.2 t, 2H (expected: 2H, CONHCH2); 2.75 t, 2H 
(Expected: 2H, CH2NH2); 1.45 s, 9H (Expected: 9H, CH3); see Table 4.9 row 6. 
 
Preparation of poly(amidoamine) carriers: Amounts of polymeric educts and 
products are given as base moles and thus refer to the simplest recurring units, 
defined by structures 25-31 normalized to y = 1. 
 
Copoly(amidoamine) 25 (80:20) 
The detailed procedure given in the following for the synthesis of 25 is 
representative of the general method for the copolymerization of 
methylenebisacrylamide (MBA) with mono-Boc-protected diamines, and 
therefore will be used to afford all the other six target copolyamidoamine carriers, 
26-31. 
Methylenebisacrylamide (MBA) (2.47g, 16mmol) was dissolved 15 mL of hot 
H2O. Upon cooling, mono-Boc derivative 22 (0.6g, 3.2mmol) predissolved in 5 
mL of H2O was added in one dash. The N2-saturated solution was stirred at 
ambient temperature for 24h then at 50oC for another 24h. 
2-(dimethylamino)ethylamine (DME) (1.13g, 12.8mmol) dissolved in 5 mL of 
H2O, was added. Stirring of the solution, resaturated with N2, was continued for 
36h at 60oC, and upon the addition of ethanolamine, EA (0.049g, 8mmol), for 
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another 2h at the same temperature. The last-named step served to eliminate 
terminal vinyl groups as potential causes of delayed crosslinking. The volatiles 
were now removed by rotating evaporation (60oC bath temperature), and the 
residual intermediary polymer was treated with 5 mL of trifluoroacetic acid (TFA) 
for 1h at room temperature. Removal of the acid under reduced pressure at 30oC 
bath temperature was followed by precipitation of the product polymer with Et2O, 
which was thoroughly washed with boiling toluene, and redissolved in 20mL of 
H2O. The pH was adjusted to 7 with NaOH, and the solution was purified by 
dialysis successively in Spectra/Por 4 tubing for 48h and for another 48h in 
Spectra/Por 6 tubing against distilled water. For the last 4h of this operation, the 
pH of the tube contents was raised to 8.5-9 with NH4OH to eliminate protonation 
effects. The retentate, pH~8, was freeze-dried to afford 0.850 g (22.1%) of beige, 
crispy and water- and methanol-soluble 25, ηinh, 24.29 mL g-1; Mw = 65 360; Mn = 
23 990; In = 2.73; Table 4.13 row 2. 
 
1H-NMR (D2O), δ/ppm: 4.6-4.5, 10H (Expected: 10H, CONHCH2HNCO), 3.0-
2.8, 21H (Expected: 20H, -CO-CH2), 2.7-2.0, 65H (Expected: 66H, CH2N (CH3)2, 
CH2-N (CH2) (CH2), CH2-NH2), 1.8-1.5, 2H (Expected: 2H, CH2CH2CH2). 
 
Copoly(amidoamine) 26 (80:20) 
In the preparation of polymer 26(80:20), 3-(dimethylamino)propylamine was 
employed in lieu of the ethylamine derivative serving as solubilizing factor. The 
adopted work-up gave 0.68g (16.8%) of water- and methanol-soluble solid 26 
characterized as follows: ηinh, 17.5 mL g-1; Mw = 11 020; Mn = 6 240; In = 1.72; 
Table 4.13 row 3. 
1H-NMR (D2O), δ/ppm: 4.6-4.5, 10H (Expected: 10H, CONHCH2HNCO), 3.0-
2.8, 21H (Expected: 20H, -CO-CH2), 2.7-2.0, 66H (Expected: 66H, CH2N (CH3)2, 
CH2-N (CH2) (CH2), CH2-NH2), 1.8-1.5, 10H (Expected: 10H, CH2CH2CH2). 
 
Copoly(amidoamine) 27 (80:20) 
This polymer was prepared by reacting MBA (2.47g, 16mmol), N-Boc-derivative 
23 (0.65g, 3.2mmol), and 3-(dimethylamino)propylamine (DMP) (1.31g, 
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12.8mmol) following the standard procedure. Polymer 27 was afforded as beige, 
crispy, water- and methanol-soluble solid in a yield of 0.72g (16.8%); ηinh, 16.86 
mL g-1; Mw = 13 210; Mn = 6 300; In = 2.09; see Table 4.13 row 4. 
 
1H-NMR (D2O), δ/ppm: 4.6-4.5, 10H (Expected: 10H, CONHCH2HNCO), 3.0-
2.8, 22H (Expected: 20H, -CO-CH2), 2.7-2.0, 70H (Expected: 68H, CH2N (CH3)2, 
CH2-N (CH2) (CH2), CH2-NH2), 1.8-1.5, 7H (Expected: 8H, CH2CH2CH2). 
 
Copoly(amidoamine) 28 (80:20) 
By the basic procedure described for the synthesis of 25, copoly(amidoamine) 26 
was prepared from MBA (2.47g, 16mmol), mono-Boc-derivative 24 (0.7g, 
3.2mmol), and 2-(dimethylamino)ethylamine (DME) (1.13g, 12.8mmol). 
Following the adopted work-up, the target polymer 28 was collected as water- and 
methanol-soluble solid in a yield of 0.636g (15.5%); it possessed the following 
characteristics: ηinh, 20.98 mL g-1; Mw = 52 000; Mn = 24 760; In = 2.1; Table 4.13 
row 5. 
 
1H-NMR (D2O), δ/ppm: 4.6-4.5, 10H (Expected: 10H, CONHCH2HNCO), 3.8-
3.5, 8H (Expected: 8H, OCH2CH2O), 3.0-2.8, 22H (Expected: 20H, -CO-CH2), 
2.7-2.0, 66H (Expected: 66H, CH2N (CH3)2, CH2-N (CH2) (CH2), CH2-NH2).  
 
Copoly(amidoamine) 29 (80:20) 
The standard method was used for the preparation of 29. The following amounts 
of reactants were used: MBA (2.47g, 16mmol), N-Boc-derivative 24 (0.7g, 
3.2mmol), and 3-(dimethylamino)propylamine (DMP) (1.31g, 12.8mmol). 
The water- and methanol-soluble polymer 29 was collected in a yield of 0.79g 
(18.4%); ηinh, 18.45 mL g-1; Mw = 14 880; Mn = 5 590; In = 2.66.   
 
1H-NMR (D2O), δ/ppm: 4.6-4.5, 10H (Expected: 10H, CONHCH2HNCO), 3.8-
3.5, 8H (Expected: 8H, OCH2CH2O), 3.0-2.8, 21H (Expected: 20H, COCH2), 2.7-
2.0, 64H (Expected: 64H, CH2N(CH3)2, CH2-N(CH2)(CH2), CH2-NH2), 1.8-1.5, 
8H (Expected: 8H, CH2CH2CH2); Table 4.12 row 7. 
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Copoly(amidoamine) 30 (80:20) 
This polymer was synthesized analogously to 25, except that the ethylamine 
derivative, 2-(dimethylamino)ethylamine (DME) serving as solubilizing factor 
was replaced by  2-(2-aminoethoxy)ethanol (AEE) (1.35g, 12.8mmol). The target 
polymer was isolated as a water- and methanol-soluble solid in a yield of 0.625g 
(15.7%); ηinh, 20.1 mL g-1. 
 
1H-NMR (D2O), δ/ppm: 4.6-4.5, 10H (Expected: 10H, CONHCH2HNCO), 3.8-
3.5, 24H (Expected: 24H, OCH2CH2O), 3.0-2.8, 20H (Expected: 20H, -CO-CH2), 
2.7-2.0, 33H (Expected: 32H, CH2-N(CH2)(CH2), CH2-NH2), 1.8-1.5, 2H 
(Expected: 2H, CH2CH2CH2); Table 4.12 row 8. 
 
Copoly(amidoamine) 31 (80:20) 
Polymer 31 was prepared by reacting MBA (2.47g, 16mmol), N-Boc-derivative 
24 (0.7g, 3.2mmol), and 2-(2-aminoethoxy) ethanol (AEE) (1.35g, 12.8mmol) 
following the standard procedure. The adopted work-up afforded 0.75g (18.4%) 
of 31 as a beige, crispy, water- and methanol-soluble solid; ηinh, 16.98 mL g-1. 
 
1H-NMR (D2O), δ/ppm: 4.6-4.5, 10H (Expected: 10H, CONHCH2HNCO), 3.8-
3.5, 31H (Expected: 32H, OCH2CH2O), 3.0-2.8, 20H (Expected: 20H, -CO-CH2), 
2.7-2.0, 33H (Expected: 32H, -CH2N (CH3)2, CH2-N (CH2) (CH2), CH2-NH2). 
 
Poly(amidoamine) 32 
MBA (1.25g, 16mmol) was dissolved in 5 mL of hot isopropanol-H2O (4:1). The 
mono-Boc derivative 22 (0.7g, 4mmol) was dissolved in 1mL of isopropanol and 
was added to the MBA solution with stirring. Upon saturation with N2, the 
resulting solution was stirred for 72h at ambient temperature. 
Following solvent removal by rotary evaporation, the residual macromomonmer 
was redissolved in 40 mL of the same solvent blend, thus providing the high 
dilution ([MBA] = 0.2M) required for the second reaction step. After cooling in 
an ice bath, 4,7,10-trioxa-1,13-tridecanediamine, TRIA (0.88g, 4mmol), 
predissolved in 10 mL of the same solvent mixture, was added, followed by 
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triethylamine, TEA (0.41g, 4mmol), and stirring of the solution, resaturated with 
N2, was continued for 24h at room temperature and another 48h at 60oC. The 
solvent was removed again under reduced pressure, 5 mL of trifluoroacetic acid 
was added, and stirring was continued for 1h at ambient temperature. The acid 
was removed under reduced pressure, and the residual material was washed with 
boiling toluene to remove traces of unreacted oligo (ethylene oxide). Polymer 
precipitation and further work-up was as described for polymer 25. There was 
obtained 0.38g (16%) of water- and methanol-soluble 32; ηinh, 15.58 mL g-1; Mw = 
28 830; Mn = 20 740; In = 1.39; Table 4.13 row 7. 
 
1H-NMR (D2O), δ/ppm: 4.6-4.5, 4H (Expected: 4H, CONHCH2HNCO), 3.8-3.5, 
12H (Expected: 12H, OCH2CH2O), 3.0-2.8, 8H (Expected: 8H, -CO-CH2), 2.7-
2.0, 15H (Expected: 16H, -CH2NHCH2, CH2-N(CH2)(CH2), CH2-NH2), 1.8-1.5, 
6H (Expected: 6H, CH2CH2CH2); Table 4.12 row 10. 
 
Poly(amidoamine) 33 
This polymer was prepared using the same procedure as in the preceding 
experiment, except that the trioxatridecanediamine (TRIA) was replaced by O,O´-
bis(3-aminopropyl)poly(ethylene glycol) 1500 (PEO) (6g, 4mmol), and the 
solvent volume in the second reaction step was increased to 50 mL. The water- 
and methanol-soluble polymer 33 was isolated in yield of 1.75g (23%); ηinh, 14.17 
mL g-1; Mw = 23 440; Mn = 11 320; In = 2.07; Table 4.12 row 8. 
1H-NMR (D2O), δ/ppm: 4.6-4.5, 4H (Expected: 4H, CONHCH2HNCO), 3.8-3.5, 
130H (Expected: 128H, OCH2CH2O), 3.0-2.8, 9H (Expected: 8H, -CO-CH2), 2.7-
2.0, 16H (Expected: 16H, CH2NHCH2, CH2-N(CH2)(CH2), CH2-NH2), 1.8-1.5, 
5H (Expected: 6H, CH2CH2CH2); Table 4.12 row 11. 
 
5.3.2 Polymer-MTX conjugates 
 
The conjugation of methotrexate to amine-functionalized polymeric carriers was 
achieved by the HBTU coupling agent method, and the experimental details, 
which follow, illustrate the standard procedure adopted for the preparation of all 
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polymer-MTX conjugates herein investigated. These included polyaspartamide- 
and polyamidoamine-MTX conjugates. 
 
5.3.2.1 Polyaspartamide-MTX conjugates 
 
Hydrolytic stability test: In an attempt to test the hydrolytic stability of the 
polyaspartamide-MTX conjugates, polyaspartamides namely 3 (90:10) and 5 
(90:10) were conjugated to folic acid, FA (chosen for its structural similarity to 
MTX). The conjugates were purified by both size exclusion chromatography and 
dialysis, isolated by freeze-drying, and characterized by 1H NMR and UV-vis 
spectroscopy. The latter purification method was repeated once more, and FA 
content assessed again by both analytical methods. 
 
Conjugate 3 (90:10)-FA 
Polymer 3 (200mg, 0.1mmol) was dissolved in 7 mL of N-methylpyrrylidone 
(NMP). Folic acid (FA) (54mg, 0.12mmol) was added to the polymer solution 
with stirring. Upon rapid stirring, HBTU (43mg, 0.11mmol) predissolved in 2 mL 
of DMF, and then added dropwise over 20min, followed by the addition of 
triethylamine (TEA) (20mg, 0.2mmol). The resulting yellow solution was 
saturated with N2 and stirred at ambient temperature for 2h and cooled at 5oC for 
1/2h. The polymeric conjugate was precipitated with 15 mL of Et2O-hexane (2:1), 
isolated upon centrifugation, thoroughly washed warm Me2CO and dissolved in 5 
mL of H2O. The pH adjustment to 10 using NaOH was followed by size exclusion 
chromatography on a 2.5 x 25 cm column packed with Sephadex G25 and eluted 
with distilled H2O. The pH of the eluate was readjusted to 7 (glacial acetic acid) to 
prevent hydrolysis, and the solution dialyzed for 48h in Spectra/Por 6 tubing. The 
pH of the retentate was adjusted to 4 (HCl) to regenerate the unconjugated 
carboxyl group of FA from its salt. The aqueous solution was stirred at ambient 
temperature for 5min, then the pH re-adjusted to 6 (NH4OH), and the dialysis in 
the same tubing was continued for another 8h with numerous changes of the 
aqueous outer phase for complete removal of inorganic salts. The retentate, pH~8, 
was freeze-dried to afford 120 mg (49%) of yellow, water-soluble conjugate 
3(90:10)-FA; ηinh, 12.15 mL g-1. 
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1H NMR (D2O), δ/ppm: 8.5-6.5, 5H (Expected: 5H; aromatic and heteroaromatic 
CH of FA); 1.8-1.6, 18H (expected: 18H; CH2CH2CH2). These data indicate 
100% FA incorporation, corresponding to 18.26% by mass.  
 
Determination of folate content in the conjugate by UV spectroscopy in H2O (pH 
~7, reference) using the absorbance at 363nm and the molar extinction coefficient 
value, ε = 6200 mol-1 cm-1, revealed 18% by mass. [Found: FA, 18% (UV), 
18.26% (NMR)]. This method was employed for all subsequent folate conjugates 
and co-conjugates. 
 
120 mg of 3(90:10)-FA were redissolved in 5mL of H2O, pH adjusted to 7, and 
the solution redialyzed against distilled H2O in Spectra/Por 6 tubing for another 
48h, and the retentate pH~8 was freeze-dried again to give 110 mg (92%) of 
yellow water-soluble powder, ηinh, 12.05 mL g-1. 1H NMR spectrum showed 
100% FA. [Found: FA, 17.98% (UV), 18.26% (NMR)]. 
 
Conjugate 5 (90:10)-FA 
This conjugate was prepared in a similar fashion to 3(90:10)-FA, except that 3 
was replaced by 5. Thus, the reaction of polymer 5 (200mg, 0.098mmol), FA 
(52mg, 0.118mmol), HBTU (40mg, 0.108mmol), and TEA (20mg, 0.196mmol), 
afforded 147mg (58%) of 5(90:10)-FA as yellow water-soluble solid, ηinh, 15.85 
mL g-1. 
1H NMR (D2O), δ/ppm: 8.5-6.5, 5H (Expected: 5H; aromatic and heteroaromatic 
CH of FA); 1.8-1.6, 18H (expected: 18H; CH2CH2CH2). These data indicate FA 
incorporation to be 100% of available NH2 anchoring group. [Found: FA, 17.9% 
(UV), 17.93% (NMR)]. 
 
147 mg of 5(90:10)-FA were redissolved in 5mL of H2O, pH adjusted to 7, and 
the solution redialyzed  against distilled H2O in Spectra/Por 6 tubing for another 
48h, and the retentate pH~8.5 was freeze-dried again to give 110mg (75%) of 
yellow water-soluble powder, ηinh, 15.75 mL g-1. 
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1H NMR (D2O), δ/ppm: 8.5-6.5, 5H (Expected: 5H; aromatic and heteroaromatic 
CH of FA); 1.8-1.6, 18H (expected: 18H; CH2CH2CH2), indication of 100% of 
FA incorporation. [Found: FA, 17.85% (UV), 17.93% (NMR)]. 
 
Synthesis of polyaspartamide-MTX conjugates  
 
Conjugate 1 (90:10)-MTX 
This conjugate was obtained by using the standard procedure leading to 3(90:10)-
FA except that folic acid (FA) was replaced by methotrexate (MTX). Thus, the 
reaction of polymer 1 (200mg, 0.102mmol), MTX (56mg, 0.122mmol), HBTU 
(43mg, 0.112mmol), and TEA (21mg, 28µL, 0.204mmol), in a total of 7 mL of 
DMF, followed by the adopted work-up procedure afforded 150mg (61%) of 
yellow, water-soluble powder 1(90:10)-MTX; ηinh, 16.15 mL g-1; Mw = 26 350; 
Mn = 17 000; In = 1.55. Found: MTX, 18.3% (UV), 18.61% (NMR). Calcd. for 
(C108H186N38O24) n (2400.9) n [1(90:10)-MTX]: MTX, 18.93%; refer to Table 
4.17, row 2. 
The MTX content in this conjugate and in the forthcomings involving this drug 
was determined by UV spectroscopy in H2O (pH ~7, reference) using the molar 
extinction coefficient value, ε = 6500 mol-1 cm-1 and the absorbance at λ = 370 
nm. 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.9H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 1.8-1.6, 20H (expected: 20H; CH2CH2CH2), 
corresponding to 98% MTX incorporation. 
 
Conjugate 2 (80:20)-MTX 
For the preparation of this conjugate the basic procedure described for the 
synthesis of 1(90:10)-MTX was used. However, carrier 2 replaced 1. Polymer 2 
(200mg, 0.207mmol) was treated with MTX (113mg, 0.249mmol), HBTU (86mg, 
0.228mmol), TEA (42mg, 0.414mmol), in a total of 7 mL of DMF. After 
conventional work-up, a yield of 155mg (53%) of yellow fluffy water-soluble 2 
(80:20)-MTX collected, and possessed the following characteristics:  
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ηinh, 19.95 mL g-1; Mw = 32 200; Mn = 18 680; In = 1.74. Found: MTX, 30.75 % 
(UV), 31.68% (NMR). Calcd. for (C63H101N23O14) n (1404.6) n [2(80:20)-MTX]: 
MTX, 32.36%; see Table 4.17, row 3. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.8H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 1.8-1.6, 10H (expected: 10H; CH2CH2CH2) 
corresponding to 96% MTX incorporation. 
 
Conjugate 3 (90:10)-MTX 
The general procedure leading to 1(90:10)-MTX was used for the preparation of 
3(90:10)-MTX from carrier 3 (200mg, 0.1mmol), MTX (55mg, 0.12mmol), 
HBTU (41mg, 0.11mmol), TEA (21mg, 0.2mmol), in a total volume of 7 mL of 
DMF. After routine work-up, the conjugate was isolated in a yield of 125mg 
(53%) as yellow water-soluble solid. 
1H NMR spectrum revealed 80%MTX incorporation therefore the conjugate 
(120mg,~0.063mmol) was retreated with MTX (23mg, 0.05mmol), HBTU (12mg, 
0.031mmol), and TEA (13mg, 0.125mmol), in a total of 6 mL of DMF-HMP 
(2:1), with the reaction period extended to 4h. The adopted work-up procedure 
afforded 90mg of the conjugate corresponding to an overall yield of 41%. The 
conjugate was characterized as follows:  
ηinh, 16.75 mL g-1; Mw = 28 250; Mn = 14 490; In = 1.95. Found: MTX, 18.36 % 
(UV), 18.7% (NMR). Calcd. for (C109H189N39O24)n (2429.9)n [3(90:10)-MTX]: 
MTX, 18.7%; Table 4.17, row 4. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 5H (Expected: 5H; aromatic and heteroaromatic 
CH of MTX); 1.8-1.6, 18H (Expected: 18H; CH2CH2CH2). MTX incorporation: 
100%. 
 
Conjugate 4 (80:20)-MTX 
High MTX incorporation in this conjugate was afforded in a two-step process as 
in the preceding experiment. From carrier 4 (200mg, 0.201mmol), MTX (109mg, 
0.241mmol), HBTU (84mg, 0.221mmol), TEA (41mg, 0.401mmol), 4 (80:20)-
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MTX was afforded in a yield of 140mg (48%) as yellow, crispy, water-soluble 
solid; ηinh, 20.18 mL g-1; Mw = 33 030; Mn = 15 300; In = 2.17. Found: MTX, 
29.80% (UV), 30.81% (NMR). Calcd. for (C64H104N24O14)n (1433.7)n [4(80:20)-
MTX]: MTX, 31.7%. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.8H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 1.8-1.6, 8H (Expected: 8H; CH2CH2CH2). These 
data indicate 96% NH2 acylation; Table 4.16, row 5. 
 
Conjugate 5 (90:10)-MTX 
For the preparation of this conjugate the two-step process was used as in the 
preceding experiments. Thus, the reaction of polymer 5 (200mg, 0.098mmol), 
MTX (54mg, 0.118mmol), HBTU (41mg, 0.108mmol), TEA (20mg, 0.196mmol), 
gave 105mg (43%) of 5(90:10)-MTX as a yellow water-soluble solid. ηinh, 15.42 
mL g-1; Mw = 25 200; Mn = 15 270; In = 1.65. Found: MTX, 18.05 % (UV), 
17.91% (NMR). Calcd. for (C111H192N38O26)n (2475)n [5(90:10)-MTX]: MTX, 
18.36%; Table 4.17, row 6. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.85H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 1.8-1.6, 18H (Expected: 18H; CH2CH2CH2), 
showing 97% MTX incorporation. 
 
Conjugate 6 (80:20)-MTX 
This conjugate was prepared in a similar fashion to 4(80:20)-MTX. The reaction 
of carrier 6 (200mg, 0.192mmol), MTX (105mg, 0.23mmol), HBTU (80mg, 
0.211mmol), TEA (39mg, 0.384mmol), afforded 6(80:20)-MTX in a yield of 
120mg (42%) as water-soluble solid. ηinh, 21.08 mL g-1; Mw = 35 030; Mn = 18 
070; In = 1.94. Found: MTX, 29.75% (UV), 30.08% (NMR). Calcd. for 
(C66H107N23O16)n (1478.7)n [6(80:80)-MTX]: MTX, 30.7%; Table 4.17, row 7. 
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1H NMR (D2O), δ/ppm: 8.5-6.5, 4.85H (Expected: 5H; aromatic and 
heteroaromatic CH CH of MTX); 1.8-1.6, 18H (Expected: 18H; CH2CH2CH2), 
indicating 97% of drug level incorporation. 
 
Conjugate 7 (90:10)-MTX 
The target conjugate was prepared using the basic procedure, in a one-step 
process, from carrier 7 (400mg, 0.202mmol), MTX (110mg, 0.242mmol), HBTU 
(82mg, 0.222mmol), TEA (41mg, 0.404mmol), in a total of 10 mL. The conjugate 
was collected as a yellow, fluffy, and water-soluble solid, in a yield of 360mg 
(74%). ηinh, 15.94 mL g-1. Found: MTX, 18.2% (UV), 18.5% (NMR). Calcd. for 
(C108H186N38O25)n (2416.9)n [7(90:10)-MTX]: MTX, 18.8%; Table 4.17, row 8. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.92H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 1.8-1.6, 18H (Expected: 18H; CH2CH2CH2). This 
data indicate 98% MTX incorporation. 
 
Conjugate 8 (90:10)-MTX 
The standard procedure leading to 7(90:10)-MTX was applied for the preparation 
of this conjugate. Thus, using a molar feed ration MTX/NH2 of 1.2., carrier 8 
(200mg, 0.123mmol) was treated with MTX (67mg, 0.148mmol), HBTU (51mg, 
0.136mmol), and TEA (25mg, 0.246mmol), in a total of 6 mL of DMF. After 
conventional work-up, the target conjugate was afforded as a deep-yellow, water-
soluble solid, in a yield of 160mg (63%); ηinh, 18.66 mL g-1; Mw = 31 860; Mn = 
18 210; In = 1.75. Found: MTX, 20.85% (UV), 21.36 % (NMR). Calcd. for 
(C82H126N30O33)n (2060.1)n [8(90:10)-MTX]: MTX, 22.06%; refer to Table 4.17, 
row 9. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.8H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 3.8-3.5, 18H (Expected: 18H; CH2-O). MTX 
incorporation: 96%. 
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Conjugate 9 (80:20)-MTX 
The target conjugate was obtained under the experimental conditions affording 
8(80:20)-MTX, except that 8 was replaced by 9, the molar feed ration of 
MTX/NH2 being maintained to 1.2.The reaction of polymer 9 (200mg, 
0.24mmol), MTX (131mg, 0.288mmol), HBTU (100mg, 0.264mmol), and TEA 
(49mg, 0.48mmol), in a total of 8 mL of DMF, gave after adopted work-up, 
172mg (55%) of water-soluble solid 9(80:20)-MTX; ηinh, 17.5 mL g-1. Found: 
MTX, 33.02% (UV), 34.61% (NMR). Calcd. for (C52H76N20O18)n (1269.3)n 
[9(80:20)-MTX]: MTX, 35.8%; Table 4.17, row 10. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.75H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 3.8-3.5, 8H (Expected: 8H; CH2-O), corresponding 
to 95% MTX incorporation. 
 
Conjugate 10 (90:10)-MTX 
The standard procedure was used for the preparation of this conjugate. However, 
minor modifications were introduced. Thus, to the rapidly stirred solution of 
carrier 10 (400mg, 0.248mmol) dissolved in 7 mL of DMF, MTX (135mg, 
0.298mmol) dissolved in 2 mL, was added. With continued stirring, a solution of 
HBTU (101mg, 0.273mmol) in 1mL, was added dropwise over a 1/6h period, this 
was followed by the addition of TEA (37mg, 0.367mmol), and the yellow 
solution, N2-saturated, was stirred at room temperature for an extended period of 
3h then cooled at 5 oC for another 1/2h. The conjugate formed was precipitated 
with150 mL of Et2O-Me2CO (2:1), thoroughly washed with precipitant, further 
purified and isolated as described for 1(90:10)-FA, yielding 380mg (74%) of 
yellow, water-soluble solid; ηinh, 16.5 mL g-1. Found: MTX, 20.65% (UV), 
21.31% (NMR). Calcd. for (C81H123N29O34) n (2047.0) n [10(90:10)-MTX]: MTX, 
22.2%; see Table 4.17 row 11. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.8H (Expected: 5H; aromatic and 
heteroaromatic CH CH of MTX); 3.8-3.5, 19H (Expected: 19H; CH2-O, CH-OH), 
corresponding to 96% MTX incorporation. 
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Conjugate 13 (90:10)-MTX 
Similarly to the preceding experiment, this conjugate was obtained from carrier 13 
(400mg, 0.198mmol), MTX (108mg, 0.238mmol), HBTU (99mg, 0.218mmol), 
and TEA (40mg, 0.396mmol), in a total of 10 mL of DMF, as a yellow, fluffy, 
and water-soluble solid, in a yield of 350mg (71%); ηinh, 16.25 mLg-1. Found: 
MTX, 18.25% (UV), 18.5% (NMR). Calcd. for (C100H162N30O42)n (2456.5)n 
[13(90:10)-MTX]: MTX, 18.5%; refer to Table 4.17 continued row 2. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 5H (Expected: 5H; aromatic and heteroaromatic 
CH of MTX); 3.8-3.5, 54H (Expected: 54H; CH2-O), showing the conjugate to 
contain MTX at the level of 100%. 
 
Conjugate 14 (80:20)-MTX 
This conjugate was obtained in a two-step process similar to that leading to 4-
MTX, except that polymer 14 was replaced 4. 14(80:20)-MTX was obtained from 
carrier 14, MTX, HBTU, and TEA, in a molar feed ratio of 1:1.2:1.1:2. Thus, 
carrier 14 (200mg, 0.198mg) treated with MTX (108mg, 0.238mmol), HBTU 
(83mg, 0.218mmol), and TEA (40mg, 0.396mmol), in a total of 8 mL of DMF. 
Conventional work-up following the retreatment step, afforded the target 
conjugate as yellow, fluffy, and water-soluble solid, in the yield of 155mg (54%); 
it possessed the following the characteristics: ηinh, 15.95 mL g-1. Found: MTX, 
30.95% (UV), 31.4% (NMR). Calcd. for (C60H92N20O22)n (1445.5)n [14(80:20)-
MTX]: MTX, 31.14%; Table 4.17 continued row 3. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 5H (Expected: 5H; aromatic and heteroaromatic 
CH of MTX); 3.8-3.5, 24H (Expected: 24H; CH2-O). These 1H NMR data 
indicate 100% of drug incorporation. 
 
Conjugate 15 (90:10)-MTX 
For the preparation of this conjugate, no major changes were introduced in 
comparison with the basic procedure. The molar feed ratio of MTX/NH2 was still 
1.2. Thus, the reaction of carrier 15 (200mg, 0.101mmol), MTX (55mg, 
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0.121mmol), HBTU (41mg, 0.111mmol), TEA (20mg, 0.201mmol), in total of 8 
mL volume of DMF, gave, after purification and freeze-drying, 160mg (65%); 
ηinh, 12.35 mL g-1. Found: MTX, 17.41% (UV), 17.95% (NMR). Calcd. for 
(C99H159N29O42) n (2427.5)n [15(90:10)-MTX]: MTX, 18.72%. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.75H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 3.8-3.5, 54H (Expected: 54H; CH2-O), 
corresponding to 95% NH2 acylation; see Table 4.16 continued row 4. 
 
Conjugate 16 (90:10)-MTX 
Under the experimental conditions leading to 10(90:10)-MTX, the reaction of 
carrier 16 (400g, 0.199mmol), MTX (109mg, 0.239mmol), HBTU (81mg, 
0.219mmol), and TEA (40mg, 0.399mmol), afforded 16(90:10)-MTX, isolated as 
yellow, fluffy, water-soluble, solid, in a yield of 390mg (80%), and possessing the 
characteristics: ηinh, 14.87 mL g-1. Found: MTX, 18.04% (UV), 18.45% (NMR). 
Calcd. for (C99H159N29O43)n (2443.5)n [16(90:10)-MTX]: MTX, 18.6%.  
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.95H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 3.8-3.5, 19H (Expected: 55H; CH2-O, CH-O), 
corresponding to 99% MTX incorporation; Table 4.16 continued row 5. 
Conjugate 17 (90:10)-MTX 
As in the preceding experiment, the basic procedure was used to synthesize this 
conjugate from carrier 17 (200mg, 0.114mmol), MTX (62mg, 0.137mmol), 
HBTU (48mg, 0.126mmol), and TEA (23mg, 0.229mmo), in a total of 7 mL of 
DMF. After the adopted work-up, the target conjugate was collected as yellow, 
crispy, water-soluble solid, in a yield of 195mg (77%); ηinh, 19.85 mL g-1; Mw = 
31900; Mn = 17060; In = 1.87. Found: MTX, 19.65 % (UV), 20.12% (NMR). 
Calcd. for (C91H144N30O33)n (2186.3)n [17(90:10)-MTX]: MTX, 20.79%; Table 
4.17 continued row 6. 
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1H NMR (D2O), δ/ppm: 8.5-6.5, 4.8H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 3.8-3.5, 45H (Expected: 45H; CH2OCH3). MTX 
incorporation: 96% 
 
Conjugate 18 (80:20)-MTX 
Without major modification of the procedure affording the preceding compound, 
except 18 substituted that carrier 17, the target conjugate was obtained from 
carrier 18 (200mg, 0.225mmol), MTX (123mg, 0.270mmol), HBTU (94mg, 
0.248mmol), TEA (46mg, 0.450mmol). The molar feed ratios of reactants were: 
1:1.2:1.1:2. After purification as described in previous experiments, and freeze-
drying, the target conjugate was collected as yellow powder, fully water-soluble, 
in a yield of 200mg (66%), and had the following characteristics: ηinh, 21.98 mL g-
1; Mw = 66 170; Mn = 31 880; In = 2.08. Found: MTX, 33.6 % (UV), 33.8% 
(NMR). Calcd. for (C56H84N20O18)n (1325.4)n [18(80:20)-MTX]: MTX, 34.3%; 
see Table 4.17 continued row 7. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.95H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 3.8-3.5, 20H (Expected: 20H; CH2OCH3). MTX 
incorporation: 99%. 
 
5.3.2.3 Poly(amidoamine)-MTX conjugates 
 
The basic procedure leading to the polyaspartamide-MTX conjugates was still 
valid for the preparation of the polyamidoamine-MTX conjugates investigated in 
this project. 
 
Conjugate 25 (80:20)-MTX 
This conjugate was synthesized from carrier 25 (200mg, 0.167mmol), MTX 
(91mg, 0.2mmol), HBTU (70mg, 0.183mmol), and TEA (34mg, 0.333mmol), in a 
total of 6 mL of DMF. After precipitation, purification, and freeze-drying, as 
described in preceding experiments, the conjugate 25(80:20)-MTX was obtained 
as yellow, crispy, water-soluble solid in a yield of 124mg (45%), and 
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characterized as follows: ηinh, 25.09 mL g-1; Mw = 86 600; Mn = 67 100; In = 1.29. 
Found: MTX, 27.74% (UV), 27.8% (NMR). Calcd. for (C74H128N28O14)n 
(1634.1)n [25(80:20)-MTX]: MTX, 27.8%; refer to Table 4.21  row 2. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 5H (Expected: 5H; aromatic and heteroaromatic 
CH of MTX); 4.8-4.5, 10H (Expected: 10H, CONHCH2HNCO). These 1H NMR 
data indicate 100% MTX incorporation. 
 
Conjugate 26 (80:20)-MTX 
In a similar fashion to the preceding experiment, carrier 26 (200mg, 0.159mmol) 
treated with MTX (87mg, 0.191mmol), HBTU (67mg, 0.175mmol), TEA (32mg, 
0.319mmol), in an overall of 6 mL of DMF, afforded, after conventional work-up, 
136mg (50%) of water-soluble solid 26(80:20)-MTX; ηinh, 19.35 mL g-1; Mw = 15 
050; Mn = 9 330; In= 1.61. Found: MTX, 26.09% (UV), 26.49% (NMR). Calcd. 
for (C78H136N28O14)n (1690.2)n [26(80:20)-MTX]: MTX, 26.89%;  see Table 4.21 
row 3. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.9H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 4.8-4.5, 10H (Expected: 10H, CONHCH2HNCO), 
corresponding to 98% MTX incorporation. 
Conjugate 27 (80:20)-MTX 
This conjugate was synthesized under the experimental conditions leading to the 
compound 27(80:20)-MTX. Thus, in the same molar feed ration of MTX/NH2 of 
1.2, carrier 27 (200mg, 0.155mmol), was treated with MTX (84mg, 0.186mmol), 
HBTU (65mg, 0.17mmol), and TEA (31mg, 0.309mmol), in DMF (6 mL). The 
work-up comprising precipitation, purification, and freeze-drying afforded 133mg 
(49%) of yellow solid 27(80:20)-MTX, fully water-soluble; ηinh, 20.65 mL g-1; 
Mw = 15 520; Mn = 10 250; In = 1.52. Found: MTX, 26.16% (UV), 26.25% 
(NMR). Calcd. for (C79H139N29O14)n (1719.2)n [27(80:20)-MTX]: MTX, 26.4%; 
Table 4.21  row 4. 
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1H NMR (D2O), δ/ppm: 8.5-6.5, 4.95H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 4.8-4.5, 10H (Expected: 10H, CONHCH2HNCO), 
indication of 99% NH2 acylation. 
 
Conjugate 28 (80:20)-MTX 
For the preparation of this conjugate, the standard procedure was employed 
without modification. The reactants were used in a molar feed ratio of 
1:1.2:1.1:2.as previously. The polymer 28 (200mg, 0.156mmol) was allowed to 
react at room temperature for 2h, with MTX (85mg, 0.187mmol), HBTU (65mg, 
0.171mmol), and TEA (32mg, 0.312mmol), in a total of 6 mL of DMF. The 
routine work-up including precipitation with Et2O-Me2CO (2:1), isolation upon 
centrifugation, dissolution in 5 mL of H2O, purification by both size exclusion 
chromatography and dialysis, and freeze-drying, gave 120mg (44%) of yellow, 
crispy, fully water-soluble solid 28(80:20)-MTX; ηinh, 22.05 mL g-1; Mw = 60 
800; Mn = 45 800; In = 1.33. Found: MTX, 25.0% (UV), 25.51% (NMR). Calcd. 
for (C77H134N28O16)n (1708.2)n [28(80:20)-MTX]: MTX, 26.6%; see Table 4.21 
row 5.  
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.8H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 4.8-4.5, 10H (Expected: 10H, CONHCH2HNCO), 
indicating 96% NH2 acylation. 
 
Conjugate 29 (80:20)-MTX 
Analogously to the preparation of 28(80:20)-MTX, with the exception that 
polymer 28 was replaced by 29, the conjugate 29(80:20)-MTX was synthesized 
from carrier 29 (200mg, 0.158mmol), MTX (86mg, 0.189mmol), HBTU (66mg, 
0.174mmol), TEA (32mmg, 0.316mmol), in a total of 6 mL of DMF. It was 
obtained 127mg (48%) of yellow, fluffy, and water-soluble conjugate 29(80:20)-
MTX; ηinh, 21.08 mL g-1; Mw = 18 660; Mn = 13 610; In = 1.37. Found: MTX, 
25.0% (UV), 25.76% (NMR). Calcd. for (C81H142N28O16)n (1764.3)n [29(80:20)-
MTX]: MTX, 25.76%; refer to Table 4.21  row 6. 
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1H NMR (D2O), δ/ppm: 8.5-6.5, 5H (Expected: 5H; aromatic and heteroaromatic 
CH of MTX); 4.8-4.5, 10H (Expected: 10H, CONHCH2HNCO), showing 100% 
MTX incorporation (see Table 4.20 row 6). 
 
Conjugate 32-MTX 
The standard procedure was used to afford this conjugate. However, the reaction 
period was extended to 3h. Thus, carrier 32 (200mg, 0.339mmol) treated with 
MTX (185mg, 0.407mmol), HBTU (138mg, 0.373mmol), and TEA (67mg, 
0.678mmol), in a total of 6 mL, at room temperature for 3h. The routine work-up 
afforded 166mg (47%) of faint-yellow, fluffy conjugate 32-MTX; ηinh, 21.95 mL 
g-1; Mw = 26 090; Mn = 13 440; In = 2.47. Found: MTX, 40.1% (UV), 40.24% 
(NMR). Calcd. for (C47H74N16O11)n (1039.3)n (32-MTX): MTX, 43.73%; Table 
4.21  row 7. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.6H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 4.8-4.5, 10H (Expected: 10H, CONHCH2HNCO), 
MTX incorporation: 92% (see Table 4.20 row 7). 
 
Conjugate 33-MTX 
In the same fashion as described for the preparation of 32-MTX, except that 
polymer 32 was replaced by 33, the conjugate 33-MTX was obtained by treating 
carrier 29 (200mg, 0.108mmol) with MTX (69mg, 0.151mmol), HBTU (49mg, 
0.13mmo), and TEA (22mg, 0.216mmol), in 6 mL of DMF. It was obtained after 
routine work-up, 150mg(60%) of faint-yellow, water-soluble solid 33-MTX, 
presenting the listed characteristics: ηinh, 21.80 mL g-1; Mw = 33 020; Mn = 14 
490; In = 1.8. Found: MTX, 15.3% (UV), 16.69% (NMR). Calcd. for 
(C105H190N16O40)n (2316.8)n [33-MTX]: MTX, 19.62%; see Table 4.21  row 8. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4H (Expected: 5H; aromatic and heteroaromatic 
CH of MTX); 4.8-4.5, 4H (Expected: 4H, CONHCH2HNCO), MTX 
incorporation: 80% (see Table 4.20 row 8). 
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An attempt to increase drug incorporation by retreating 50mg (~0.085mmol) of 
conjugate with MTX (31mg, 0.068mmol), HBTU (16mg, 0.042mmol), and TEA 
(17mg, 0.169mmol), in a total of 3 mL of DMF, at room temperature for a more 
extended reaction period of 4h, was unsuccessful, as the 1H NMR spectrum 
revealed only 80% NH2 acylation. 
 
5.3.3 Polymer-ferrocene conjugates  
 
5.3.3.1 Synthesis of ferrocenylbutanoic acid derivatives 
 
Synthesis of ferrocenylbutanoic acid: This ferrocenylation agent was prepared 
according to the procedure described in the literature 167. Several products of close 
melting points were thoroughly mixed to give a batch of mp: 116-119oC (Lit.170 
119-120oC).  
The solid-state IR spectrum showed a C=O band at 1705 cm-1 as well as CH out-
of-plane bending (ferrocenyl) at 810 cm-1.  
Anal. Found: C, 61.60; H, 5.85%. Calcd. For C14H16FeO2 (272.14): C, 61.79; H, 
5.93%. 
 
1H-NMR (CDCl3), δ/ppm: 4.25-4.1, 8.5H (expected: 9H, CH of ferrocenyl); 2.4-
2.2, 4H (expected: 4H, CH2CH2CH2); 1.9-1.7, 2H (expected: 2H, CH2CH2CH2). 
 
Synthesis of p-nitrophenyl 4-ferrocenylbutanoate (Fc-ONp):   
4-Ferrocenylbutanoic acid (2.178g, 8mmol) and p-Nitrophenol, pNOH (1.35g, 
9.6mmol) were dissolved in 20 mL of dry ethyl acetate, and stirred in an ice-water 
bath. Dicyclohexylcarbodiimide, DCC (1.62g, 7.92mmol) was added, in small 
portions. Stirring was continued for a period of 1/2h in the ice-water then at room 
temperature for another 2h. Dicyclourea was filtered off, and thoroughly washed 
with 36 mL of ethyl acetate used in several portions. The filtrate and washings 
were combined, and spun to dryness by rotating evaporation (40oC bath 
temperature).The residue was recrystallized from hot 95% ethanol containing 1% 
acetic acid (to prevent hydrolysis of the ester). The recrystallization repeated once 
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more, afforded 2.04g (65%) of brownish material. Several products of close 
melting points were thoroughly mixed to give a batch of 4.8g; mp: 70-71 0C. 
Anal. Found: C, 60.98; H, 5.19; N, 3.54 %. Calcd. For C20H19FeO4N (393.22): C, 
61.09; H, 4.87; N, 3.56%. Rf = 0.59 (silica gel, CH2Cl2: Hexane (2:1)). 
 
1H-NMR (CDCl3), δ/ppm: 8.25-7.25, 4H (expected: 4H, CH of aromatic ring); 
4.25-4.1, 9H (expected: 9H; CH of ferrocenyl); 2.4-2.2, 4H (expected: 4H, 
CH2CH2CH2); 1.9-1.7, 2H (expected: 2H, CH2CH2CH2). 
p-nitrophenyl group; λ = 274nm ε = 9500mol-1L cm-1 in DMSO. 
 
Synthesis of N-succinimidyl 4-ferrocenylbutanoate (Fc-OSU): 
This ferrocene derived active ester was prepared from 4-ferrocenylbutanoic acid 
and N-hydroxysuccinimide (HSU) as described below: 
4-Ferrocenylbutanoic acid (2.72g, 10mmol) was dissolved in 50 mL of ethyl 
acetate upon heating. On cooling at ambient temperature, N-hydroxysuccinimide, 
HSU (1.38g, 12mmol) was added in small portions, and the solution stirred, then 
placed in an ice bath, with stirring continued. Dicyclohexylcarbodiimide, DCC 
(2.48g, 12mmol) predissolved in 5 mL of ethyl acetate was added dropwise over 
0.5-1h period, and stirring continued in the ice bath for a period of 4h then at 
room temperature for another 48h. Afterwards, dicyclourea was filtered off, and 
thoroughly washed with 3 x 5 mL of ethyl acetate. The filtrate and washings were 
combined, spun to dryness by rotating evaporation (50oC bath temperature), and 
the residue, recrystallized from isopropanol. The fractions of close melting point 
were collected to afford a batch of 3.15g (85%). mp: 67-70oC. 
Anal. Found: C, 58.5; H, 5.15; N, 3.8 %. Calcd. For C18H19FeO4N (369.2): C, 
58.6; H, 5.19; N, 3.79%. 
 
1H-NMR (CDCl3), δ/ppm: 4.25-4.1, 9H (expected: 9H, CH of ferrocenyl); 3.0-
2.75, 4.1H (Expected: 4H, CH2, succinimidyl), 2.4-2.2, 4.1H (expected: 4H, 
CH2CH2CH2); 1.9-1.7, 2.1H (expected: 2H, CH2CH2CH2). 
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5.3.3.2 Preparation of polymer-ferrocene conjugates 
The incorporation of ferrocene into amine-functionalized carriers was achieved by 
amidation through two coupling methods. These included, first, direct free acid -
primary amine coupling mediated by HBTU agent, Method (1), and, second, 
coupling via the p-Nitrophenol (HONp) active ester of ferrocenylbutanoic acid, 
Method (2). In one case, the succinimide ester of the ferrocenylbutanoic acid was 
used to demonstrate the drug-binding potential of the poly(amidoamine) polymers 
on ferrocenylation in other organic solvents namely methanolic medium than 
dimethylformamide. 
 
Conjugate 1-Fc (HBTU) 
This conjugate was obtained using the Method (1) detailed below. 
Carrier 1 (200mg, 0.102mmol) was dissolved in 5 mL of DMF with stirring. In a 
separate vessel, 4-ferrocenylbutanoic acid (33mg, 0.12mmol) and HBTU (42mg, 
0.11mmol), dissolved in 2 mL of DMF, were stirred for a period of 1h at ambient 
temperature, protected from direct light, then added in one dash to the carrier 
solution, followed by the addition of TEA (21mg, 0.204mmol). The resulting 
brownish solution was saturated with N2, and stirred at room temperature for 
another 2h, still protected from the light. Afterwards, the reaction vessel was 
cooled at 5oC for 0.5h, then the conjugate was precipitated with 20 mL of Et2O-
hexane (2:1), isolated upon centrifugation, thoroughly washed with warm acetone, 
Me2CO, and dissolved in 5 mL of H2O. The pH was adjusted from ~9 to 10 upon 
NaOH addition, and the product was purified by size exclusion chromatography 
on 2.5 x 25 cm column packed with Sephadex G-25 and eluted with distilled H2O. 
The pH of the eluate was readjusted to 7 (glacial acetic acid) to prevent 
hydrolysis, ~10mg of ascorbic acid was added to preclude ferrocene oxidation to 
ferricenium salts, and the solution was dialyzed for 48h in Spectra/Por 6 tubing. 
The retentate, pH~8, was freeze-dried to afford 120 mg (53%) of tan, fluffy, and 
water-soluble 1-Fc (HBTU), possessing the following characteristics: ηinh, 15.96 
mL g-1. Found: Fe, 2.45% (UV), 2.52% (NMR). Calcd. for (C102H180N30O21Fe)n 
(2218.6)n [1-Fc (HBTU)]: Fe, 2.52%. Refer to Table 4.27 row 2. 
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1H NMR (D2O), δ/ppm: 4.3-4.25, 9H (Expected: 9H; CH of ferrocenyl); 1.8-1.5, 
22H (Expected: 22H, CH2CH2CH2), indicating 100% NH2 acylation. 
 
The Fe content by mass of this conjugate (and the forthcomings) was derived 
from the ferrocene content UV spectroscopically determined in H2O using the 
molar extinction coefficient value, ε = 100 mol-1 cm-1, and the absorbance at λ = 
440 nm, of ferrocene proper. 
 
Conjugate 1-Fc (ONp) 
Method (2) was used to afford that conjugate. Thus, carrier 1 (200mg, 
0.102mmol) and Fc-ONp (48mg, 0.122mmol) were dissolved in 2 mL of dry 
DMSO, protected from direct light, and the solution was stirred at room 
temperature; overnight then ethanolamine (EA) (8mg, 0.122mmol) was added to 
aminolyze the unreacted Fc-ONp. Stirring was continued at the stated temperature 
for another 3h. Thereafter, the polymeric conjugate was precipitated with 20 mL 
of Me2CO:Et2O (3:1), isolated upon centrifugation, thoroughly washed with 3x 5 
mL of Me2CO, dissolved in 5 mL of H2O. The pH was adjusted from ~9 to 10 
upon NaOH addition, and the product was purified by size exclusion 
chromatography on 2.5 x 25 cm column packed with Sephadex G-25 and eluted 
with distilled H2O. The pH of the eluate was readjusted to 7 (glacial acetic acid) to 
prevent hydrolysis, ~10mg of ascorbic acid was added to preclude ferrocene 
oxidation, and the solution was dialyzed exhaustively for 48h in Spectra/Por 6 
tubing. The retentate, pH~8, was freeze-dried to give 125 mg (55%) of 1-Fc 
(ONp) as a tan-colored, fluffy, and water-soluble solid.  ηinh, 15.92 mL g-1.  
Found: Fe, 2.48% (UV), 2.52% (NMR). Calcd. for (C102H180N30O21Fe)n (2218.6)n 
[1-Fc (ONp)]: Fe, 2.52%. Refer to Table 4.31 row 2. 
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 9H (Expected: 9H; CH of ferrocenyl); 1.8-1.5, 
22H (Expected: 22H, CH2CH2CH2). These 1H NMR data showed 100% Fc 
incorporation. 
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Conjugate 2-Fc (ONp) 
This conjugate was prepared analogously to 1-Fc (ONp) by replacing carrier 
1(90:10) by its variant 2(80:20). Thus, from carrier 2 (200mg, 0.21mmol), Fc-
ONp (97mg, 0.248mmol) and EA (15mg, 0.248mmol), it was obtained after work-
up 142mg (55%) of the target conjugate 2-Fc (ONp) as tan-colored, fluffy and 
fully water-soluble material. ηinh, 13.15 mLg-1. Found: Fe, 4.48% (UV), 4.55% 
(NMR). Calcd. for (C57H95N15O11Fe)n (1222.3)n [2-Fc (ONp)]: Fe, 4.57%). See to 
Table 4.31 row 3. 
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 8.73H (Expected: 9H; CH of ferrocenyl); 1.8-
1.5, 12H (Expected: 12H, CH2CH2CH2). These 1H NMR data showed 97% Fc 
incorporation. 
 
Conjugate 3-Fc (HBTU) 
Similarly to the basic Method (1) leading to 1-Fc (HBTU), the conjugate 3-Fc 
(HBTU) was obtained by treating carrier (200mg, 0.1mmol) with 
ferrocenylbutanoic acid (33mg, 0.11mmol), HBTU (42mg, 0.11mmol), TEA 
(20mg, 0.2mmol), in a total of 7 mL of DMF. After conventional work-up, it was 
obtained 125mg (56%) of tan-colored, water-soluble, solid 3-Fc (HBTU), 
characterized as follows: ηinh, 13.7 mL g-1. Found: Fe, 2.48% (UV), 2.49% 
(NMR). Calcd. for (C103H183N31O21Fe)n (2247.6)n [3-Fc (HBTU)]: Fe, 2.49%; 
Table 4.27 row 3. 
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 9H (Expected: 9H; CH of ferrocenyl); 1.8-1.5, 
20H (Expected: 20H, CH2CH2CH2). These 1H NMR data showed 100% Fc 
incorporation. 
 
Conjugate 3-Fc (ONp) 
For the preparation of this conjugate the standard procedure that afforded 1-Fc 
(ONp) was used. Thus, the reaction of polyasparatamide 3 (200mg, 0.1mmol), Fc-
ONp (47mg, 0.12mmol), and EA (7mg, 0.12mmol), in a total of 2 mL of DMSO, 
gave, after routine work-up, 130mg (58%) of fluffy, fully water-soluble 
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compound 3-Fc (ONp). ηinh, 13.25 mL g-1. Found: Fe, 2.46% (UV), 2.49% 
(NMR). Calcd. for (C103H183N31O21Fe)n (2247.6)n [3-Fc (ONp)]: Fe, 2.49%; Table 
4.31 row 4. 
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 9H (Expected: 9H; CH of ferrocenyl); 1.8-1.5, 
20H (Expected: 20H, CH2CH2CH2). These 1H NMR data indicate 100% NH2 
acylation. 
 
Conjugate 4-Fc (ONp) 
This conjugate was obtained in a fashion similar to that leading to the preceding 
conjugate with the exception that carrier 3(90:10) was replaced by 4(80:20). Thus, 
the treatment of carrier 4 (200mg, 0.2mmol) with Fc-ONp (94mg, 0.241mmol) 
and EA (15mg, 0.241mmol) in a total of 2mL of DMSO, afforded after work-up 
148mg (58%) of the target conjugate 4-Fc (ONp) as tan-colored and water-
soluble solid. ηinh, 12.85 mL g-1. Found: Fe, 4.42% (UV), 4.45% (NMR). Calcd. 
for (C58H98N16O11Fe)n (1251.4)n [4-Fc (ONp)]: Fe, 4.46%; Table 4.31 row 5. 
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 9H (Expected: 9H; CH of ferrocenyl); 1.8-1.5, 
10H (Expected: 10H, CH2CH2CH2). These 1H NMR data indicate 100% NH2 
acylation. 
 
Conjugate 5-Fc (HBTU) 
This conjugate was obtained by the direct coupling Method (1). Thus, carrier 5 
(200mg, 0.098mmol) treated with ferrocenylbutanoic acid (37mg, 0.137mmol), 
HBTU (45mg, 0.118mmol) and TEA (20mg, 0.196mmol), afforded 146mg (64%) 
of tan, fluffy and fully water-soluble solid. ηinh, 12.5 mL g-1. Found: Fe, 2.39% 
(UV), 2.41% (NMR). Calcd. for (C105H186N30O23Fe)n (2292.7)n [5-Fc (HBTU)]: 
Fe, 2.44%; Table 4.27 row 4. 
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 8.91H (Expected: 9H; CH of ferrocenyl); 1.8-
1.5, 20H (Expected: 20H, CH2CH2CH2). These 1H NMR data indicate 99% NH2 
acylation. 
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Conjugate 5-Fc (ONp) 
For the preparation of this conjugate, the Method (2) was employed. Thus, 125mg 
(55%) of water-soluble solid were obtained from carrier 5 (200mg, 0.098mmol) 
and Fc-ONp (46mg, 0.118mmol), in a ratio NH2: active ester of 1:1.2. The 
conjugate was found to possess the following characteristics: ηinh, 11.95 mL g-1. 
Found: Fe, 2.39% (UV), 2.37% (NMR). Calcd. for (C105H186N30O23Fe)n (2292.7)n 
[5-Fc (ONp)]: Fe, 2.44%; Table 4.31 row 6.  
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 8.7H (Expected: 9H; CH of ferrocenyl); 1.8-1.5, 
20H (Expected: 20H, CH2CH2CH2), corresponding to drug incorporation of 97% 
level. 
 
Conjugate 7-Fc (ONp) 
Polymer 7 (400mg, 0.202mmol) and Fc-ONp (95mg, 0.242mmol) were reacted in 
DMSO solution for a period of 6h at RT followed by the addition of EA (15mg, 
0.242mmol). The reaction was continued for another 2h at RT. The routine work-
up comprising precipitation in non-solvent, isolation upon centrifugation, 
fractionation and purification by both size exclusion chromatography and 
exhaustive dialysis under pH control, and isolation in solid state by freeze-drying, 
afforded 270mg (59%) of the target conjugate as tan-colored and water-soluble 
compound.  ηinh, 14.5 mL g-1. Found: Fe, 2.42% (UV), 2.39% (NMR). Calcd. for 
(C102H180N30O22Fe)n (2234.6)n [7-Fc (ONp)]: Fe, 2.5%); see Table 4.31 row 7.  
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 8.51H (Expected: 9H; CH of ferrocenyl); 1.8-
1.5, 20H (Expected: 20H, CH2CH2CH2). This indicated the drug incorporation of 
95% level. 
 
Conjugate 8-Fc (ONp) 
The Method (2) was employed for the obtaining of this conjugate. The reaction of 
carrier 8 (200mg, 0.123mmol) with Fc-ONp (58mg, 0.148mmol) and EA (9mg, 
0.148mmol) in total of 2 mL of DMSO, at ambient temperature over a period of 
10h, gave after adopted work-up 160mg (69%) of water-soluble solid 8-Fc 
  
193
(ONp); ηinh, 17.75 mL g-1. Found: Fe, 2.94% (UV), 2.97% (NMR). Calcd. for 
(C76H120N22O30Fe)n (1877.8)n [8-Fc (ONp)]: Fe, 2.97%. See Table 4.31 row 8. 
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 9H (Expected: 9H; CH of ferrocenyl); 3.8-3.5,      
18 (Expected: 18H, OCH2OH). The spectroscopic results revealed the conjugation 
extent to be of 100%. 
 
Conjugate 10-Fc (ONp) 
In a fashion analogous to that leading to the preceding conjugate with the 
exception of carrier 8 being replaced by 10, conjugate the target conjugate was 
obtained in a yield of 71% as faintly yellow solid from carrier 10 and Fc-ONp in 
ratio 1:1.2. The conjugate possessed full water-solubility. ηinh, 13.75 mL g-1. 
Found: Fe, 2.88% (UV), 2.92% (NMR). Calcd. for (C75H117N21O31Fe)n (1864.8)n 
[10-Fc (ONp)]: Fe, 3.0%; Table 4.31 row 9. 
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 8.73H (Expected: 9H; CH of ferrocenyl); 3.8-
3.5, 19H (Expected: 19H, CH-OH, OCH2OH). These spectroscopic data indicated 
97% NH2 acylation. 
 
Conjugate 11-Fc (ONp) 
Polymer 11 (400mg, 0.25mmol) was treated with Fc-ONp (118mg, 0.3mmol) in 
DMSO medium for a period of 6h at ambient then EA (18mg, 0.3mmol) was 
added, and treatement continued for another 2h at the same temperature. After 
routine work-up, the target conjugate 11-Fc (ONp) was isolated in yield of 340mg 
(73%) as tan-colored, fluffy and fully water-soluble solid.  ηinh, 13.5 mL g-1. 
Found: Fe, 2.98% (UV), 2.97% (NMR). Calcd. for (C75H117N21O30Fe)n (1848.8)n 
[11-Fc (ONp)]: Fe, 3.02%); Table 4.31 row 10. 
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 8.79H (Expected: 9H; CH of ferrocenyl); 3.8-
3.5, 18H (Expected: 18H, CH2O); indicating the drug incorporation of the 98% 
level. 
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Conjugate 12-Fc (ONp) 
The reaction of polymer 12 (400mg, 0.24mmol), Fc-ONp (113mg, 0.288mmol) 
and EA (18mg, 0.288mmol) in a total of 4 mL of DMSO, afforded after 
conventional work-up the conjugate 12-Fc (ONp) as tan-colored water-soluble 
solid in a yield of 350mg (75%) with inherent viscosity, ηinh, 14.28 mL g-1. Found: 
Fe, 2.85% (UV), 2.82% (NMR). Calcd. for (C78H123N21O32Fe)n (1922.9)n [12-Fc 
(ONp)]: Fe, 2.9%); Table 4.31 row 11. 
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 8.75H (Expected: 9H; CH of ferrocenyl); 3.8-
3.5, 26H (Expected: 26H, CH2O). These data indicated 97% of drug 
incorporation. 
 
Conjugate 13-Fc (ONp) 
The Method (2) was used for the preparation of this conjugate. Carrier 11 (200mg, 
0.099mmol) was allowed to react with Fc-ONp (47mg, 0.119mmol) and EA 
(7mg, 0.119mmol), in a total volume of DMSO of 2 mL, over a period of 2h. The 
routinely work-up including purification by size exclusion chromatography and 
exhaustive dialysis, and freeze-drying, afforded 170mg (75%) of the target 
conjugate as a tan-colored and fully hydrophilic solid, possessing the following 
characteristics: ηinh, 15.25 mL g-1. Found: Fe, 2.41% (UV), 2.46% (NMR). Calcd. 
for (C94H156N22O39Fe)n (2274.3)n [13-Fc (ONp)]: Fe, 2.46%; Table 4.31 row 12. 
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 9H (Expected: 9H; CH of ferrocenyl); 3.8-3.5, 
18H (Expected: 19H, CH2OCH2OH). These data indicated 100% NH2 acylation. 
 
Conjugate 14-Fc (ONp) 
Analogously to the preceding preparative experiment with exception of carrier 13 
being replaced by its variant 14, the target conjugate was obtained from carrier 14 
and Fc-ONp in ratio of 1:1.2, in a yield of 57%, and was found to retain full 
water-solubility. ηinh, 13.5 mL g-1. Found: Fe, 4.3% (UV), 4.35% (NMR). Calcd. 
for (C54H86N12O19Fe)n (1263.2)n [14-Fc (ONp)]: Fe, 4.42%); Table 4.31 row 13. 
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1H NMR (D2O), δ/ppm: 4.3-4.25, 8.82H (Expected: 9H; CH of ferrocenyl); 3.8-
3.5, 24H (Expected: 24H, CH2OCH2OH), corresponding to drug incorporation 
level of 98%. 
 
Conjugate 16-Fc (ONp) 
The Method (2) was employed for the synthesis of conjugate 16-Fc (ONp). Thus, 
used in the similar (physical and stoichiometric) conditions as those leading to the 
preceding conjugate, carrier 16 (200mg, 0.1mmol) and with Fc-ONp (47mg, 
0.12mmol) afforded after work-up, 105mg (46%) of the target conjugate as faint-
yellow solid, fully hydrophilic. ηinh, 12.86 mL g-1. Found: Fe, 2.45% (UV), 2.43% 
(NMR). Calcd. for (C93H153N21O40Fe)n (2261.3)n [16-Fc (ONp)]: Fe, 2.47%.  
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 8.82H (Expected: 9H; CH of ferrocenyl); 3.8-
3.5, 55H (Expected: 55H, CH-OH, CH2OCH2OH), corresponding to drug 
incorporation level of 98%; Table 4.31 row 14. 
 
Conjugate 17-Fc (ONp) 
This conjugate was prepared in a fashion similar to that leading to the preceding 
conjugate with minor change concerning the replacement of carrier 16 by 17. 
Thus, carrier 17 (200mg, 0.114mmol) treated with Fc-ONp (54mg, 0.137mmol) 
and EA (8mg, 0.137mmol), in total volume of DMSO of 2 mL, gave after work-
up, 175mg (74%) of a tan-colored and water-soluble solid. ηinh, 18.5 mLg-1. 
Found: Fe, 2.73% (UV), 2.79% (NMR). Calcd. for (C93H153N21O40Fe)n (2003.1)n 
[17-Fc (ONp)]: Fe, 2.79%; Table 4.31 row 15.  
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 9H (Expected: 9H; CH of ferrocenyl); 3.8-3.5, 
45H (Expected: 45H, CH2OCH3). These data showed 100% NH2 acylation 
 
Conjugate 19-Fc (ONp) 
For the preparation of this conjugate, the Method (2) was employed. Thus, the 
reaction of polymer 19 (400mg, 0.232mmol) with Fc-ONp (109mg, 0.278mmol) 
and EA (17mg, 0.278mmol) in DSMO medium at ambient temperature for a 
  
196
period of 8h, afforded after routine work-up the target conjugate 19-Fc (ONp) as 
water-soluble solid and characterized as follows: ηinh, 16.89 mL g-1. Found: Fe, 
2.75% (UV), 2.80% (NMR). Calcd. for (C84H136N21O30Fe)n (1975.1)n [19-Fc 
(ONp)]: Fe, 2.8%; Table 4.31 row 16.  
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 9H (Expected: 9H; CH of ferrocenyl); 3.8-3.5, 
45H (Expected: 45H, CH2OCH3), indicating 100% NH2 acylation. 
 
Conjugate 20-Fc (ONp) 
Polymer 20 (400mg, 0.223mmol) was allowed to react with Fc-ONp (105mg, 
0.267mmol) and EA (16mg, 0.267mmol) in a similar fashion as that leading to the 
preceding conjugate. After work-up, the conjugate 20-Fc (ONp) was isolated as 
tan-colored material possessing full water solubility and the following 
characteristics: ηinh, 15.45 mL g-1. Found: Fe, 2.70% (UV), 2.68% (NMR). Calcd. 
for (C84H136N21O30Fe)n (2049.1)n [20-Fc (ONp)]: Fe, 2.73%.  
 
1H NMR (D2O), δ/ppm: 4.3-4.25, 8.82H (Expected: 9H; CH of ferrocenyl); 3.8-
3.5, 53H (Expected: 53H, CH2O-, CH2OCH3). These data indicate the 
incorporation of drug of 98% level; Table 4.31 continued row 2. 
 
Conjugate 25-Fc (HBTU) 
This poly(amidoamine)-derived conjugate was obtained using the acylation 
Method (1) as described for 1-Fc (HBTU). In a molar feed ratio Fc/NH2 of 1.2, 
poly(amidoamine) 25 (200mg, 0.167mmol), 4-ferrocenylbutanoic acid (68mg, 
0.251mmol), HBTU (82mg, 0.217mmol), and TEA (34mg, 0.333mmol), in a total 
of 7 mL of DMF, afforded 95 mg (39%) of tan-colored, fully water soluble 25-Fc 
(HBTU). ηinh, 16.25 mL g-1. Found: Fe, 3.82% (UV), 3.85% (NMR). Calcd. for 
(C68H122N20O11Fe)n (1451.7)n [25-Fc (HBTU)]: Fe, 3.85%. See Table 4.27 row 5. 
 
1H NMR (D2O), δ/ppm: 4.8-4.5, 10H (Expected: 10H, CONHCH2HNCO), 4.3-
4.25, 9H (Expected: 9H; CH of ferrocenyl); 1.8-1.5, 4H (Expected: 4H, 
CH2CH2CH2). These 1H NMR data indicate 100% NH2 acylation. 
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Conjugate 25-Fc (ONp) 
Method (2) was applied for the preparation of this conjugate from carrier 25 
(200mg, 0.167mmol), Fc-ONp (79mg, 0.2mmol), and EA (12mg, 0.2mmol), in 2 
mL of DMSO. After work-up as described in the preceding experiments, it was 
obtained conjugate 25-Fc (ONp) in a yield of 124mg (51%), tan-colored and 
water-soluble. ηinh, 14.5 mL g-1. Found: Fe, 3.8% (UV), 3.85% (NMR). Calcd. for 
(C68H122N20O11Fe)n (1451.7)n [25-Fc (ONp)]: Fe, 3.85%. 
 
1H NMR (D2O), δ/ppm: 4.8-4.5, 10H (Expected: 10H, CONHCH2HNCO), 4.3-
4.25, 9H (Expected: 9H; CH of ferrocenyl); 1.8-1.5, 4H (Expected: 4H, 
CH2CH2CH2). Ferrocene incorporation: 100%; Table 4.31 continued row 3. 
 
Conjugate 26-Fc (HBTU) 
Using the Method (1) similarly to the synthesis of 25-Fc (HBTU), this polymeric 
drug conjugate was obtained from carrier 26 (200mg, 0.159mmol), 
ferrocenylbutanoic acid (65mg, 0.239mmol), HBTU (78mg, 0.208mmol), and 
TEA (32mg, 0.319mmol), in a total of 7 mL of DMF. The routine work-up 
afforded the target conjugate 26-Fc (HBTU) in a yield of 100mg (42%) as tan-
colored, water-soluble solid. It possessed the following characteristics: 
ηinh, 19.79 mL g-1. Found: Fe, 3.63% (UV), 3.7 (NMR). Calcd. for (C72N30O11Fe)n 
(1507.8)n [26-Fc (HBTU)]: Fe, 3.7%. See Table 4.27 row 6. 
 
1H NMR (D2O), δ/ppm: 4.8-4.5, 10H (Expected: 10H, CONHCH2HNCO), 4.3-
4.25, 9H (Expected: 9H; CH of ferrocenyl); 1.8-1.5, 12H (Expected: 12H, 
CH2CH2CH2). Ferrocene incorporation: 100%. 
 
Conjugate 27-Fc (HBTU) 
This conjugate was prepared similarly to 25-Fc (HBTU), except that 
poly(amidoamine) 25 was replaced by 27. Thus, carrier 27 (200mg, 0.155mmol), 
treated with 4-ferrocenylbutanoic acid (63mg, 0.233mmol), HBTU (77mg, 
0.202mmol), TEA (31mg, 0.309mmol), in a total of 7 mL of DMF, gave 102mg 
(43%) of water-soluble solid 27-Fc (HBTU). ηinh, 18.5 mL g-1. Found: Fe, 3.57% 
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(UV), 3.64% (NMR). Calcd. for (C73H132N21O11Fe)n (1535.8)n [27-Fc (HBTU)]: 
Fe, 3.64%. Refer to Table 4.27 row 7. 
 
1H NMR (D2O), δ/ppm: 4.8-4.5, 10H (Expected: 10H, CONHCH2HNCO), 4.3-
4.25, 9H (Expected: 9H; CH of ferrocenyl); 1.8-1.5, 10H (Expected: 10H, 
CH2CH2CH2), showing 100% NH2 acylated. 
 
Conjugate 27-Fc (ONp) 
The basic procedure leading to 25-Fc (ONp), was used for the preparation of this 
compound. Polymer 27 (180mg, 0.140mmol) was treated with Fc-ONp (66mg, 
0.168mmol), and EA (10mg, 0.168mmol), in a total of 2 mL of DMSO. The 
routine work-up comprising precipitation, purification by both size exclusion 
chromatography, and freeze-drying, gave 90mg (42%) of water-soluble solid 27-
Fc (ONp). ηinh, 17.05 mL g-1. Found: Fe, 3.58% (UV), 3.64% (NMR). Calcd. for 
(C73H132N21O11Fe)n (1535.8)n [27-Fc (ONp)]: Fe, 3.64%. 
 
1H NMR (D2O), δ/ppm: 4.8-4.5, 10H (Expected: 10H, CONHCH2HNCO), 4.3-
4.25, 9H (Expected: 9H; CH of ferrocenyl); 1.8-1.5, 10H (Expected: 10H, 
CH2CH2CH2), showing 100% ferrocene incorporation; Table 4.31 continued row 
4. 
 
Conjugate 28-Fc (HBTU) 
Method (1) was employed to afford this conjugate. Poly(amidoamine) 28 (200mg, 
0.156mmol) treated ferrocenylbutanoic acid (64mg, 0.234mmol), HBTU (77mg, 
0.203mmol), TEA (32mg, 0.312mmol), in a total of 7 mL of DMF, gave 120mg 
(43%) of water-soluble solid 28-Fc (HBTU), characterized as follows: ηinh, 21.2 
mL g-1. Found: Fe, 3.61% (UV), 3.66% (NMR). Calcd. for (C71H128N20O13Fe)n 
(1525.8)n [28-Fc (HBTU)]: Fe, 3.66%; Table 4.27 row 8. 
 
1H NMR (D2O), δ/ppm: 4.8-4.5, 10H (Expected: 10H, CONHCH2HNCO), 4.3-
4.25, 9H (Expected: 9H; CH of ferrocenyl); 3.8-3.5, 9H (Expected: 8H, 
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OCH2CH2O); 1.8-1.5, 10H (Expected: 10H, CH2CH2CH2), indicating 100% NH2 
acylation. 
 
Conjugate 28-Fc (ONp) 
In a similar fashion to that leading to the conjugate 27-Fc (ONp), from carrier 28 
(130mg, 0.101mmol), Fc-ONp (48mg, 0.122mmol), and EA (8mg, 0.122mmol), it 
was obtained 65mg (42%) of the target conjugate 28-Fc (ONp), as tan-colored, 
fluffy, and water-soluble compound. ηinh, 22.05 mL g-1. (Found: Fe, 3.60% (UV), 
3.66% (NMR). Calcd. for (C71H128N20O13Fe)n (1525.8)n [28-Fc (ONp)]: Fe, 
3.66% 
 
1H NMR (D2O), δ/ppm: 4.8-4.5, 10H (Expected: 10H, CONHCH2HNCO), 4.3-
4.25, 9H (Expected: 9H; CH of ferrocenyl); 3.8-3.5, 9H (Expected: 8H, 
OCH2CH2O); 1.8-1.5, 10H (Expected: 10H, CH2CH2CH2), indicating 100% NH2 
acylation; Table 4.31 continued row 5. 
 
Conjugate 32-Fc (HBTU) 
Similarly to the preparation of 1-Fc (HBTU), except that polyaspartamide 1 was 
replaced by poly(amidoamine) 32, conjugate 32-Fc (HBTU) resulted from the 
reaction of carrier 32 (100mg, 0.17mmol), ferrocenylbutanoic acid (56mg, 
0.204mmol), HBTU (71mg, 0.187mmol), TEA (34mg, 0.34mmol), in a total of 7 
mL of DMF. The adopted work-up afforded conjugate 32-Fc (HBTU) in yield of 
105mg (73%). It was found tan-colored and fully water-soluble. ηinh, 16.3 mL g-1. 
Found: Fe, 6.25% (UV), 6.3% (NMR). Calcd. for (C40H66N8O8Fe)n (856.9)n [32-
Fc (HBTU)]: Fe, 6.52%. See Table 4.27 row 9. 
 
1H NMR (D2O), δ/ppm: 4.8-4.5, 4H (Expected: 4H, CONHCH2HNCO), 4.3-4.25, 
8.7H (Expected: 9H; CH of ferrocenyl); 3.8-3.5, 14H (Expected: 12H, 
OCH2CH2O); 1.8-1.5, 8H (Expected: 8H, CH2CH2CH2). These 1H NMR data 
indicate 97% NH2 acylation. 
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Conjugate 32-Fc (ONp) 
The reaction of carrier 32 (180mg, 0.339mmol), Fc-ONp (160mg, 0.407mmol) 
and EA (25mg, 0.406mmol) in DSMO medium afforded after conventional work-
up 149mg (48%) of target conjugate conjugate 32-Fc (ONp) as fully water-
soluble solid which possessed the followings characteristics: ηinh, 15.55 mL g-1. 
Found: Fe, 6.54% (UV), 6.45% (NMR). Calcd. for (C40H66N8O8Fe)n (856.9)n [32-
Fc (ONp)]: Fe, 6.52%. Ree Table 4.31 continued row 6. 
 
1H NMR (D2O), δ/ppm: 4.8-4.5, 4H (Expected: 4H, CONHCH2HNCO), 4.3-4.25, 
8.9H (Expected: 9H; CH of ferrocenyl); 3.8-3.5, 13H (Expected: 12H, 
OCH2CH2O); 1.8-1.5, 9H (Expected: 8H, CH2CH2CH2). These 1H NMR data 
indicate 99% NH2 acylation. 
 
Conjugate 33-Fc (HBTU) 
The free acid HBTU mediated coupling Method (1) was applied. However, the 
molar feed ratio COOH/NH2 was increased to 1.3 instead of 1.2 as for the 
preparation of 32-Fc (HBTU). Thus, from carrier 33 (200mg, 0.108mmol), 
ferrocenylbutanoic acid (35mg, 0.130mmol), HBTU (39mg, 0.119mmol), TEA 
(22mg, 0.216mmol), in a total of 7 mL of DMF, it was obtained 95mg (41%) of 
fully water-soluble conjugate 33-Fc (HBTU) possessing the following 
characteristics: ηinh, 16.34 mL g-1. Found: Fe, 2.3% (UV), 2.33% (NMR). Calcd. 
for (C98H182N8O37Fe)n (2134.4)n [33-Fc (HBTU)]: Fe, 2.62%; Table 4.27 row 10. 
 
1H NMR (D2O), δ/ppm: 4.8-4.5, 4H (Expected: 4H, CONHCH2HNCO), 4.3-4.25, 
8.1H (Expected: 9H; CH of ferrocenyl); 3.8-3.5, 130H (Expected: 128H, 
OCH2CH2O); 1.8-1.5, 7H (Expected: 8H, CH2CH2CH2). Ferrocene incorporation: 
90%. 
 
Conjugate 33-Fc (ONp) 
The basic procedure affording conjugate 25-Fc (ONp) was used for the 
preparation of the compound 33-Fc (ONp) without major modification except 33 
replaced that carrier 25. The molar feed ratio of active ester/NH2 remained 1.2. 
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Thus, carrier 33 (200mg, 0.108mmol) treated with Fc-ONp (51mg, 0.13mmol), 
and EA (8mg, 0.13mmol), in a total of 2 mL of DMSO, gave after conventional 
work-up, 100mg (44%) of light-brown, water-soluble solid 33-Fc (ONp). ηinh, 
16.85 mL g-1. (Found: Fe, 2.58% (UV), 2.53% (NMR). Calcd. for 
(C98H182N8O37Fe)n (2134.4)n [33-Fc (ONp)]: Fe, 2.62%; Table 4.31 continued 
row 7.  
 
1H NMR (D2O), δ/ppm: 4.8-4.5, 4H (Expected: 4H, CONHCH2HNCO), 4.3-4.25, 
8.7H (Expected: 9H; CH of ferrocenyl); 3.8-3.5, 130H (Expected: 128H, 
OCH2CH2O); 1.8-1.5, 7H (Expected: 8H, CH2CH2CH2). Ferrocene incorporation: 
97%. 
 
Conjugate 32-Fc (OSU) 
For the preparation of this conjugate the active ester technique was used. 
However, major modifications were introduced. These concerned the active ester 
compound, the reaction medium as well as the molar feed ratio of reactants. Thus, 
contrarily to the preceding experiments, the Fc-ONp active ester was replaced by 
Fc-OSU, methanol was used instead of DMSO. Consequently, the reaction period 
was extended. The molar feed ratio of active ester/NH2 was 1.3 rather than 1.2 as 
previously. 
Thus, carrier 32 (180mg, 0.305mmol) and Fc-OSu (146mg, 0.396mmol) were 
dissolved in 5 mL of MeOH. The brown solution protected from direct light was 
stirred at room temperature for 72h. The solvent was completely removed upon 
rotary evaporation, and the polymeric residue, precipitated with 15 mL of Et2O: 
Me2CO (2:1) was dissolved in 5 mL of H2O. The pH was adjusted from ~9 to 10 
(NaOH) and the product was purified as routinely by size exclusion 
chromatography and dialysis. Freeze-drying of the retentate, pH~8.5, gave 102mg 
(40%) of light-brown, water-soluble solid 32-Fc (OSU). ηinh, 15.05 mL g-1. 
Found: Fe, 6.01% (UV), 6.08% (NMR). Calcd. for (C40H66N8O8Fe) n (856.9) n 
[32-Fc (OSU)]: Fe, 6.52%; see Table 4.31 continued row 8. 
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1H NMR (D2O), δ/ppm: 4.8-4.5, 4H (Expected: 4H, CONHCH2HNCO), 4.3-4.25, 
8.4H (Expected: 9H; CH of ferrocenyl); 3.8-3.5, 14H (Expected: 12H, 
OCH2CH2O); 1.8-1.5, 10H (Expected: 8H, CH2CH2CH2). These 1H NMR data 
indicate 93% NH2 acylation. 
 
5.3.4 Polyaspartamide conjugates with two drug systems 
 
These conjugates were synthesized in a two-step process combining both methods 
employed for the preparation of ferrocene conjugates. The first step consisting of 
binding of the first drug system to the polymeric carrier was achieved via 
coupling mediated by HBTU, and the anchoring of the second drug was brought 
about either by the preceding method or the active ester method. 
 
Conjugate 1 (90:10)-FA/MTX 
Step (1): Carrier 1 (600mg, 0.306mmol) and FA (95mg, 0.214mmol) were 
dissolved in 10 mL of NMP-HMP-DMF (4:3:3) upon heating. To this rapidly 
stirred solution at RT, was added dropwise over 0.5h period HBTU (70mg, 
0.184mmol) predissolved in 2 mL of DMF. This was followed by the addition of 
TEA (62mg, 0.612mmol). The resulting yellow solution was saturated with N2 
and stirring was continued at RT for 2h, then cooled at 5oC for another 0.5h. 
Thereafter, the routine work-up as in preceding experiments, gave 550mg (82%) 
of yellow, crispy, fully water-soluble material homoconjugate 1(90:10)-FA, ηinh, 
15.05 mL g-1. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 2.9H (Expected: 5H; aromatic and 
heteroaromatic CH of FA); 1.8-1.6, 20H (expected: 20H; CH2CH2CH2). These 
data indicate 58% FA incorporation. Found: FA, 11.05% (UV), 11.58% (NMR). 
 
Step (2): The homoconjugate 1(90:10)-FA (H) (200mg, 0.102mmol) and MTX 
(33mg, 0.072mmol) were dissolved in 8 mL of NMP-HMP (1:1) upon heating. On 
cooling and rapid stirring at RT, HBTU (23mg, 0.061mmol) predissolved in 2 mL 
of DMF, was added dropwise over 20min period followed by the addition of TEA 
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(21mg, 0.204mmol). The solution was saturated with N2 and stirring was 
continued at RTfor 3h then cooled at 5oC for another 0.5h. 
The conventional work-up gave 150mg of co-conjugate 1(90:10)-FA/MTX as a 
yellow material possessing full solubility; ηinh, 15.05 mL g-1.   
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.58H (Expected: 5H; hetero- and aromatic CH 
of FA); 1.8-1.6, 20H (expected: 20H; CH2CH2CH2), showing 92% (FA+MTX) 
incorporation. 
 
In order to increase the drug incorporation, 1(90:10)-FA/MTX (150mg, 
~0.077mmol) was retreated with MTX (28mg, 0.061mmol), HBTU (15mg, 
0.038mmol) and TEA (16mg, 0.153mmol), in a total of 7 mL of NMP-HMP (1:1), 
the reaction period being extended to 4h. After routine work-up, the co-conjugate 
was isolated in a total yield of 80mg (53%). ηinh, 16.01 mL g-1. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.83H (Expected: 5H; hetero- and aromatic CH 
of FA); 3.5-3.0, 23H (Expected: 22H, CONHCH2); 1.8-1.6, 20H (expected: 20H; 
CH2CH2CH2). 1H NMR data indicated the compound to contain (FA+MTX) at the 
level of 97%; see Table 4.35 row 2. 
 
UV spectroscopy determination of MTX 
As methotrexate and folic acid show identical 1H NMR spectra, especially in the 
aromatic region, it was impossible to determine the exact content of drug (MTX) 
in the final compound by 1H NMR spectroscopy. Therefore, UV spectroscopy was 
used to assess MTX content using the molar extinction coefficient value, ε = 6500 
mol-1cm-1 and the absorbance at λ = 370 nm. To this end, solutions of same 
concentration of both homo- and co-conjugate were prepared and absorbance at λ 
= 370 nm of the co-conjugate solution (reference, homoconjugate solution) read. 
The co-conjugate was found to contain 8% MTX by mass. 
 
Assuming that no cleavage of folate occurred during the second step, 39% MTX 
incorporation, obtained by subtracting 58% FA from the count of 97% 
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(FA+MTX) established by NMR spectroscopy, was determined; this 
corresponded to 7.45% by mass. Found: FA, 11.05% (UV), 11.58% (NMR); 
MTX, 8% (UV), 7.45% (NMR). 
 
Conjugate 3 (90:10)-FA/MTX 
This co-conjugate was prepared similarly to the preceding except that carrier 3 
replaced 1. Thus, from carrier 3 (600mg, 0.3mmol), FA (93mg, 0.21mmol), 
HBTU (68mg, 0.18mmol), and TEA (61mg, 0.6mmol), it was obtained 580mg 
(87%) of water-soluble homoconjugate 3(90:10)-FA (H). ηinh, 13.25 mL g-1.  
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 2.16H (Expected: 5H; aromatic and 
heteroaromatic CH of FA); 1.8-1.6, 18H (expected: 18H; CH2CH2CH2). These 
data indicate 43% FA incorporation. Found: FA, 8.2% (UV), 8.7% (NMR). 
 
The reaction of 3(90:10)-FA (H) (200mg, 0.1mmol) with MTX (32mg, 
0.07mmol), HBTU (23mg, 0.06mmol), and TEA (20mg, 0.2mmol) afforded 
105mg (47%) of yellow co-conjugate, showing 74% (FA+MTX) incorporation. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 3.75H (Expected: 5H; hetero- and aromatic CH 
of FA); 1.8-1.6, 18H (expected: 18H; CH2CH2CH2).  
The retreatment of this co-conjugate (100mg, ~0.05mmol) with MTX (18mg, 
0.04mmol), HBTU (10mg, 0.025mmol), and TEA (10mg, 0.1mmol), gave after 
conventional work-up   3(90:10)-FA/MTX as yellow, water-soluble solid, in an 
overall of 65mg (65%). ηinh, 14.5 mL g-1. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 4.8H (Expected: 5H; aromatic and 
heteroaromatic CH of FA); 3.5-3.0, 22H (Expected: 22H, CONHCH2); 1.8-1.6, 
18H (expected: 18H; CH2CH2CH2). These data indicate 96% (FA+MTX) 
incorporation. Found: MTX, 10.58% (UV), 10% (NMR); see Table 4.35 row 3. 
The % MTX (by NMR) in this co-conjugate was determined in the same fashion 
as for the preceding co-conjugate.  
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Conjugate 1 (90:10)-FA/Fc 
Step (1): The reaction of carrier 1 (400mg, 0.204mmol) with FA (63mg, 
0.143mmol), HBTU (46mg, 0.122mmol), and TEA (41mg, 0.408mmol), after 
worked-up in conventional fashion, gave a yellow, fully water-soluble, 
homoconjugate 1(90:10)-FA (H) in a yield of 280mg (63%). ηinh, 16.75 mL g-1. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 2.54H (Expected: 5H; aromatic and 
heteroaromatic CH of FA); 1.8-1.6, 20H (expected: 20H; CH2CH2CH2). FA 
incorporation: 58%. Found: FA, 11.25% (UV), 11.58% (NMR). 
 
Step (2): The target co-conjugate was obtained by reacting the homoconjugate 
with the ferrocene active ester. Thus, homoconjugate (200mg, 0.102mmol) treated 
with Fc-ONp (28mg, 0.072mmol), and EA (4mg, 0.072mmol), afforded 1(90:10)-
FA/Fc as fluffy, tan, water-soluble compound, in a yield of 150mg (70%), 
possessing the following characteristics: ηinh, 18 mL g-1. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 2.57H (Expected: 5H; aromatic and 
heteroaromatic CH of FA); 4.3-4.25, 4.4 (Expected: 9H, CH of ferrocenyl); 3.5-
3.0, 21.7H (Expected: 22H, CONHCH2); 1.8-1.6, 21H (expected: 21H; 
CH2CH2CH2), showing 51% FA and 49% Fc incorporation, corresponding to 
100% NH2 acylation.  
Found: 9.55% (UV), FA, 9.8% (NMR); Fe, 1.25% (OES), 1.2% (NMR); Table 
4.35 row 4. 
 
Conjugate 3 (90:10)-FA/Fc 
This co-conjugate was prepared similarly to the preceding without major change 
except that carrier 3 replaced 1. 
The first step afforded 200mg (60%) of water-soluble homoconjugate, ηinh, 14.05 
mL g-1, resulting from the reaction of carrier 3 (300mg, 0.150mmol) with FA 
(46mg, 0.105mmol), HBTU (34mg, 0.09mmol), TEA (30mg, 0.3mmol). 
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1H NMR (D2O), δ/ppm: 8.5-6.5, 2.3H (Expected: 5H; hetero- and aromatic CH of 
FA); 1.8-1.6, 18H (expected: 18H; CH2CH2CH2). FA incorporation: 46%. 
Found: FA, 8.95% (UV), 9.3% (NMR). 
 
In the second step, the preceding homoconjugate (130mg, 0.065mmol), treated 
with Fc-ONp (20mg, 0.052mmol), and EA (3mg~5µL, 0.052mmol), in a total of 2 
mL of DMSO, afforded the target co-conjugate 3(90:10)-FA/Fc as water-soluble 
material in a yield of 80 m (58%). ηinh, 15.5 mLg-1. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 2.28H (Expected: 5H; aromatic and 
heteroaromatic CH of FA); 4.3-4.25, 4.8 (Expected: 9H, CH of ferrocenyl); 3.5-
3.0, 21.5H (Expected: 22H, CONHCH2); 1.8-1.6, 19H (expected: 19H; 
CH2CH2CH2), showing 45% FA and 53% Fc incorporation, corresponding to 98% 
NH2 acylation.  
Found: FA, 8.75% (UV), 9% (NMR); Fe, 1.12% (OES), 1.28% (NMR); refer to 
Table 4.35 row 5. 
 
Conjugate 1 (90:10)-MTX/Fc 
This conjugate was obtained by the two-step procedure leading the preparation of 
1(90:10)-FA/Fc. However, a major modification was introduced in the step (1) 
where FA was replaced by MTX. 
Step (1): Carrier 1 (400mg, 0.204mmol) was reacted with MTX (65mg, 
0.143mmol), HBTU (46mg, 0.122mmol), and TEA (41mg, 0.408mmol), in total 
volume of 10 mL, for 2h. The homoconjugate 1(90:10)-MTX (H) worked-up in 
conventional fashion was found to be yellow, fully water-soluble, and in a yield of 
290mg (65%). ηinh, 16.5 mLg-1. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 2.4H (Expected: 5H; hetero- and aromatic CH of 
MTX); 1.8-1.6, 20H (expected: 20H; CH2CH2CH2). These data indicate 48% 
MTX incorporation. Found: MTX, 9.25% (UV), 10% (NMR). 
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Step (2): The homoconjugate (200mg, 0.102mmol) and Fc-ONp (32mg, 
0.082mmol) were dissolved in 2 mL of DMSO, and stirred at room temperature 
for 5h. EA (5mg, 0.082mmol) was added and stirring was continued at room 
temperature for another 3h. The routine work-up comprising precipitation, 
isolation upon centrifugation, purification by both size exclusion chromatography 
and aqueous dialysis, and freeze-drying afforded 150mg (70%) of tan-colored, 
fluffy, water-soluble solid 1-(90:10)-MTX/Fc. ηinh, 17.05 mL g-1. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 2.21H (Expected: 5H; aromatic and 
heteroaromatic CH of MTX); 4.3-4.25, 4.95 (Expected: 9H, CH of ferrocenyl); 
3.5-3.0, 23H (Expected: 22H, CONHCH2); 1.8-1.6, 20.6H (expected: 21H; 
CH2CH2CH2). These data indicate 44% MTX and 55% Fc incorporation, 
corresponding to 99% NH2 acylation. Found: MTX, 8.37% (UV), 8.7% (NMR); 
Fe, 1.24% (OES), 1.34% (NMR). Refer to Table 4.35 row 6. 
 
Conjugate 3 (90:10)-MTX/Fc 
In a fashion similar to that leading to 1(90:10)-MTX/Fc, the target conjugate was 
synthesized in two steps. 
In the first step, carrier 3 (400mg, 0.2mmol) treated with MTX (64mg, 
0.14mmol), HBTU (46mg, 0.12mmol), and TEA (41mg, 0.4mmol), in a total 
volume of 10 mL, afforded 250mg (56%) of yellow, fully water-soluble, 
homoconjugate 3(90:10)-MTX (H). ηinh, 14.25 mL g-1. 
 
1H NMR (D2O), δ/ppm: 8.5-6.5, 2.15H (Expected: 5H; hetero- and aromatic CH 
of MTX); 1.8-1.6, 18H (expected: 18H; CH2CH2CH2) showing 43%NH2 
acylation. Found: MTX, 8.02% (UV), 8.96% (NMR). 
 
In the second step, the homoconjugate (200mg, 0.1mmol) and Fc-ONp (31mg, 
0.08mmol) were dissolved in 2 mL of DMSO, and stirred at room temperature for 
10h. EA (5mg, 0.082mmol) was added and stirring continued at room temperature 
for another 3h. The routine work-up afforded 125mg (70%) of tan-colored, fluffy, 
water-soluble solid 3(90:10)-MTX/Fc. ηinh, 15.3 mL g-1. 
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1H NMR (D2O), δ/ppm: 8.5-6.5, 2.1H (Expected: 5H; hetero- and aromatic CH of 
MTX); 4.3-4.25, 5.1 (Expected: 9H, CH of ferrocenyl); 3.5-3.0, 23H (Expected: 
22H, CONHCH2); 1.8-1.6, 19H (expected: 19H; CH2CH2CH2). These data 
indicate 42% MTX and 56% Fc incorporation, corresponding to 98% NH2 
acylation. Found: MTX, 8.23% (UV), 8.66% (NMR); Fe, 1.28% (OES), 1.35% 
(NMR). See Table 4.35 row 7. 
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CHAPTER 6 
CONCLUSION AND PERSPECTIVE 
The clinical usefulness of antitumor medicinal drugs has been severely limited by 
several factors such as poor water solubility, charge or polarity (which prevents 
cell entry by passive diffusion), lack of cell specificity, systemic toxicity, and a 
tendency to induce drug resistance. Among various strategies, the bioreversible 
binding of a medicinal drug to water-soluble and biocompatible carrier polymers 
represents an advanced technology that is designed to circumvent the critical 
pharmacological obstacles which the drug must clear for efficacious biological 
action. The polymer-drug conjugate resulting from the carrier-drug anchoring step 
acts as a prodrug which protects the active drug while in circulation and delivers it 
in free form at the target site. Carrier conjugation thus serves to enhance the 
drug’s therapeutic effectiveness. 
 
Two primary objectives motivated this research project.  Firstly, the synthesis of 
water-soluble conjugates by bioreversible conjugation of the two selected 
anticancer drug models, methotrexate and the organoiron compound ferrocene, 
with water-soluble macromolecules. Secondly, evaluation of the antiproliferative 
activities of the synthesized conjugates and their comparison with those of the free 
drugs. 
 
In order to fulfil these objectives, two macromolecular carrier types with suitable 
functionality for drug binding were synthesized. The first type comprised 
polyaspartamides, which were obtained in 52-74% yield by an aminolytic ring-
opening process in polysuccinimide, and were characterized by inherent 
viscosities in the range of 10-20 mL g-1. The weight-average molecular weight of 
these polymers (determined by gel permeation chromatography) was, for the most 
part, in the 20 000 - 30 000 range. This was sufficiently low to suppress inherent 
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polymer toxicity but high enough to retard renal clearance, and it showed no 
correlation with increasing viscosity. 
The second type of carriers used for drug anchoring was based on 
poly(amidoamine) structures. These carriers obtained in yields of 15-23%, and 
possessing inherent viscosities in the 14-24 mL g-1, were prepared in a two step-
process. The first step comprised the Michael addition of mono-N-Boc-protected 
amine nucleophiles to bisacrylamide under careful control of experimental 
conditions, and the second step involved deprotection of the amino side group 
terminals so generated with trifluoroacetic acid to afford the appropriate 
functionality for drug binding.   
 
Anchoring of methotrexate (MTX) to the primary amine-functionalized polymer 
of both types was brought about through formation of a biofissionable amide bond 
in a one-step coupling process. The resulting conjugates were purified by a 
combination of size exclusion chromatography and aqueous dialysis, and were 
isolated in the solid state in yields of 41-80%. In most cases a high extent of 
conjugation (95-100%) was reached, and the drug incorporation was 15-40% by 
mass. The weight-average molecular weight (25 000 – 86 000) of the conjugates 
increased as the inherent viscosity (12-25 mL g-1) increased.  
 
The water-soluble polymer-bound MTX conjugates were submitted for a 
preliminary biological activity assessment against various human cell lines, 
namely the human adenocarcinoma of the cervix (HeLa), the colorectal 
adenocarcinoma, (Colo 320 DM), and the human leukemic lymphoblast (CEM/S) 
and its resistant sub-line (CEM/E).  
Overall, the in vitro tests revealed very promising cell growth-inhibitory activity, 
and the following conclusions were drawn: 
 
(i) The polyaspartamide-MTX conjugates showed higher antiproliferative 
activity than free MTX against CEM/S and CEM/E cell lines. No distinct 
evidence of a structure-performance relationship was established.  
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(ii) There was a structure-performance relationship against HeLa and Colo 
cells lines. Thus, the tert-amine side chain terminals conjugates, 
irrespective of the carrier-type, were more effective than the free drug, 
while hydroxyl- or methoxy side chain terminals conjugates were found to 
be ineffective. The difference in cytotoxic performance suggested that the 
adsorptive pinocytotic mechanism of intracellular uptake, expected to 
occur with tert-amine functionalized conjugates, was more pronounced 
than the fluid-phase endocytosis by which other conjugates enter the 
intracellular compartment.    
 
(iii) The tert-amine side chain terminals conjugates showed higher 
antiproliferative activities against the resistant cell line (Colo) than the 
sensitive one (HeLa). 
 
(iv) The tert-amine side chain terminals conjugates of polyaspartamide-type 
showed higher cell growth-inhibitory activity than their counterparts of 
poly(amidoamine)-type. 
 
(v) The poly(amidoamine)-MTX conjugates containing intrachain PEO 
segments, whether short or long, were found to be less effective than the 
free drug.  
 
The results of this project showed the binding of methotrexate to the two water-
soluble macromolecular carrier types to be a promising approach to enhance its in 
vitro cancer cell-killing efficacy. However, prior to in vivo testing, an effort will 
have to be made to firmly establish structure-cytotoxic performance relationships.   
 
The investigation of the metal-containing drug model of the ferrocene type was 
narrowly focused on establishing the polymer-binding efficiency of two coupling 
methods. The primary amino group on selected carriers of both types was chosen 
as the cooperating functional group for reaction with the ferrocene-attached 
carboxylic acid group that allowed anchoring via the biofissionable amide bond. 
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Conjugations, achieved by either HBTU-mediated or ONp active ester processes, 
reached 98-100% extent of acylation and were therefore equivalent in efficiency.  
The results of this study also showed the possibility of using not only the aprotic 
dimethylformamide, but also the protic methanol as a reaction medium in the 
conjugation of ferrocene, via 4-ferrocenylbutanoic acid, to poly(amidoamine)-type 
carriers. 
  
Let us now conclude on the co-conjugation. Drug co-conjugation is a route for the 
simultaneous delivery of two or more anticancer compounds. The expected 
benefits are synergistic effects, which can potentially lead to reduction in doses 
and side effects caused by high dose of single drug, and the prevention of the 
development of multi-drug resistance.  
Multidrug-binding ability of polyaspartamide-type carriers was demonstrated by 
the co-conjugation of methotrexate and ferrocene with selected carriers. Folic 
acid, a cell entry facilitator, was co-conjugated with methotrexate or ferrocene in a 
two-step process involving HBTU and active ester coupling methods. The 
resulting water-soluble folate-drug co-conjugates, obtained in yields of 53-75%., 
and characterized by inherent viscosities in the range of 16-20 mL g-1, were 
screened against HeLa and Colo cell lines for antiproliferative activities. 
The following preliminary conclusions were drawn from the in vitro tests.  
 
(i) On the basis of the IC50 values, the presence of folate reduced the 
cytotoxicity of polymer-drug conjugate. This was more pronounced with 
folate-ferrocene co-conjugates than with folate-methotrexate co-
conjugates.  
 
(ii) The cytotoxicity decreases as the percentage of incorporated folate 
increases. 
 
Future research should be focused on investigating a considerably larger number 
of folate-drug co-conjugates in order to draw realistic conclusions regarding the 
impact of folic acid incorporation on the cytotoxic performance of polymer-bound 
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methotrexate or ferrocene. Cytotoxicity of ferrocene-methotrexate co-conjugates 
should be investigated in order to evaluate the advantages associated with the co-
conjugation of these two drug models. This would open up the possibility of 
extending the multidrug co-conjugation approach to other anticancer compounds. 
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